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Review methods: Two published NICE guidelines were used as case studies: prostate cancer and atrial
were produced for six of the nine prostate cancer topics considered, and for five of eight AF topics. The
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58other topics were not evaluated owing to lack of data or time constraints. The modelled results suggested
‘economic priorities’ for an update that differed from priorities expressed in the stakeholder survey.fibrillation (AF). Discrete event simulation (DES) was used to model the recommended care pathways and
to estimate consequent costs and outcomes. For each guideline, researchers not involved in model
development collated a shortlist of topics suggested for updating. The modelling teams then attempted to
evaluate options related to these topics. Cost-effectiveness results were compared with opinions about the
importance of the topics elicited in a survey of stakeholders.
Results: The modelling teams developed simulations of the guideline pathways and disease processes.
Development took longer and required more analytical time than anticipated. Estimates of cost-effectivenessAbstract
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Background: National Institute for Health and Care Excellence (NICE) clinical guidelines (CGs) make
recommendations across large, complex care pathways for broad groups of patients. They rely on
cost-effectiveness evidence from the literature and from new analyses for selected high-priority topics.
An alternative approach would be to build a model of the full care pathway and to use this as a platform
to evaluate the cost-effectiveness of multiple topics across the guideline recommendations.
Objectives: In this project we aimed to test the feasibility of building full guideline models for NICE
guidelines and to assess if, and how, such models can be used as a basis for cost-effectiveness
analysis (CEA).
Data sources: A ‘best evidence’ approach was used to inform the model parameters. Data were drawn
from the guideline documentation, advice from clinical experts and rapid literature reviews on selected
topics. Where possible we relied on good-quality, recent UK systematic reviews and meta-analyses.v
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Limitations: We did not conduct systematic reviews to inform the model parameters, and so the results
might not reflect all current evidence. Data limitations and time constraints restricted the number of
analyses that we could conduct. We were also unable to obtain feedback from guideline stakeholders
about the usefulness of the models within project time scales.
Conclusions: Discrete event simulation can be used to model full guideline pathways for CEA, although
this requires a substantial investment of clinical and analytic time and expertise. For some topics lack of
data may limit the potential for modelling. There are also uncertainties over the accessibility and
adaptability of full guideline models. However, full guideline modelling offers the potential to strengthen
and extend the analytical basis of NICE’s CGs. Further work is needed to extend the analysis of our case
study models to estimate population-level budget and health impacts. The practical usefulness of our
models to guideline developers and users should also be investigated, as should the feasibility and
usefulness of whole guideline modelling alongside development of a new CG.
Funding: This project was funded by the Medical Research Council and the National Institute for Health
Research through the Methodology Research Programme [grant number G0901504] and will be published
in full in Health Technology Assessment; Vol. 17, No. 58. See the NIHR Journals Library website for further
project information.
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new models to evaluate cost-effectiveness for every clinical question, and so specific topics for economic
analysis are prioritised. There are three potential risks with this approach: (1) estimates of cost-effectiveness
The aims of the project were therefore to:
l investigate the feasibility of modelling whole service pathways from NICE CGs to estimate the
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58cost-effectiveness of possible changes to the pathwaysmight not be available for some topics with potentially important resource consequences; (2) methods and
assumptions used for economic analysis at different points in the pathway might be inconsistent; and
(3) systemic effects and interactions between decisions might be neglected.
Another approach to economic evaluation in CGs would be to build a model of the full care pathway and
to use this as a platform to evaluate changes that are being contemplated. This has some putative
advantages. Though a big initial investment of time and resources, once developed the full guideline
model should enable analysis of a range of cost-effectiveness questions and provide the flexibility to
address unanticipated questions, which often arise during or after guideline development. The full
guideline model would also provide a common framework of methods, baseline data and assumptions,
to improve the consistency of cost-effectiveness estimates. Furthermore, embedding the decision options
within the context of the whole pathway provides the potential to account for systemic interactions
between options. However, there are some technical and practical obstacles to the adoption of a full
guideline modelling approach in the NICE CGs programme. To reflect guideline pathways, the models
would most likely need to be large and complex, and would therefore be challenging to build and to
validate. It is therefore unclear whether or not full pathway modelling in NICE CGs is realistic, and what
value it would add to the more conventional piecewise approach to economic analysis.
Objectives
The Modelling Algorithm Pathways in Guidelines (MAPGuide) project was set up to test the feasibility and
usefulness of full pathway modelling in NICE CGs. We chose to test the concept first outside of routine
guideline development by building models for two existing guidelines. The guidelines chosen as case
studies were both due to be reviewed by NICE to determine whether or not they should be updated. This
offered an opportunity to identify new evidence and suggested changes to the guidelines raised by experts
and stakeholders, which provided some real cost-effectiveness questions to be addressed by our models.
Stakeholders for the two guidelines were surveyed to elicit their views on the relative importance of the
topics as a comparison for the economic priorities identified by the models.Scientific summary
Background
National Institute for Health and Care Excellence (NICE) clinical guidelines (CGs) make recommendations
for the care of people with defined diseases or conditions in the NHS in England and Wales. The
recommendations are drawn up by a Guideline Development Group (GDG) after consideration of evidence
of the benefits, harms and costs of various diagnostic and treatment options. As NICE CGs are usually very
broad, covering large complex pathways of care for heterogeneous groups of patients, the approach to
assessing clinical and economic evidence is inevitably selective. The GDG identifies key ‘clinical questions’
within the scope, and evidence for these questions is identified, critiqued and summarised in a series of
systematic reviews. Evidence of cost-effectiveness is drawn from relevant literature or from original
evaluations conducted by guideline economists. Timelines and resources are not usually sufficient to buildxi
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to the care pathways. The disease process models were developed following review of other published
models, descriptions of epidemiology and discussions with clinical experts. The implemented models were
SCIENTIFIC SUMMARY
xiidesigned to estimate the mean discounted health-care costs and outcomes (quality-adjusted life-years;
QALYs) over a lifetime horizon for a representative heterogeneous cohort of patients treated according to
the defined pathway, and following the NICE reference case for economic evaluations. The models were
implemented as individual-level discrete event simulations (DES) programmed using a specialist software
package (SIMUL8 Professional version 15.0; SIMUL8 Corporation, Boston, MA, USA).l use this approach to estimate the potential value of updating selected topics within the guidelines,
as estimated by the likelihood of a change in recommendation and the potential impact of any such
change on expected net benefits (NBs)
l compare the economic priorities for updates obtained from formal modelling with those elicited during
the routine NICE guideline review process.
Methods
Two published NICE guidelines were selected as case studies: prostate cancer and atrial fibrillation (AF).
These guidelines were chosen from the 17 guidelines due to be reviewed by NICE within our timelines
(between January and September 2011). The criteria for selecting the case studies were (a) that the
published guideline contained a relatively well-formulated pathway suitable for modelling; (b) that they
addressed important topics that were likely to be updated; (c) that there was thought to be uncertainty or
controversy over which topics should be updated; and (d) the guidelines would address different patient
groups or disease areas, and hence would present different challenges for the modellers.
The project consisted of three streams of work led by different teams of researchers: the first team
(CC and MW) identified the potential update topics and conducted and analysed the surveys of
stakeholders; the second team (SW, PT and AM) developed the prostate cancer model and used it to
evaluate possible update topics for this guideline; and the third team (MTB, JE, AA and JL) developed the
AF model and evaluated possible update topics for this disease area. The modelling teams did not
influence the choice of topics and did not see their list of topics until the design of the base-case model
had been finalised. They were also not shown the results of the stakeholder surveys until after the
base-case models had been implemented. The two modelling teams met regularly to discuss progress and
difficulties encountered, and to agree the general principles to be followed.
The potential update topics were elicited from the review decision documents published on the NICE
website. One researcher (CC) read the documents and collated a list of suggested topics with advice from a
second researcher who has extensive experience in systematic reviewing and guideline development (MW).
A shortlist of topics for each guideline was agreed by members of the research team who were not involved
in developing the models. Information about the selected topics and relevant new evidence cited in the
review documents was collated. Surveys were then conducted with registered stakeholders for the two
guidelines to elicit their opinions about the importance of including the selected topics in a future update of
the guidelines. Participants were presented with a short summary of the shortlisted topics and then asked
to rate them in terms of importance (using a five-point Likert scale) and to rank them in order of priority for
inclusion in a future update. Results were summarised using simple descriptive statistics and graphs.
The modelling teams began with background reading to familiarise themselves with the guideline and
current issues in the field. The boundaries for the modelling exercises were defined by the scopes for the
original guidelines. The model designs consisted of two main elements: a ‘service pathway model’, which
specifies the expected care that patients with defined characteristics would receive according to the current
guideline recommendations; and a ‘disease process model’, which specifies how patients’ health status or
risk of events is expected to change conditional on their characteristics and treatment. The pathway models
were developed following detailed examination of the guideline documents, and then checked with clinical
experts. Published NICE Technology Appraisal (TA) guidance within the scope of the guidelines was addedNIHR Journals Library www.journalslibrary.nihr.ac.uk
The optimal strategy within each topic was identified by incremental cost-effectiveness analysis (CEA),
or equivalently by calculation of incremental net benefits (INBs). Results are reported using a primary
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58cost-effectiveness threshold of £20,000 per QALY gained. The relative ‘economic priority’ for which topics
should be included in an update was determined on the basis of two pieces of information: (i) the
probability that the currently recommended base-case option is not the optimal strategy within that topic
and (ii) the magnitude of the potential gain in NB (difference between the optimum and base-case
strategies). These statistics were used by the modelling teams to rank the topics in order of importance
for inclusion in an update. This ranking was then compared with that obtained from the survey of
guideline stakeholders.
Results
Both modelling teams succeeded in building a DES representing the guideline pathway and disease
process. Development took nearly 24 months, and required more than one whole-time equivalent year of
analyst time for each full guideline model. The scope of both models was very broad, and included the
large majority of the guideline pathways and recommendations, though with some exceptions.
Nine potential update topics were identified from the NICE review documents for the prostate cancer
guideline, and eight topics for the AF guideline. Survey responses were received from 27 out of 239
registered stakeholders for prostate cancer. Two topics were rated as ‘very important’ for inclusion in an
update of the guideline by the majority of respondents: active surveillance (AS) in previously unscreened
‘low-risk’ men, and effective techniques for performing radical prostatectomy. For AF, 32 out of 182
stakeholders responded to the survey, and two topics were rated as ‘very important’ by the majority of
these respondents: new oral anticoagulants (OACs), and stratification tools to assess bleeding risk before
antithrombotic medication.
Cost-effectiveness analysis was conducted with the prostate cancer model for six of the nine potential
update topics. Two of the remaining topics were not modelled because of an absence of necessary
information, and there was no need for CEA of the final topic owing to likely dominance of one of the
options. The model indicated that for three topics in particular, there was a high potential for increased
NB: brachytherapy with external beam radiotherapy for localised or locally advanced disease; pelvicThe starting characteristics for patients entering the models were taken from samples of individual data
from a general practice database for AF and a disease register for prostate cancer. It was beyond the
scope of this project to conduct systematic reviews to inform all model parameters. Information was
therefore identified from the original guideline, supplemented with new evidence from rapid reviews of
the literature and discussions with clinical experts. The impact of uncertainty over model parameters was
considered through probabilistic sensitivity analysis. The models were each evaluated over two nested
levels of iteration: an internal level to reflect variability between individual patients (first-order uncertainty);
and an external level to represent uncertainty over population parameters (second-order uncertainty).
The modelling teams checked for errors and inconsistencies during model development. The models were
also verified to test for correct programming and validated to ensure consistency with expected results
(e.g. that survival times and levels of service use were realistic).
The modelling teams then attempted to estimate the cost-effectiveness of questions related to their list of
possible update topics. This involved running the models for the base-case pathways, and then for a series
of strategies reflecting possible changes to the pathways. Additional data required for the alternative
strategies were obtained from the original guideline or new evidence identified by stakeholders or experts,
or by rapid literature searches. It is important to note that the economic analyses presented in this report
were not based on full evidence reviews and have not been informed by an expert guideline group. Our
focus was to assess the modelling methods and their usefulness in the context of identifying priorities for
inclusion in a guideline update. The results should not be used to inform clinical practice.xiii
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radiotherapy with adjuvant hormone therapy for localised disease; and continuous versus intermittent
2. Further development of the case study models to assess the existence and magnitude of possible
interactions between changes to different parts of the care pathways.
SCIENTIFIC SUMMARY
xiv3. Extension of the case study models to estimate budget and health impacts across a whole patient
population (rather than for single incident cohort).
4. To apply the full guideline modelling approach to a new NICE guideline.
5. Further development of methods:
i. methods for eliciting expert opinion and reaching consensus about the structure of disease process
and service pathway models to inform guideline development and economic modelling
ii. methods for robust model calibration to infer missing or unobservable parameters in complex
decision modelshormone therapy for metastatic prostate cancer.
For AF, cost-effectiveness estimates were obtained for five out of eight topics. Two topics were not
evaluated as they related to areas excluded from the scope of the model, and one topic was omitted due
to time constraints. The results for the five modelled topics suggested that stroke and bleeding risk
thresholds for oral anticoagulation and the comparison of rate and rhythm control strategies should be
treated as priorities for inclusion in an update; as there was a fair probability that the current guideline
recommendations were not optimal and a high potential for health gain and cost savings. The estimated
economic priorities for update topics differed from those elicited from stakeholders.
Conclusions
This project has demonstrated that models can be developed to cover the large part of complicated CG
pathways, and that these models can be used to evaluate a range of cost-effectiveness questions across
the pathways. This approach has the potential to produce consistent estimates of cost-effectiveness that
account for systemic effects of placing decision options within a broad pathway of care. Implementation of
the models was facilitated by the use of DES, which can provide a relatively compact representation of the
flow of a heterogeneous cohort of patients through a very complex care pathway.
However, there are some barriers to the routine adoption of this approach in the NICE CGs programme.
The most obvious is that it is unlikely to be possible within current timelines and health economic
resources, because of the demands of developing such large models and the need for specialist DES
expertise. It is also unlikely that this approach will work for all CGs, due to data limitations. Nevertheless,
we believe that the approach does show sufficient promise to warrant further investigation.
Learning from this project should enable faster development of full guideline models in the future. The
two case studies provide a set of methods and terminology that could be adapted for other applications.
We also identify some considerations for future development, including the need for clarity about the
boundaries of the model; the need for clarity over whether the model pathway is meant to reflect
recommended or current practice; and the importance of conceptual modelling of both the service
pathway and of the disease process.
We recommend five priorities for further research:
1. The case study models have been made available to the National Collaborating Centre (NCC) teams
developing updates of the guidelines. Research should be conducted to seek the opinions of the
members of the NCC technical teams, the GDGs, stakeholders and the NICE guidelines team to
determine whether or not they made use of the models, and, if so, whether or not the results
were useful.NIHR Journals Library www.journalslibrary.nihr.ac.uk
iii. development of standardised software templates or methods of presentation to help guideline
economists to develop flexible and accessible guideline models in consultation with other
methodologists, GDGs and stakeholders
iv. methods to test the internal and external validity of full guideline models.
Funding
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Chapter 1 Background
This chapter presents the background to economic evaluation in clinical guidelines and discusses the roleof modelling.
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about if or how this information ought to be considered.3
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58patients and policy-makers who face resource constraints to evaluate the options. The 2011 Io
committee also discussed this issue, but chose not to comment on the role of costs or cost-eff
guideline decision-making. Similarly, the G-I-N recently advised that recommendations should
scientific evidence of benefits, harms and ‘if possible’ costs, but did not make any more explicdevelopers of clinical practice guidelines ‘need not’ use economic criteria in drawing up recommendations
on what constitutes appropriate care; not because costs should be or can be avoided, but because the
committee could not agree that guideline developers are necessarily the right people to be making these
judgements. Instead, they put forward the ‘modest proposal’ that guideline developers should present
information about the costs and health implications of alternative interventions to help practitioners,
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SO16hods of evidence review and synthesis, the role of cost-effectiveness in guidelines is much more
troversial. In 1992 the influential IoM committee debated this question.1 They concluded thatThe role of cost-effectiveness in guidelines
Although there is now broad agreement over the need to base clinical guidelines (CGs) on formaliseduideline development and quality of reporting (www.agreetrust.org). The Guidelines International
ork (G-I-N) was founded in 2002 to provide a network for guideline developers and users, to help
ce duplication of effort and to promote best practice in guidelines (www.g-i-n.net).Clinical practice guidelines are statements that include recommendations intended to optimize patient
care that are informed by a systematic review of evidence and an assessment of the benefits and
harms of alternative care options.2
In addition to the use of systematic reviews, they defined criteria for guidelines ‘we can trust’, including
transparency, composition of the Guideline Development Group (GDG), and external review.
Several international collaborations have been established to further the use of robust processes and
methods for guideline development. For example, the Appraisal of Guidelines for Research and Evaluation
Enterprise (AGREE) was founded to develop and promote a critical appraisal checklist to evaluate processesIn their 2011 statement, the IoM revised their definition to:Introduction to clinical guidelines
Evolution of evidence-based guidelines
Guidelines on clinical practice have been developed by professional bodies in many countries for many
years now. Initially based on informal consensus and expert opinion, the influence of evidence-based
medicine has led to the adoption of more formalised methods of development. In 1992, the US Institute of
Medicine (IoM) defined guidelines as:
. . . systematically developed statements to assist practitioner and patient decisions about appropriate
health care for specific clinical circumstances.11
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A dissenting member of the 1992 IoM committee and witness to the 2011 committee, David Eddy has
been a prominent advocate for the explicit consideration of costs alongside health outcomes in guidelines.
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2patients.12 The criticisms levelled at this approach by Eccles and Mason included technical limitations of the
model, particularly relating to the (as it now seems) quite primitive deterministic analysis of uncertainty.NIHRnticoagulation to prevent stroke in patients with atrial fibrillation (AF), which is coincidentally a
stion that we address in our case study in Chapter 5. The North of England guideline used a Markov
ision model to estimate the cost and QALY impact of treatment with warfarin for various groups ofand weigh up this information qualitatively. In the alternative modelling approach, there is a formal
processing of information to produce a quantitative summary of the expected costs and health
consequences of the available options. The summary is often in the form of an incremental cost-
effectiveness ratio (ICER), such as the additional cost per quality-adjusted life-year (QALY) gained which,
when compared against a benchmark cost-effectiveness threshold, provides an indication of the ‘right
decision’ (if not a definitive decision rule).11
Eccles and Mason argued against modelling in CGs, based on their experience working on the Department
of Health funded, North of England guidelines in the 1990s.10 This view was influential in early approaches
to guidelines commissioned by the National Institute for Health and Care Excellence (NICE), since when
NICE was established in 1999 it effectively inherited the Department of Health guidelines programme. The
example that Eccles and Mason used to criticise the modelling approach is the North of England guidelineaccount of economic considerations in CGs.10 In the profile approach, various measures of hea
derived from clinical studies are summarised alongside estimated costs. The GDG then discuss,He argued:
. . . health interventions are not free, people are not infinitely rich, and the budgets of programs are
limited. For every dollar’s worth of health care that is consumed, a dollar will be paid. Furthermore,
the costs will be paid by present and future patients.4
This argument was taken up by Alan Williams,5,6 who noted that to optimise outcomes across a
population, guideline developers must take account of the sacrifices imposed on other current or future
patients when scarce health-care resources are devoted to a subset of patients who are the concern of a
particular guideline. This requires an appreciation of the relative costs and health effects of alternative
treatment options for the defined subgroups of patients, and an understanding of what health benefits
could be obtained by using resources in other ways (opportunity costs). The methods of economic
evaluation are designed to assist decision-makers in making such comparisons.7
In practice, explicit consideration of cost or cost-effectiveness in guidelines is unusual.8 A search of the
National Guideline Clearinghouse online database found that of 1616 guidelines published between 2000
and 2005, only 369 (23%) included any formal cost analysis.
Assessing cost-effectiveness: profiles vs. models
Even when it is accepted that cost-effectiveness ought to influence guideline recommendations, there is
still controversy over how this should be done. Eddy defined two broad approaches to designing practice
policies.4 In what he called the ‘implicit’ approach, experts are asked to weigh up pertinent information in
their heads, deliberate and reach a collective decision. This consensus process is, he argues, satisfactory for
many types of decision problem, but it is inadequate when there are complex and uncertain trade-offs
between costs, benefits and harms. For this type of question, Eddy proposed an ‘explicit’ approach to
decision-making, characterised by ‘an explicit and systematic analysis of evidence, estimation of outcomes,
calculation of costs, and assessment of preferences’. This latter approach includes formalised methods of
clinical decision analytic modelling and health economic evaluation.9
A related distinction between ‘profiles’ and ‘models’ has permeated discussions about how to take
lth effectJournals Library www.journalslibrary.nihr.ac.uk
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or balance sheet approach – has been proposed as a means of bringing economic evaluation more into
line with society’s values.19 However, the predominant view among health economists active in the field of© Que
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e have significant concerns over technical aspects of modelling and over the validity of the summaryevidence and its applicability to their particular decision problem. Although the GRADE Working Group
notes that formal economic modelling results can help to inform judgements about the balance between
positive and negative outcomes, it highlights the downsides of modelling. In particular, it states that
modelling reduces transparency and that it is susceptible to bias and uncertainty arising from the many
assumptions that are required and the poor-quality data that are often available to support a model.
This rather negative attitude to explicit economic evaluation and modelling in the field of CGs contrasts
with the predominant view in Health Technology Assessment (HTA).15 This may be because cost
containment was often seen as an important motivator for the development of HTA, or possibly because
of the influence of Archie Cochrane and his reflections on effectiveness and efficiency.16 In addition,
whereas the objective of guidelines is usually defined as informing clinical decision-making and optimising
patient outcomes, the objective of HTA is more clearly directed at informing policy-making and optimising
population outcomes, which makes the trade-offs between alternative uses of scarce resources more
apparent. For example, HTA International (HTAi) defines HTA as:
. . . a multidisciplinary field that addresses the health impacts of technology, considering its specific
healthcare context as well as available alternatives. Contextual factors addressed by HTA include
economic, organizational, social, and ethical impacts. The scope and methods of HTA may be adapted
to respond to the policy needs of a particular health system.
www.htai.org
Of course, beliefs about the role of economic considerations and the use of modelling do also vary
between HTA agencies and practitioners. For example, although many European agencies have been
willing to bring in explicit consideration of cost-effectiveness and the use of modelling, the criteria and
methods used by these agencies differ.17 Further, while the public and policy-makers in the USA are
generally unreceptive to cost-effectiveness or modelling, it has been argued that ‘US health policy-makers
in the private and public sectors continue in a quieter fashion to develop strategies to use evidence of
comparative value’.18enting the advantages and disadvantages of alternative management options to a guideline panel.13,14
GRADE system provides a formalised process for identifying, appraising and summarising evidence
ting to important outcomes, which may include differences in resource use where relevant. The GRADE
king Group advises that guideline panels may ‘legitimately ignore’ information on resource use, but
, if a panel chooses to consider this information, it should first assess the quality of the underlyingHowever, they also argued that the use of a model detracted from the quality of interaction of the
guideline group with the evidence:
Once the clinical problem had been scoped there was little remaining role for the group and they
were not called upon to discuss the evidence or the implications of the model.10
Eccles and Mason acknowledged that there are situations where simple modelling exercises are necessary
and useful to the decision-making process, but they argued that the touchstone for such exercises is
‘parsimony’, to ensure that guideline developers and users can understand and, if necessary, replicate the
results. In general, they advocated the use of a simple balance sheet to present disaggregated health
effects and costs for the consideration of the guideline group.
More recently, the international Grading of Recommendations Assessment, Development and Evaluation
(GRADE) Working Group has also promoted a profile approach as a ‘simple but powerful’ way of3
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4The development process for NICE guidelines is outlined in Box 2. After referral of the topic from the
Department of Health, a scope is prepared by the NCC and, after consultation with stakeholders, finalised
and agreed by NICE. This document defines the populations, health-care settings and types of
interventions to be included or excluded, and sets the boundaries for the work of the GDG.
The GDG is the independent advisory committee that develops the guidance. It meets over a period of
12–18 months, usually monthly. Unlike NICE’s Technology Appraisal (TA) Committees, a GDG is specially
convened for each guideline. The composition of the GDG is tailored to the guideline topic. In addition to
health-care professionals, patient and public representatives, and sometimes health-care managers or
commissioners, the GDG includes members of the NCC technical team who are responsible for conducting
the evidence reviews and any related analyses. The technical team includes individuals with skills in projectThe NICE currently commissions guidelines from four National Collaborating Centres (NCCs) (B
addition, an Internal Clinical Guidelines (ICG) team at NICE develops the short guidelines. The
functions of the NCC and ICG teams are to convene and to provide secretariat and technical s
functions to the GDGs.Process for development of NICE guidelines
ox 1). InNIHRmmendations to the NHS. Though compliance with NICE guidelines is not compulsory, and no special
ing is available to support their implementation, they are used to set standards for NHS organisations
professionals and can have a major impact on patient care.27Guidance from the Institute will include guidelines for the management of certain diseases or
conditions and, where appropriate, it will cover all aspects of the management of that condition –
from prevention to self-care through primary care, secondary care and more specialist services.26
Between May 2001 and July 2012, NICE published 153 CGs, including eight inherited guidelines
commissioned by the Department of Health, and 26 updates of previously published NICE guidelines. A
further 56 guidelines were in development at that time.
There are NICE guidelines for diverse patient groups and conditions, including topics in mental health,
women and children’s health, cancer, and acute and chronic disease. Each guideline encompasses a wide
range of management options for the defined patient group, including aspects of disease prevention, case
identification, assessment and diagnosis, treatment, monitoring, ongoing care and self-management.
Although NICE has now introduced a ‘short guidelines’ programme, which develops guidelines with a
narrower focus, most NICE guidelines are still very broad in scope and make a large number ofThe development of CGs is a core function of NICE:HTA is that modelling is an ‘unavoidable fact of life’, and has the clear advantage of providing an explicit
and reproducible summary of the balance of benefits, harms and cost.20 Although there may be legitimate
concerns about the potential for inappropriate use of data, and problems with the transparency and
validity of models,21 steps can be taken to minimise these dangers.22–24
There has also been discussion about the use of systematic reviews to identify and summarise published
‘economic evidence’ to put before decision-makers. This is standard practice in both HTA and guidelines,
but it has been argued that this is a largely futile exercise, as estimates of cost or cost-effectiveness
obtained in one context are rarely transferable to another.25 Modelling provides a more satisfactory
method for synthesising clinical and economic evidence to provide a coherent aid to decision-making.
These arguments might equally be applied to guideline development.
The NICE clinical guidelines programme
Purpose and scope of NICE guidelinesJournals Library www.journalslibrary.nihr.ac.uk
BOX 1 National Collaborating Centres
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58BOX 2 National Institute for Health and Care Excellence guideline development process28
1. Guideline topic referred to NICE by Department of Health.
l National Clinical Guideline Centre (NCGC) Hosted by the Royal College of Physicians, in partnership with the
Royal College of General Practitioners, Royal College of Nursing and Royal College of Surgeons of England.
l National Collaborating Centre for Cancer (NCC-C) Hosted by Velindre NHS Trust in Cardiff in partnership
with Cardiff University and other organisations.
l National Collaborating Centre for Women’s and Children’s Health (NCC-WCH) Hosted in a partnership
led by the Royal College of Obstetricians and Gynaecologists, which includes the Royal College of
Paediatrics and Child Health, Royal College of Midwives, Royal College of Nursing and a range of
other stakeholders.
l National Collaborating Centre for Mental Health (NCCMH) Partnership between the Royal College of
Psychiatrists and the British Psychological Society.management, information science, systematic reviewing and health economics. The GDG has the following
key functions: to define specific review questions within the guideline scope; to consider the clinical and
economic evidence related to these questions; to use expert consensus if evidence is poor or lacking; to
formulate guideline recommendations; and to respond to comments from the stakeholders.
The whole process of guideline development, from referral to publication, takes 18–24 months for
standard guidelines and 9–11 months for short guidelines.
Around the time of publication, NICE produces implementation support tools to encourage uptake
of the guideline. These include a costing tool, which identifies any significant resource impacts of
recommendations and estimates the budget impact for NHS bodies, to help them in planning
for implementation.
All NICE guidelines are reviewed periodically to check whether or not they need updating. NICE conducts a
formal review of the need to update a guideline 3 years after publication. This involves consultation with
the original GDG, collection of intelligence and focused literature searches. A draft review decision is
published for consultation with stakeholders and then finalised by NICE. This may result in a decision to
update the guideline in part or in whole, not to update the guideline, to transfer it to a ‘static’ list, or to
2. Stakeholders register interest: National organisations representing patients and carers, and health
professionals can register as stakeholders. Stakeholders are consulted throughout the guideline
development process.
3. Scope prepared: NCC prepares the scope, setting out what the guideline will and will not cover. Following
consultation with stakeholders, the scope is agreed and signed off by NICE.
4. GDG established: Includes health professionals, representatives of patient and carer groups and technical experts.
5. Draft guideline produced: The GDG assesses the available evidence and makes recommendations.
6. Consultation on the draft guideline: Public consultation period for registered stakeholders to comment on
the draft guideline.
7. Final guideline produced: GDG finalises the recommendations; the NCC produces the final guideline.
8. Guidance issued: NICE formally approves the final guideline and issues its guidance to the NHS.
5
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withdraw it. The review decision is published by NICE, and includes a summary of new evidence and topics
that need to be updated, as well as a full list of stakeholder comments and responses from NICE.
Methods for development of NICE guidelines
Methods for the development of NICE guidelines are specified in The Guidelines Manual.29 There are four
key steps to assembling and interpreting the evidence base to support GDG decision-making (Box 3).
Cost-effectiveness in NICE guidelines
NICE has always had a clear remit to consider both clinical effectiveness and cost-effectiveness in its
guidelines.26 The decision-making principles employed by NICE are outlined in its Social Value Judgements
paper.30 This emphasises the importance but also the boundaries of cost-effectiveness in NICE guidance.
Those developing clinical guidelines, technology appraisals or public health guidance must take into
account the relative costs and benefits of interventions (their ‘cost-effectiveness’) when deciding
whether or not to recommend them.30
Decisions about whether to recommend interventions should not be based on evidence of their
relative costs and benefits alone. NICE must consider other factors when developing its guidance,
including the need to distribute health resources in the fairest way within society as a whole.30
BOX 3 National Institute for Health and Care Excellence guideline development methods29
1. Formulate the review questions.
¢ Structure review questions.
¢ Use patient experiences to inform the review questions.
¢ Agree the review protocols and finalise the economic plan.
2. Identify the evidence.
¢ Develop search strategy for each review question.
¢ Search relevant databases.
¢ Ensure sensitivity and specificity of search.
BACKGROUND
6¢ Formulate research recommendations.¢ Update existing NICE guidance (if identified in the scope).
¢ Summarise evidence and present results.
4. Develop guideline recommendations.
¢ Interpret the evidence to make recommendations.
¢ Formulate recommendations, paying particular attention to wording.
¢ Identify key priorities for implementation.NIHR¢ Select relevant studies.
¢ Assess quality of selected studies for clinical effectiveness and cost-effectiveness.
¢ Conduct new economic evaluations on selected topics.¢ Consider stakeholder submissions of evidence, if applicable.
3. Review the evidence.Journals Library www.journalslibrary.nihr.ac.uk
To help guideline groups to take account of cost-effectiveness, a health economist is employed as part of
the technical team for all NICE guidelines. It has been argued that guideline economists are too isolated
within GDGs, the majority of whose members are clinicians or patient representatives with a special interest
in the guideline topic and who may therefore be reluctant to rule against clinically effective interventions on
the grounds of cost-effectiveness.31 This claim has, however, been refuted by NICE and the NCCs.32–34
The methods used by guideline economists have evolved over the 12 years that NICE has been developing
guidelines. As mentioned above, economists were initially discouraged from developing their own models.
This has changed, and The Guidelines Manual29 now broadly recommends a combination of profile and
modelling approaches: with models being developed to address selected questions in each guideline, and
reliance on summaries of published economic evidence or GDG judgement alone for other questions. Most
guidelines now include at least one original model-based economic analysis.35
In addition to providing general advice to the GDG on economic issues, the guideline economist is
expected to review published economic evaluations, prioritise questions for further economic analysis, and
conduct de novo economic evaluations for selected questions. Early in the guideline development process,
the economist, in discussion with the rest of the technical team and GDG, prepares an ‘economic plan’
that identifies the initial priorities for further economic analysis and the proposed methods for addressing
these questions. The criteria for judging the value of a new economic analysis are: the overall ‘importance’
of the recommendation, which depends on the number of patients affected and the costs and health
impacts per patient; current uncertainty over cost-effectiveness; and likelihood that further economic
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58BOX 4 Principles for economic evaluation in NICE guidelines
l The economist should carry out the analysis in collaboration with the rest of the GDG.
l Economic analyses should be explicitly based on the guideline’s review questions.
l An economic analysis should be underpinned by the best-quality clinical evidence, based on and
consistent with that identified in addressing the guideline’s review question.
l The structure of the model should be discussed and agreed with the GDG.
l All CEAs should be validated.
l There should be the highest level of transparency in reporting methods and results.
l Incremental analysis should be used when comparing mutually exclusive options.
l Considerations of potential bias and limitations should be discussed by the GDG.
l Sensitivity analysis should be used to explore the impact of potential sources of bias and uncertainty.
Probabilistic sensitivity analysis is the preferred method for taking account of uncertainty arising from
imprecision in model parameters.
CEA, cost-effectiveness analysis.
analysis will clarify this uncertainty.
This is not always straightforward, and economic plans can and do change during guideline
development.35The Guidelines Manual advises on how new economic analyses should be conducted and
reported.29 Analyses are expected to follow the same ‘reference case’ as NICE TAs.36 This specifies, for
example, how to measure health effects (in QALYs), the perspective to be used for costing [NHS and local
authority funded Personal Social Services (PSS) services] and the rates for discounting costs and QALYs
(3.5%). The Guidelines Manual also defines some general principles for modelling in guidelines (Box 4).
NICE has adopted the GRADE framework for assessing the quality of clinical evidence within its guidelines
programme,37 and has developed a similar framework13 for reviewing and presenting cost-effectiveness
estimates from published studies or new models.7
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Methods for modelling in guidelines
s because
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8upstream selection of patients. This issue was recognised in the NICE guideline on colorectal c
the GDG chose not to pursue economic analysis for diagnosis, staging or assessment questionCritique of the current NICE approach
The selective approach to economic modelling currently used in NICE guidelines is pragmatic, as the
economist’s time is limited. NICE guidelines are often large and complex, typically covering around 15–20
review questions along a pathway of care, although sometimes many more. Each question may relate to a
choice between several different interventions for various subgroups of patients. Modelling will not
necessarily enhance GDG decision-making for all questions. For example, if there is clear evidence of a lack
of clinical benefit for an intervention, it will sometimes be obvious that it cannot be cost-effective.
Alternatively, if there is a lack of evidence of benefit, modelling on the basis of expert opinion alone might
not help the group to reach consensus. Modelling might also be unnecessary if high-quality analyses
directly relevant to the decision problem already exist; in a recent UK HTA report for instance. A selective
approach to modelling the remaining questions might therefore be sufficient to ensure that the really
important economic issues in a guideline are identified and addressed.
However, there are three main risks associated with this selective approach. The first is that important
economic issues may be missed or inadequately considered. The existing economic evidence base is usually
sparse and patchy, so one cannot rely on published estimates of cost-effectiveness for all of the review
questions of interest. For example, a systematic review of economic evaluations of colorectal cancer
services found no relevant UK cost-effectiveness estimates for large sections of the care pathway, including
surveillance, radiotherapy and end-of-life care.38 After excluding questions for which economic evidence
would clearly not add value, and those covered by sufficient existing evidence, there are usually more
cost-effectiveness questions than can be answered with conventional modelling within the resources and
timelines of the guideline. Taking the NICE guideline on the diagnosis and management of colorectal
cancer (CG131) published in November 2011, the scope specified 15 key clinical questions to be
addressed in the guideline.39 Of these, the economic plan concluded that one question was already
covered by literature, and that cost-effectiveness was not relevant for two questions (one relating to a
prognosis and one to support for patients). Of the remaining 12 questions, three were rated as high
priority for further economic analysis, four as medium priority and five as low priority. In the event,
economic analysis was completed for one high priority topic. This low coverage of economic evidence
might have been an inevitable consequence of sparse data and limited modelling resources. However, it is
also possible that the expectation that economic analysis will only address a small proportion of guideline
questions in a guideline leads to an overly cautious approach, in which difficult (but possibly important)
analyses are abandoned.
A second possible risk of the current NICE approach is that GDGs may be forced to make decisions on the
basis of inconsistent economic evidence, estimated using different methods, assumptions and data. This
could lead to inconsistent application of the cost-effectiveness benchmark to recommendations within a
guideline, between guidelines, and between guidelines and other forms of NICE guidance (such as TAs or
public health guidance). As an example, in their review of published economic evidence relating to
colorectal cancer, Tappenden and colleagues38 concluded that where economic evidence was available it
was ‘incongruent and difficult to interpret’ between different parts of the same pathway and where
multiple analyses existed to address a given decision problem. They identified inconsistencies in
methodology (‘doing things differently’) and also in scoping (‘doing different things’).
The third risk with selective economic modelling is that it may neglect systemic effects and interactions
between questions. The sequencing of tests and treatments within the pathway may radically alter costs
and health outcomes. In addition, the cost-effectiveness of the options at any node in the pathway may
depend on upstream and downstream decisions. For example, the cost-effectiveness of a test depends on
downstream treatment decisions, and conversely the cost-effectiveness of a treatment depends on
ancer, whereNIHR Journals Library www.journalslibrary.nihr.ac.uk
they thought it would be difficult to construct a model structure to take account of downstream events
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model for colorectal cancer.48 This also used DES to model current practice, following patients from initial
presentation with suspected colorectal cancer through to end-of-life care. The simulation model was
then used to provide a baseline for estimation of the cost-effectiveness of a range of potential (largely
hypothetical) service developments.
Building on the work of Pilgrim and colleagues,48 Tappenden and colleagues49 later developed a methods
framework for developing and using Whole Disease Models to inform resource allocation decisions in
cancer. This methods framework was then applied to inform the development of a Colorectal Cancer© Que
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SO16tments that individuals would receive, conditional on their characteristics and histories. The pathway
of a similarly broad scope to that in many NICE CGs, and this example illustrates well how Alan
iams’ vision of a map of an entire guideline might be operationalised.6other). The simulation included an explicit model of the care pathway, coding the sequence of tests and
trea) to estimate costs and health outcomes of a defined diagnostic and treatment pathway across a
ulation with CHD.46,47 Outcomes were determined for simulated individuals through random sampling
e time to CHD events [unstable angina and myocardial infarction (MI)] and death (CHD related andAnother example is the Department of Health-funded CHD model, which used discrete event simulation
(DESence, prevalence, mortality and related resource costs across a population. It used a compartmental
e-transition modelling technique, similar to that used for modelling infectious disease dynamics, in
ch the progress of groups (rather than individuals) is tracked over discrete intervals of time.over time to evaluate emerging technologies or to incorporate new evidence. One well-know
is the pioneering coronary heart disease (CHD) policy model.44,45 This was designed to estimatebeyond test accuracy.39
This combination of sparse and inconsistent published economic evidence and limited capacity for
modelling means that guideline recommendations are often not supported by quantitative estimates of
cost-effectiveness.
Therefore, there are potential problems with the current NICE approach, but is there a feasible alternative?
Alan Williams made a radical suggestion in his 2004 Office of Health Economics (OHE) lecture:
I think that guideline development needs to be strengthened from the outset by injecting into the
process a strong dose of decision-analytic expertise, so as to ensure that the whole territory is
mapped out in a systematic way, rather than leaving the creation of a comprehensive flowchart until
later, when all the bits and pieces on which we have more information have been sorted out . . .
To do this we need not only a large-scale map of what to do at particularly tricky junctions, but also a
small-scale map of the entire system covering all the relevant highways and byways, and estimating
the traffic flows along each . . .
‘An impossible task’ did I hear someone mutter? If creating such a map is horrendously complicated,
it is because reality is horrendously complicated, but if traffic analysts can do it, surely the health care
analysts can do it too! Indeed, the more complex the reality is, the more dangerous it is to rely on
intuitive short-cuts rather than careful analysis.6
Examples of full pathway models
A number of ‘generic’ models have been designed to provide a platform for evaluation of a range of
interventions for a defined patient group, most notably in the areas of cardiovascular and metabolic
disease.40–42 These may be useful for situations where decision-makers want a model that can be adapted
43 n example9
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Whole Disease Model to examine its potential value in supporting economic analysis within the NICE CG
atte
refle
artifi
ast cancer.51
BACKGROUND
10A contributory factor to this was time spent in understanding how to use DES to model this problem.
Additionally, development of a DES model might sometimes be quicker for a larger decision problem,
because of the so-called ‘curse of dimensionality’.52 To represent very large decision problems, with
multiple subgroups of patients and treatment pathways, aggregate models can require a huge number of
health states. For example, Weinstein and colleagues’ CHD policy model stratified patients into 5400
different subgroups, on the basis of differing risk factors.44 They then struggled with the problem of howlonger to develop. This view was supported by a study that compared parallel development of
Markov model to evaluate the cost-effectiveness of alternative adjuvant therapies for early breRelated to the question of complexity, is the choice of modelling technique. It has been argued that,
although individual-level simulation approaches (such as DES) provide greater flexibility than aggregate
approaches (such as decision trees or Markov models), they also require specialist skills and may take
a DES and aNIHRmpt to represent them as a whole. Inevitably, the pathways represented in CGs are always partial
ctions of the meta-pathway of the NHS, where patients have multiple diseases and move across the
cial boundaries of guideline demarcations.on the diagnosis and management of colorectal cancer (CG131). Although the model was not used
directly to inform guideline recommendations, the Whole Disease Model was capable of providing a
platform for the economic analysis of 11 of the 15 guideline topics, compared with only one with the
conventional approach. The Colorectal Cancer Whole Disease Model required around 12 months
development time; however, it should be recognised that the authors had considerable previous
experience in developing models of colorectal cancer interventions.
Risks and benefits of pathway modelling
The idea of building a model of the full patient pathway to serve as a foundation for economic evaluation
in NICE guidelines is attractive.
In an ideal world, we could develop a single model for a whole disease pathway from diagnosis,
incorporating all the different decision points along the way. Looking at a condition in this holistic
manner would help to ensure the whole care pathway recommended in the guideline represents the
most cost-effective use of resources.35
A full guideline model has the potential to provide a coherent framework for economic evaluation of a
wide range of decision problems within a guideline, ensuring that all analyses are based on a common set
of methods, assumptions and data sources. In addition to straightforward comparisons of alternative
interventions at an individual node in the pathway, a full guideline model could be used to look at the
sequencing of interventions, and also to explore interactions between interventions across different parts
of the pathway. Once developed, a full guideline model could be reused to consider other related
questions or to incorporate new evidence.
However, this is an ambitious vision. There are technical and practical barriers to the creation of the type
of large and complex model that would be needed to cover the wide scope of most NICE guidelines. The
general advice in modelling is that simplicity is an advantage, and that the model structure should be as
simple as possible while addressing the decision problem and reflecting the nature of the disease and the
health-care context.43 There are certainly potential disadvantages with complex models, as they are likely
to be more prone to verification (programming) errors, more difficult to validate, and more difficult to
explain to decision-makers than simple models. However, it should also be recognised that ‘more complex
areas require models that respect complexity’.50 Thus, full guideline models might need to be complex to
properly reflect the complexity of guideline pathways. This depends, though, on the extent to which the
real-life pathway is interconnected, such that health outcomes and costs in one part of the pathway
depend on what happens in another part of the pathway. If the pathway can be segmented, without too
serious a loss of realism, it might be safer and more efficient to build several smaller models rather than toJournals Library www.journalslibrary.nihr.ac.uk
to incorporate coronary angioplasty, which would have doubled this number.45 DES has some technical
advantages in such cases, since DES can model individual patients and therefore enable them to carry
information about their characteristics and history. This can enable a more compact representation of a
heterogeneous mix of patients and complex sequences of decisions and chance events. Thus, the simplicity
view, or it
DG time is
structure
and data inputs, and in interrogating and interpreting its results, the model will not have credibility and
will not influence GDG decisions.10 Similarly, the ability of external stakeholders to understand and critique
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58the findings might be compromised if modelling methods are too complicated.
The balance between these possible advantages and disadvantages of full guideline modelling is unknown.
There is limited evidence to assess whether or not this approach is feasible, given the practical constraints
of resources and timelines for NICE guidelines. It is also uncertain whether or not the investment will
succeed in delivering greater availability or coherence of cost-effectiveness evidence to support guideline
recommendations. However, it is certainly plausible that once a full guideline model is developed, it could
provide significantly greater insight and ongoing support for decision-making across CG updates and
related TAs.
The Modelling Algorithm Pathways in Guidelines project
Aims and objectives
The motivation for the Modelling Algorithm Pathways in Guidelines (MAPGuide) project was to test the
feasibility and potential usefulness of modelling entire care pathways for NICE CGs. These models are
hereafter referred to as ‘full guideline models’. The aims set for the study were:
l to investigate the feasibility of modelling pathways recommended in NICE CGs to estimate associated
patient flows, health outcomes and costs
l to illustrate how such models can be used as a basis for assessing the incremental cost-effectiveness of
possible variations in the care pathway
l to use this approach to estimate the value of updating selected topics within the guidelines
l to compare the update priorities obtained from formal modelling with those elicited during the routine
NICE guideline review process.
In order to achieve these aims, we set six key objectives (Box 5).guideline decision-making. For example, it might help to define the key clinical questions for re
might help the GDG to put this evidence into context. However, there are potential dangers. G
limited, and unless they can be seriously engaged with understanding and defining the modelof a model is a function of the size of the decision problem rather than the modelling technique.50
Similarly, it is sometimes said that data requirements are greater for complex models compared with
simple models,50 or for individual-level simulations than for aggregate models.52 However, this is not
necessarily true, as data requirements relate more to the size of the modelled problem than to the model
structure or technique. For example, the parallel DES and Markov models of adjuvant therapy for early
breast cancer mentioned above needed similar data inputs.51 Although collapsing the number of health
states may create a simpler model structure, it is still necessary to estimate weighted means for the
transition probabilities, costs and health outcomes for the new combined states.
In addition to these technical issues, there may be wider implications of adopting a more holistic approach
to modelling in NICE guidelines. On the positive side, it is possible that the more analytic approach to
mapping out the pathway, that would be required from the outset, could improve evidence collection or11
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BOX 5 Project objectives
BACKGROUND
12Background to the project
The project was funded by the Medical Research Council (MRC) and the National Institute for Health
Research (NIHR) under their Methodology Research Programme call for research to underpin NICE
decision-making. This scheme was intended to fund research into methodological questions of direct
relevance to NICE, and followed a scoping study to identify and prioritise topics. One of the highlighted
topics was ‘assessing the cost effectiveness of “long” or complex diagnostic/treatment pathways’.53
Projects were expected to be completed within 2 years, to provide rapid feedback to inform policy.
The MAPGuide research team included NICE and NCC staff, as well as academic health economists and
simulation modellers. The team has expertise in guideline methodology and systematic reviewing (PA and
MW), economic evaluation (MTB, JL, IM, AM, FR, PT, SW and DW), and simulation modelling (AA, JE, PT
and ST). Members of the team also have experience of working in the NICE CGs programme in various
capacities: as technical members of GDGs (JL, IM, AM, MW, SW and DW); as senior NCC staff supervising
the work of technical teams (MW and DW); and as members of the internal NICE guidelines team
advising on methodology (PA, JL and FR). The team also has experience of working on NICE TAs
(JL, AM and PT).
The project consisted of three main strands of research, which were led by different teams of researchers.
Identification of the potential update topics and the survey of stakeholders were led by CC and MW with
advice from other members of the project team who were not directly involved with the modelling.
Development and application of the simulation models were led by two teams of researchers. The prostate
cancer modelling team was based in the London School of Hygiene and Tropical Medicine (SW and AM) in
collaboration with the School of Health and Related Research within the University of Sheffield (PT). The
AF modelling team was based at Brunel University (JE, MTB, AA and JL). A Project Management
Committee comprising all collaborators and researchers met regularly and oversaw the work.1. Select two NICE guidelines to serve as illustrative examples.
2. Collate suggestions for topics that could be included in future updates of the guidelines from review
documents published on the NICE website.
3. Ask stakeholders for each guideline to rate the suggested topics in terms of priority for inclusion in an update.
4. For each guideline, build a simulation model of the current recommended pathway.
5. Adapt the models to estimate the cost-effectiveness of possible changes to pathways related to the
possible update topics.
6. Feedback the results from step 5 to the people consulted in step 3, and invite them to reassess their ratings
of priorities for update.Rationale for the study design
Two NICE guidelines were selected as case studies to test the feasibility of the full guideline modelling
approach. The guidelines were chosen using pre-defined criteria, which included the existence of a
relatively well-formulated clinical pathway that we believed to be a pre-requisite for full guideline
modelling. The study therefore represented an attempt at a ‘proof of concept’ that the full guideline
model approach could work for selected NICE guidelines, rather than a test of whether or not it would
work for all NICE guidelines.
The idea of using two case studies, rather than one, was to test whether or not the full pathway modelling
approach could work for different types of guidelines and to explore whether or not different modelling
teams would adopt different modelling approaches. The models were developed by the two teams of
analysts who worked separately, but came together to discuss technical and practical issues.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
When designing the project, the research team was conscious of the challenging deadlines and resource
n a standard
NICE guideline: 9 months of analyst time over a period of 18 months for each guideline.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58The two case studies were chosen from a list of published guidelines due for 3-year review by NICE to
determine whether or not they should be updated. This was intended to provide a convenient opportunity
to elicit some questions about possible variations to the pathways in the published guidelines that might
potentially be included in a future update of the guidelines. These potential update topics were meant to
provide a test for the modellers to assess whether or not they could adapt their baseline models to address
some real cost-effectiveness questions.
We also conducted a survey of stakeholders to elicit their opinions about the relative importance of the
potential update topics. This was intended to provide a comparison for the model results, to assess
whether or not they might add value to current methods for selecting update topics. Our original plan was
to report a summary of the model methods and results to the stakeholders in a second round survey, and
to ask for them if these results would have changed their prioritisation of the topics (objective 6;
see Box 5). However, in the event we were not able to complete this final step of the research plan. This
was because development of the models took longer than we had anticipated, and the NCCs started to
update the two guidelines that we had chosen as case studies earlier than initially scheduled. This meant
that by the time that we had obtained results from the models the development process for updating the
two guidelines was already under way. Conducting a second survey at this time could have been disruptive
for the NCC and NICE, as stakeholders might have confused our research findings with outputs from the
real update. We therefore abandoned the second rounds of the stakeholder surveys. Instead, we simply
compared the relative importance attached to the selected potential update topics by stakeholders in our
first round survey with the implied importance of these topics based on the results of the model analyses.
The separation of the team identifying potential update topics and conducting the stakeholder surveys
from the two modelling teams was intended to avoid bias. The modelling teams did not influence the
choice of potential update topics, and were not told what topics had been chosen until after the design of
their baseline model had been agreed. This prevented knowledge of the topics influencing the modellers’
decisions about the model design, to provide a more robust test of the flexibility of the models to address
a range of topics.
Structure of the report
The next chapter provides an overview of the study design and methods. Detailed methods and results for
the three main strands of work are reported in the following chapters:
Chapter 3, Stakeholder surveys The identification of potential update topics and the surveys
of stakeholders.
Chapter 4, Case study 1: full guideline model for prostate cancer Development of the baseline
simulation model and use of the model to investigate possible update topics for our first case study of
prostate cancer.using the models were similar in magnitude to those available to NCCs for health economics iconstraints of ‘live’ guideline development. The team was also aware that elicitation of an agreed pathway
at the beginning of guideline development has proved difficult in the past – topics are usually referred to
NICE precisely because there is high uncertainty or disagreement about what is, or should be, standard
practice. It was thought to be too risky to test the approach within the real guideline development
process. The team therefore decided to first test the feasibility of applying the full pathway modelling
approach to two published NICE guidelines. This meant that we started with relatively well-articulated
pathways and existing reviews of evidence, which provided a baseline for modelling. If this did not work,
attempts to develop such models for new NICE guidelines would be unlikely to succeed. However, to
provide a realistic test of the logistics of full pathway modelling, the resources available for developing and13
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Chapter 5, Case study 2: full guideline model for atrial fibrillation Model development and analysis for our
second case study of AF.
In the discussion (see Chapter 6) the findings across the three strands of research are summarised. We also
discuss the strengths and limitations of the study, highlight implications for modelling in NICE guidelines
and make research recommendations.
BACKGROUND
14NIHR Journals Library www.journalslibrary.nihr.ac.uk
We selected two published NICE guidelines as case studies to test whether or not the full guideline
existence of a relatively well-formulated pathway in the current guideline
lue in a real
update of the guidelines
l guidelines for different patient groups or disease areas, likely to present different challenges for
endix 2),
and chose the following case studies.
otential for
modelling. After consultation with the NCC-C and a clinical expert, it appeared that an update was likely.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Surveys were conducted with registered stakeholders for the two guidelines to elicit their opinions about
the importance of the selected potential update topics. Participants were presented with a short summary
of the potential topics and then asked to rate each in terms of importance (using a Likert scale), and also
to rank them in order of priority for inclusion in a future update of the guideline. Results were summarisedStakeholder surveysAtrial fibrillation (CG36)55
Developed by the National Collaborating Centre for Chronic Conditions (NCCCC) (now the NCGC), this
guideline was published in 2006. This guideline also had a clear pathway, with strong potential for
modelling. The NCGC reported that there was a fair likelihood that the guideline would be updated.
Identification of potential update topics
The review decisions for the prostate cancer and AF guidelines were published on the NICE website in
July 2011 and December 2011 respectively. One researcher (CC) read the review decision and related
documents, and collated a list of topics that had been suggested for inclusion in a future update. This list
was checked by a second researcher (MW), who is very experienced in systematic reviewing and guideline
development. A shortlist of topics for inclusion in the stakeholder surveys and for modelling was agreed by
members of the research team who were not involved in developing the models.project team that this guideline has a reasonably clear, well mapped-out pathway with good pProstate cancer (CG58)54
This guideline was developed by the NCC-C, and published in February 2008. It was agreed among theThe project management committee discussed the options in relation to these criteria (see Appthe modellers
l the presence of uncertainty or controversy over which topics should be updated.l important topics likely to be updated, so that the models would be likely to have future vamodelling approach could work. In order to allow sufficient time for modelling within the 2-year study
period, we considered guidelines due for an update decision by NICE between January and September
2011. This resulted in a list of 17 guidelines that we could have chosen for case studies (see Appendix 2).
The criteria for selection of the case studies defined in our project proposal (see Appendix 1) were:
lSelection of case studiesChapter 2 Overview of methods
This chapter sets out an overview of the methods used in the study.15
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in the form of simple descriptive statistics and graphs. The survey methods and results are described in
detail in Chapter 3.
Model development
Defining the scope and boundary of the base-case models
The research team had to agree some general principles to define the scope and boundaries for the
base-case models (Box 6). These principles were chosen to ensure that the base-case models
would provide suitable foundations for assessing the cost-effectiveness of possible changes to the
guideline recommendations.
Model design
The modelling teams began the process of model design with some background reading to familiarise
themselves with their guideline and current issues in the field. They carefully reviewed the published
guideline documentation, including the Full Guideline and the Quick Reference Guide (QRG). They also
conducted rapid searches to identify other related guidance and key sources of information about their
topic. This included NICE guidance and HTA reports, published economic evaluations, guidelines from
other national or international bodies, and Cochrane reviews. Ideas for potential model structures and
sources of data were identified from these sources.
Model design broadly followed the phases of ‘problem-oriented’ and ‘design-oriented’ conceptual
is.
ropriate.
BPH, benign prostatic hyperplasia.
OVERVIEW OF METHODS
167. The starting cohort should reflect a realistic mix of characteristics for patients entering the care p
8. The NICE reference case for economic evaluations should be followed.36
9. Uncertainty over model parameters should be incorporated through probabilistic sensitivity analys
Deterministic sensitivity analysis should be used to explore key structural uncertainties, where appmodelling:57,58 starting with the development of an understanding and description of the relevant health
services and disease processes; and followed with the specification of a structure for the applied simulation
model and the required information. In practice, there was some iteration between these phases.
Two problem-oriented models were developed in each case study:
l A service pathway model, which details the recommended sequence of tests and treatments defined
in the guideline. It shows the health services that patients would receive conditional on their
characteristics, if the guideline were to be fully implemented.
BOX 6 Principles for defining base-case models
1. Follow the same scope as for the published guideline. This defines which patient groups, interventions and
comparators are to be included or excluded from the model.
2. Reflect as far as possible the pathways recommended in the current guideline, rather than actual practice
in the health service, which might vary.
3. Current NICE TA recommendations within the scope of the guideline should be incorporated in full.
4. Pathways for other related NICE guidelines should not be modelled explicitly. For example, in modelling
the NICE prostate cancer guideline we decided not to attempt to cover the diagnosis and treatment of
BPH, which is addressed in another NICE guideline.56
5. Model parameters should be derived from evidence from the original guideline, or from more recent
sources identified by rapid reviews or expert advice.
6. Costs and health outcomes should be estimated for an incident cohort of patients over a lifetime horizon.
athway.NIHR Journals Library www.journalslibrary.nihr.ac.uk
l A disease process model, which details how patients’ health status or risk of events changes over time,
conditional on their characteristics and the health services that they receive. This provides the
The service pathway models were developed following detailed examination of the guideline documents,
In addition, to reflect patient heterogeneity, estimates of relationships between the above parameters
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subgroups or continuous covariates. The characteristics included sociodemographic factors (age and sex),
clinical factors (stage or severity of disease), and history (existing comorbidities or treatments received).
Model parameters were estimated from a variety of sources, obtained from information available in the
original guideline, supplemented with new evidence identified from rapid reviews of the literature or from
expert opinion. We sought to use the best available sources of evidence, but could not conduct our own
systematic reviews, as this was beyond the scope of this project. Where possible, we relied on reviews
from the NICE guideline, or from recent high-quality systematic reviews as the source of effectiveness
evidence (e.g. Cochrane reviews, HTA reports, or assessment reports for NICE TAs). However, it is
important to note that the results presented below are not all based on full systematic reviews and that
they have not been informed by an expert CG group. They are intended to be indicative of priorities for
full evaluation in a guideline update, and should not be used to inform clinical decisions.
Model implementation
The full guideline models were implemented using a DES technique that represented individual patients as
entities.59 This provided a flexible and relatively compact format for mapping the complicated guideline
pathways and predicting outcomes for heterogeneous patient populations.and were then checked with clinical experts. To support modelling, the flow charts representing the
pathway had to be much more detailed than the ‘algorithms’ in the QRG version of the guidelines. Some
of the ambiguities and discontinuities in the QRG algorithms could be resolved by examination of the
precise wording of recommendations, and other text in the full guideline document (particularly the ‘from
evidence to recommendations’ sections). The modelling teams resolved remaining uncertainties through
discussion with clinical experts.
The disease process models were developed in parallel with the service pathway models. They were
designed following review of related published models, descriptions of disease epidemiology (aetiology,
progression and prognosis) from the guideline and other background documents, review of outcome
measures in the clinical effectiveness data, and discussions with clinical experts. An important factor in
finalising the structure of the outcomes models was data availability: including information about baseline
risks, treatment effects and quality of life.
Data identification and selection
Parameters required for the models included:
l disease epidemiology (incidence and prevalence of the condition, risks of adverse events, rates of
disease progression, and mortality rates)
l diagnostic accuracy (e.g. sensitivity and specificity) for any tests in the pathway (including tests used for
‘screening’, ‘identification’, ‘diagnosis’, ‘staging’, ‘assessment’, and ‘monitoring’)
l clinical effectiveness of any treatments included in the pathway
l quality-of-life (utility) impact of disease states, events, and treatment side effects
l costs of tests, treatments and ongoing care.underlying ‘engine’ that drives patients through the clinical pathway, and is determined by a theory of
the natural history of the disease and the way in which treatment effects are expected to interact with
that natural history.17
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The models begin with a cohort of patients (the simulation ‘entities’) with a defined set of personal
oston, MA,
asier
rimentation
support and has the ability to publish models on the internet. It has also been used within the NHS, as part
of a public private partnership arrangement between the software developer (SIMUL8 Corporation) and
els was
reviewed by an experienced modeller with expertise in DES, who worked with the teams to ensure that
OVERVIEW OF METHODS
18any identified errors or inconsistencies were corrected.
Cost-effectiveness analysis
Calculation of base-case results
In the base-case model, health effects (QALYs) and the costs of interventions and disease-related care were
accumulated for simulated individuals (and whole cohorts) as they progressed through the pathway and
disease states, until death. To account for time preference, costs and health outcomes were discounted to
the point of model entry, using a continuous discounting approach.63 The results of a defined pathway
for each simulated patient i were therefore collected as discounted lifetime sums of costs Ci and effects
Ei (QALYs).
In analysing the results of individual-level (micro-simulation) models it is essential to take account of three
ways in which model outputs can vary:64
l Patient heterogeneity, which reflects how model outputs differ across individuals with different
characteristics. Within the population of interest (patients entering the pathway), there is a joint
probability distribution over some set of initial attributes X which are functionally related in the model
to the outputs Y = (C,E).
l Parameter uncertainty (‘second-order uncertainty’) results from uncertainty over values of model input
parameters arising from inevitably imperfect knowledge. This uncertainty is represented through a jointexample, that survival times and levels of service use are realistic). In addition, each of the modthe NHS Institute for Innovation and Improvement.62
Verification and validation
The modelling teams checked for errors and inconsistencies throughout model development, following
best practice for quality assuring simulation59 and decision-analytic models.22–24 The models were verified
internally (to ensure correct programming) and validated (to ensure consistency with expected results – forThe models were programmed using SIMUL8 Professional version 15.0 (SIMUL8 Corporation, B
USA), a dedicated DES package. This was selected as it is generally considered as one of the e
simulation packages to learn, while providing appropriate modelling complexity, excellent expecharacteristics (‘attributes’) at the point of entry to the pathway. The models then follow patients through
the care pathway, applying specified rules which dictate the route that patients take as a function of their
attributes. These rules may be deterministic (e.g. patients aged < 60 years receive treatment A, those
aged ≥ 60 years receive treatment B) or probabilistic (e.g. 40% of patients receive treatment A, 60%
treatment B). For the latter, probability parameters are combined with Monte Carlo (random) sampling to
determine the patient’s route through each part of the model. The times to key events (e.g. disease
progression, onset of complications or mortality) are sampled for each individual at model entry, and
modified as patients progress through the pathway and receive treatments, or if they experience other
events. Time-to-event estimates are based on Monte Carlo sampling from survival functions (Weibull,
exponential, etc.) fitted to reflect the individual’s risk.60 When sampling time-to-event values, care is
needed to account for ‘competing risks’: where one, and only one, of a mutually exclusive set of events
can occur.61 Care is also needed to appropriately modify time-to-event estimates when things change, for
example when someone with AF starts anticoagulation treatment their risk of thromboembolism (TE) falls
and the time to event rises. Individuals’ attributes are also updated over time, as they receive different
types of health-care intervention and as they experience key events, as defined by the conceptual models.NIHR Journals Library www.journalslibrary.nihr.ac.uk
nd/or
changes to the model inputs. The alternative versions of the model were run separately, and the results
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individual patient samples and population parameter values that did not differ between the strategies were
held constant for each probabilistic iteration j.
Modification of base-case model for update topics
As described above, members of the research team not involved in the modelling drew up a shortlist of
topics for each model. The shortlisted topics each related to some possible changes to the current
pathway, including:
l substitution of different tests or treatments at given points in the pathway
l changes to patient eligibility criteria or thresholds for tests or treatments
l different sequencing of tests or treatments and/or
l addition of tests or treatments as an extra step in the pathway.
In addition to the list of topics, sources of new evidence that might support changes to the guideline
pathway were identified from the review documents.
After development of the base-case version of their models, the modelling teams were given the short list
of topics and summary of related new evidence. The modelling teams then attempted to modify their
model to represent alternative recommendations that might possibly result from an update of each topic.
The modifications ranged from simple changes to input parameters, to minor rewriting of sections of code.
We did not attempt any substantial structural changes to the code. Where necessary, we sought additional
evidence to support CEA of the topics. As noted above, it was not possible to conduct systematic reviews
within the constraints of this project, as this would have required the methodological and subject expertise
of the full guideline development process, and our intention was to investigate and illustrate modelling
methods, rather than to derive recommendations for clinical practice. The results presented are indicative
of the potential value of updating aspects of a guideline, based on the level of reviewing and consultation
currently used by NICE and the NCCs when reviewing guidelines for update.alternative strategies. Each strategy consisted of one or more changes to the service pathway aprobability density function over some set of input parameters B which are related through the model
to the outputs Y.
l Stochastic uncertainty (‘first-order uncertainty’) reflects how outputs for individuals can vary in the
model due to chance. This arises because of the stochastic (Monte Carlo) sampling of events and
outcomes for individuals. Thus, results may differ for two individuals with identical starting attributes Xi
and a given set of input parameters Bj.
We conducted a probabilistic analysis65,66 of our models to estimate the expected cost
_
C and effect
_
E
across a representative but heterogeneous population of patients treated according to the defined
pathways, and to estimate the uncertainty around these outputs. This required a nested iteration to
integrate over both stochastic and parameter levels of uncertainty: an outer probabilistic sensitivity analysis
loop where N sets of input parameters were drawn (Bj, j = 1,2, . . . , N); and an inner individual-level loop
where, for each set of input parameters, n sets of patient characteristics were drawn (Xi, i = 1,2, . . . , n),
and the model was run to calculate the results for each patient (Yi,j = f(Bj,Xi) + εi). Results were averaged
across the individual-level iterations
–
Y j ¼ Σni¼1Yi,j, and the distribution of the
–
Y j ( j = 1,2, . . . , N) used to
estimate overall mean results ð –Y ¼ ΣNj¼1
–
Y jÞ and to characterise uncertainty around these results. The choice
of the number of probabilistic iterations (N) and the number of individual patients per iteration (n) was
made through experimentation: by gradually increasing n until the
–
Y j were stable, and then gradually
increasing N until
–
Y was stable.
The above process describes how results were derived for one defined pathway [starting with the
modelled version of the current guideline recommendations (the ‘base-case pathway’)]. To use the models
to conduct cost-effectiveness analysis (CEA), the simulation model was then adapted to reflect a range of19
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le. This is an
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20indication of the appropriateness of the scope and depth of the models, and how easily they can be
adapted to answer cost-effectiveness questions.Our first method for assessing the usefulness of the full guideline models was to consider the
of the shortlisted topics that the modelling teams managed to address within the time availabEach set of mutually exclusive options was compared within a full incremental analysis either in terms of
ICERs, or using an incremental net benefit (INB) approach. For the ICER analyses, options that were subject to
simple or extended dominance were ruled out of the analysis, and ICERs calculated for each remaining option:
ICERk,k−1 ¼ ð–Ck− –Ck−1Þ/ð –Ek− –Ek−1Þ ð1Þ
where
–
Ek and
–
Ck are the expected health outcomes (QALYs) and costs under strategies k; and
–
Ek−1
and
–
Ck−1 are the expected health outcomes and costs, respectively, under the next most expensive
non-dominated strategy. Results were compared against a cost-effectiveness threshold (λ), which was
set to the more conservative, lower limit of the range that NICE suggests to its advisory bodies: £20,000
per QALY. The strategy with the highest ICER below the threshold of λ represents the most
cost-effective option.
For some analyses an equivalent INB approach was more convenient (particularly where there were a large
number of strategies to compare). The INB is defined as:
INBk,b ¼ λð –Ek− –EbÞ−ð –Ck− –CbÞ ð2Þ
In this case, each strategy (k) is compared against the base-case strategy (b). A positive INB result suggests
that pathway k is more cost-effective than the base-case pathway b (at the NICE conservative threshold of
£20,000 per QALY). The strategy with the largest INB is the most cost-effective of the strategies tested.
The probabilistic results were used to provide an estimate of decision certainty for each comparative
result. We calculated the proportion of probabilistic iterations for which the INB statistic was positive,
p(INBk,b > 0). This is an estimate of the probability that pathway k is more cost-effective than pathway b.
As the analyses were not based on systematic reviews or GDG input, we did not fully characterise the
uncertainty surrounding the cost-effectiveness estimates. The results should therefore be seen as
preliminary estimates intended to inform a decision about updating the topic, and should not be used to
reach definitive conclusions. In addition to this incremental comparison of alternative strategies within each
topic, we also sought to compare combinations of strategies between topics to investigate whether or not
there were interactions between them. We had originally intended to also present ‘value of information’
(VOI) estimates [e.g. expected value of perfect information (EVPI)], as another indication of the potential
gains that might be obtained by updating a topic. However, on reflection we decided that these would
not provide an appropriate measure of priority for updating. For example, a potential change in
recommendation with a high estimated INB associated with little uncertainty would have a low EVPI, but
would still be an important inclusion in a guideline update. There would also be little to gain from
updating a topic associated with high uncertainty (and a high EVPI) unless there was a reasonable
expectation that the uncertainty could be resolved by further reviewing and/or GDG discussion.
Usefulness of the full guideline models
proportionThe models were rerun for each pathway modification, and the same sets of (discounted lifeti
QALY results were accumulated as for the base-case model.The teams were asked to try to model all of the topics on their shortlist, but as time for the analysis was
limited they were invited to prioritise.
Incremental analysis
me) cost andNIHR Journals Library www.journalslibrary.nihr.ac.uk
Second, we compared the results of the modelling exercise with the survey respondents’ stated priorities
over the importance of the shortlisted topics for inclusion in an update. The modelling teams made
judgements about the relative ‘economic priority’ of the modelled topics on the basis of two key sets of
information: (i) the estimated probabilities that the current guideline recommendations are suboptimal,
p(INBk,b > 0) for some k; and (ii) the estimated size of potential gain in NB from the alternative strategies
tested, MAX(INBk,b) for all k over a defined population (standardised at 1000 incident cases in this report).
A third method for assessing the potential usefulness of the complex full guideline models was to search
for evidence of interactions between the cost-effectiveness of strategies across topics. This would suggest
that there are systemic effects that would not be captured by a conventional piecewise analysis of
isolated topics.
A final, pragmatic test for the usefulness of the models is whether or not the collaborating centres and
GDGs now working on updates of the two guidelines choose to make use of them. During the course of
the project both modelling teams have had discussions with the health economists working on the
guideline updates, and agreed to make the models available to them.
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two NICE
CGs (AF and prostate cancer) to determine their opinions on topics that may potentially be updated within
gested topics
Initially, two surveys were planned: the first of which would be administered before the modelling process
Ethical approval
ased at
Brunel University and the London School of Hygiene and Tropical Medicine. Approval from an NHS ethics
committee was not necessary as the participants were not identified on the basis of their status as NHS
Potential update topics for the surveys were identified by one researcher (CC) after review of the following
l NICE’s review proposal and any related consultation documents
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58l the table of stakeholder consultation comments and responses
l NICE’s final review decision and any supporting documentation.
From these documents lists of possible update topics and new evidence relating to those topics were
compiled for each guideline. These topics were defined at the level of ‘key clinical issues’:documents, obtained from the NICE website:patients or staff, and no research was conducted on NHS premises.
Identification of potential update topicsEthical approval was applied for and received from the university research ethics committees bin order to elicit opinions on some potential update topics to the guideline, whereas the second survey
would be administered after the modelling process to determine whether or not respondents’ views
changed in response to feedback about the model results. However, in the event only one survey was
carried out, as the models were not completed before NICE and the NCCs began the guideline update
process; to continue by sending out a second survey may have caused confusion and so this was
abandoned. Instead, estimates of the cost-effectiveness of potential changes to the pathway associated
with update topics were obtained from the models, and compared with the stated priorities of
stakeholders about the relative importance of updating topics.
As the aim of the surveys was to test the usefulness of the modelling, they were conducted by a
researcher (CC) from Brunel University who was not involved in the model development process. Advice
and guidance regarding identification of topics and survey development was received from an experienced
systematic reviewer and guideline developer at the NCGC (MW).
MethodsThe aim of the survey was to elicit experts’ views about the importance of including some sug
in an update of the CGs [prostate cancer (CG58)54 and AF (CG36)55].those guidelines.
Aims and objectivesAs part of the MAPGuide study, we conducted an online survey of registered stakeholders forChapter 3 Stakeholder surveys
This chapter explains how the case studies and update topics were chosen and describes the surveys ofstakeholder priorities.
Introduction23
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NIHRquestionnaire was compiled using an online commercial survey tool, SurveyMonkey (SurveyMonkey®
d, SurveyMonkey, Palo Alto, CA, USA; www.surveymonkey.com). The survey invited participants to rate
relative importance of including each topic in a potential future update of the guideline, using a Likert
e with five options ranging from ‘not important’ to ‘very important’ with an option to choose ‘no
ion’. Participants were also asked to rank the suggested topics in order of preference for inclusion in
pdate. Free-text comment boxes were added to seek qualitative information and reasons for
onses. Online links to information sheets were provided. These were developed by the surveyKey clinical issues relate to the effectiveness and cost effectiveness of interventions or tests that are
being considered for a given population. These issues should be developed out of a care pathway or a
similar analytical framework. They are not the same as review questions, which specify in some detail
the particular interventions to be compared and the health outcomes of interest . . . Nevertheless, key
clinical issues should be as specific as possible, indicating the relevant population and the alternative
strategies that are being considered.
Chapter 2 p. 22; The Guidelines Manual, 200929
A second researcher (MW) reviewed the list and both researchers then used the following criteria to derive
a shortlist of topics:
l all update topics specified in NICE’s review decision
l topics which had substantive support from stakeholders and other experts.
To avoid overburdening respondents, it was also decided by the researchers undertaking the survey that
the maximum number of topics for each survey would be 10.
Regarding the choice of which topics to include in the shortlist, if both researchers were in agreement,
this topic was included. If there was uncertainty over a topic’s inclusion, both researchers reviewed
the evidence for that topic to determine if there was sufficient information about the update topic to
warrant its inclusion, if not it was excluded. To limit the number of topics, some were also excluded if it
was deemed the other topics may have more impact on the guideline pathway or had more
stakeholder support.
A number of topics were excluded from the prostate cancer survey shortlist including a topic regarding
the addition of guidance for the use of an 18F-choline positron emission tomography computerised
tomography (CT) scan for diagnosis of recurrent disease after radical prostatectomy or radiation therapy.
This was recommended in the guideline as an option for patients with biochemical recurrence after
negative magnetic resonance imaging (MRI) and bone scans. This topic was excluded as there were limited
papers available to confirm its importance as an update topic. Another topic that was excluded was that
pertaining to the use of docetaxel as a first-line treatment option for men with hormone-refractory
prostate cancer. This particular drug was already included as a recommendation within the current
guideline, and a review of the TA of the drug has been postponed until 2013. It was decided to exclude
this topic as it is already recommended within its licensed indication within the guideline and these criteria
could not be amended.
A number of topics were also excluded from the shortlist for the AF survey, including the introduction of a
nationwide opportunistic screening programme by integrating manual pulse checks as part of national
screening flu programmes or chronic disease management. This was excluded as it was deemed to be
outside the current scope of the guideline.
The final topics included in the surveys were agreed on by the MAPGuide project management committee
members who were not involved in the modelling process. Potential update topics chosen for the prostate
cancer survey (nine topics) and for the AF survey (eight topics) are listed in Boxes 7 and 8.
Survey developmentJournals Library www.journalslibrary.nihr.ac.uk
BOX 7 Potential update topics for prostate cancer guideline
cancer.
E Degarelix (Firmagon , Ferring) (a LHRH antagonist) for men with advanced hormone-dependent prostate
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58cancer (locally advanced or metastatic).
F Intermittent hormone therapy vs. continuous hormone therapy for men with metastatic prostate cancer.
G Radium-223 chloride versus strontium-89 for men with hormone-refractory prostate cancer and painful
bone metastases.D LDR in addition to external beam radiotherapy for men with localised or locally advanced prostate
®A Pelvic radiotherapy with adjuvant hormonal therapy for men with localised prostate cancer.
B Effective techniques for performing radical prostatectomy.
C HDR in addition to external beam radiotherapy for men with localised or locally advanced prostate cancer.researcher (CC) and provided details of the original guideline recommendation and the section of the
clinical pathway on which the update topic would have an impact, and specific details of the proposed
update topic (new evidence on the topic and comments from stakeholders) which were taken from the
guideline review documents.
Pilot study
A pilot study was conducted to test the adequacy and suitability of the survey. The sample for the pilot
was drawn from outside the survey sample. The pilot sample consisted of contacts of the Project
Management Committee from other related GDGs and clinicians with an interest in the relevant guideline.
The pilot sample for each study consisted of three clinicians who were contacts of the Project
Management Committee.
H IMRT and IGRT as an alternative to conventional therapy for men undergoing radiation treatment.
I AS in previously unscreened ‘low-risk’ men.
AS, active surveillance; HDR, high-dose-rate brachytherapy; IGRT, image-guided radiation therapy;
IMRT, intensity-modulated radiation therapy; LDR, low-dose-rate brachytherapy; LHRH, luteinising
hormone-releasing hormone.
BOX 8 Potential update topics for AF guideline
A Prophylaxis for the prevention of post-operative AF.
B AADs as PCV for people with AF.
C Rhythm versus rate control strategies for persistent AF; updating eligibility of subgroups including those
with hypertension, previous MI and CHF.
D Treatment for maintaining sinus rhythm in people with AF after cardioversion. Alternative risk
factor-based scoring systems to estimate stroke and embolism risk.
E Stratification tools to assess bleeding risk before prescription of antithrombotic medication.
F Apixaban (Eliquis®, Bristol-Myers Squibb), rivaroxaban (Xarelto®, Bayer) or dabigatran etexilate (Pradaxa®,
Boehringer Ingelheim) (anticoagulants) versus warfarin as thromboprophylaxis for patients deemed at
moderate or high risk of stroke or systemic embolism.
G Catheter ablation for paroxysmal and persistent AF.
AAD, antiarrhythmic drug; CHF, congestive heart failure; PCV, pharmacological cardioversion.
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An internal pilot was also carried within the Health Economics Research Group based at Brunel University
s, ex-GDG
in the
The following numbers of registered stakeholders, GDG members and NCC staff were invited to
The list of stakeholders included a wide range of individuals affiliated with organisations with an interest in
cer survey
giving a response rate of 19% for AF and 14% for prostate cancer. The response rate was expected to be
STAKEHOLDER SURVEYS
26similar to the number of stakeholders that responded to NICE’s call for comments from registered
stakeholders on the review consultation document for both guidelines which listed potential topics that
may either be updated or added to both guidelines (21 stakeholder organisations provided comments on
the review consultation document for the AF guideline and 27 stakeholder organisations provided
comments on the review consultation document for the prostate cancer guideline, a response rate of 13%
and 14% respectively).Thirty-two persons responded to the AF survey and 27 persons responded to the prostate canboth guideline topics, including: patient organisations, specialist societies (doctors, nurses and other
professions allied to medicine), industry, and other health service organisations.
As the registered stakeholder list is held by NICE, it was not appropriate for the researcher to send an
invite to participate in the survey directly to the stakeholders. Therefore, an e-mail (prepared by the
researchers and approved by the ethical committee) inviting registered stakeholders to participate in the
research project was sent by the NICE Centre for Clinical Practice project manager, along with a Frequently
Asked Questions (FAQ) sheet providing further information about the study and a link to the online
questionnaire. The researcher contacted ex-GDG members, NCC staff and other experts named in the
guideline directly with an invite to participate in the study.
No reminders were sent to individuals who did not respond to the initial invitation to participate, as we did
not have direct access to the e-mail addresses of stakeholders.
Analysis of responses
Results from the survey were entered into SPSS 15.0.1.1 for Windows (IBM, Armonk, NY, USA), and
descriptive statistics including simple measures of central tendency (median) and frequency (distribution)
results were calculated. Qualitative data obtained from the additional comment fields in the surveys were
compiled and analysed for similar themes.
Results
Response rateparticipate in the surveys:
l prostate cancer guideline survey: registered stakeholders n = 225, GDG members n = 14 (total n = 239)
l AF guideline survey: registered stakeholders n = 168, GDG members n = 14 (total n = 182).The sample for the survey was drawn from the list of registered stakeholders for the guideline
members and NCC staff who contributed to the development of the guideline and are named
published guideline on the NICE website.to ensure that the survey would be suitable for lay-persons without clinical knowledge of either prostate
cancer or AF.
A small number of changes were made to the surveys after the pilot, including amendments of any
grammatical or spelling errors, some changes were made to the layout (for example enlargement of the
font size), but no changes were made regarding the chosen topics.
Survey of experts and elicitation of views about potential update topicsNIHR Journals Library www.journalslibrary.nihr.ac.uk
Missing data
Eighteen of the 27 respondents to the prostate cancer survey invite completed the survey and all 18
completed both questions. Seven respondents added a comment in the ‘additional comments and
information’ fields.
Not all persons who responded to the AF survey invite completed the survey. Twenty-five of the 33
respondents completed question one (rating question) and 23 of these 25 respondents also completed
question 2 (ranking question). Thirteen respondents added a comment in the ‘additional comments and
information’ fields.
Two respondents answered question 1 but not question 2; one of these respondents’ answers to the
rating question differed from the remainder of the sample. They were the only respondent to enter ‘no
opinion’ for all eight topics. The other respondent who did not complete question 2 rated three of the
topics (3, 4 and 5) as being somewhat important and rated the rest as important for question 1; this was a
similar response to those who completed both questions in the AF survey.
Organisational affiliation of respondents
Of the 25 respondents who completed the AF survey, 44% were affiliated to the health services sector,
20% to industry, 12% to charities, 8% to specialist societies and 16% to ‘other’ such as educational and
informational organisations. Of the 18 respondents who completed the prostate cancer survey, 50% were
affiliated to the health services sector, 17% to charities and patient-led societies, 17% to industry, 11% to
specialist clinical groups and 5% to ‘other’ such as educational and informational organisations.
Median responses
TABLE 1 Responses to prostate cancer survey
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Question 2: Rank in order of importance for inclusion in an update of the guideline: 1 most important to 9 leaD LDR in addition to external beam radiotherapy 4 4.5
E Degarelix for men with advanced hormone-dependent
prostate cancer
3.5 8
F Intermittent hormone therapy vs. continuous
hormone therapy
4 3
G Radium-223 chloride vs. strontium-89 3.5 8
H IMRT and IGRT as an alternative to
conventional radiotherapy
4 5
I AS in previously unscreened ‘low risk’ men 5 2.5
AS, active surveillance; HDR, high-dose-rate brachytherapy; IGRT, image-guided radiation therapy; IMRT,
intensity-modulated radiation therapy; LDR, low-dose-rate brachytherapy.
Question 1: Rate the importance of including the topic in an update of the guideline: 5 ‘very important’, 4 ‘important’,
3 ‘no opinion’, 2 ‘somewhat important’ and 1 ‘not important’.
st important.B Effective techniques for performing radical prostatectomy 5 2
C HDR in addition to external beam radiotherapy 4 4.5Topic Description
Question 1,
median rating (n = 18)
Question 2,
median rank (n = 18)
A Pelvic radiotherapy with adjuvant hormonal therapy 4 5The median results for question 1 (rating question) and question 2 (ranking question) are presented in
Tables 1 and 2 for the prostate cancer and AF surveys respectively.
Distributions of results
The frequency distributions of rating and ranking responses for each topic are shown in Appendix 3.27
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TABLE 2 Responses to AF Survey
Topic Description
Question 1,
median rating (n = 25)
Question 2,
median rank (n = 23)
A Prophylaxis for the prevention of post-operative AF 3 7
B AADs as PCV for people with AF 4 4
C Rhythm vs. rate control strategies for persistent AF 4 5
D Treatment for maintaining sinus rhythm in people with
AF after cardioversion
4 5
E Alternative risk factor based scoring systems to estimate
stroke and embolism risk
4 4
F Stratification tools to assess bleeding risk before
prescription of antithrombotic medication
5 3
STAKEHOLDER SURVEYS
28deemed the most important to update by respondents to both questions.Comparison of rating and ranking results
There were some differences in the overall results to the two questions (rating and ranking) regarding
which topics were perceived as the most important to update. Tables 3 and 4 display the three topics
G Apixaban, rivaroxaban or dabigatran etexilate
(anticoagulants) vs. warfarin
5 2
H Catheter ablation for paroxysmal and persistent AF 4 6
AAD, antiarrhythmic drug; PCV, pharmacological cardioversion.
Question 1: Rate the importance of including the topic in an update of the guideline: 5 ‘very important’, 4 ‘important’,
3 ‘no opinion’, 2 ‘somewhat important’ and 1 ‘not important’.
Question 2: Rank in order of importance for inclusion in an update of the guideline: 1 most important to 9 least important.The results also show that there is a similarity in the individual respondent’s answers to questions 1 and 2.
The prostate cancer survey had 18 respondents, and the results were analysed to determine if each
respondent’s three top rated topics for question one (rated on a Likert scale from not important to very
important) matched with their top three ranked topics for question 2. Eight respondents gave the same
response to both questions. For three respondents it was not possible to tell if the responses matched, as
their answer to the first question rated all the topics the same (either rated all as most important or as no
opinion). One respondent had ranked the topic they had rated the most important as second most
important to update, so there was a slight discrepancy between results, and they had rated all the other
topics as important so it was not possible to determine any correlation. Six respondents rated and ranked
the first two topics they deemed as the most important to update the same; however, they gave a
TABLE 3 Top three prostate cancer topics
Priority Question 1 (median rating) Question 2 (ranking)
1 AS in previously unscreened ‘low risk’ men AS in previously unscreened ‘low-risk’ men
2 Effective techniques for performing radical
prostatectomy
Effective techniques for performing radical prostatectomy
3 IMRT and IGRT as an alternative to conventional
radiotherapy for men undergoing radiation
therapy
Radium-223 chloride vs. strontium-89 for men with
hormone-refractory prostate cancer and painful
bone metastases
AS, active surveillance; IGRT, image-guided radiation therapy; IMRT, intensity-modulated radiation therapy.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 4 Top three AF topics
3 Alternative risk factor based scoring systems to Catheter ablation for paroxysmal and persistent
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58different response for the third topic, whereby a topic that may have been rated as either most important
or important to update may have been ranked the least important to update.
Of the 27 AF respondents who completed the survey, only 25 completed both questions. Therefore for
two respondents it was not possible to compare their rating and ranking scores. Of the 25 respondents
who completed both questions, 12 have similar responses for question one and question two (topics rated
most important were also ranked in the top three). Seven respondents had the same response for both the
ranking and rating questions for the first relevant topic but not for the remainder. It was not possible to
compare the score for two respondents as for question one they had rated all the topics the same (either
rated all as most important or as no opinion).
From analysing the data, it seems there may also have been confusion over the ranking of the topics – two
respondents may have perceived the ranking score (scale 1–8) as going from least important (1) to most
important (8) to update. This can be seen with the correlation of data whereby one respondent rated topic
H (catheter ablation for paroxysmal and persistent AF patients) as the ‘most important’ to update yet
ranked it last, and ranked the topic they deemed the least important as the first to be updated. Also,
similarly, the other respondent rated topic G [apixaban, rivaroxaban or dabigatran etexilate (anticoagulants)
vs. warfarin] as ‘most important’ to update yet ranked it as the least important (ranked number 8) topic to
update.
The difference between the overall top rated and ranked topics and the difference between individual’s
responses to questions one and two may be due to a number of similar factors; one being the number of
topics in the survey which may have meant that respondents may not have remembered what rating they
had given the topics when they went to rank the topics (there was a facility to toggle back and forward
between the survey questions, but this may not have been used). Another reason may be that respondents
hold strong opinions on one or two topics but not on all the topics so this could explain dissimilar rankings
after the respondent had chosen what they deemed to be the most important topic to update. With the
AF survey, there also seems to have been confusion over the direction of ranking scores. The Likert scale
asked respondents to rate topics on a scale ranging from ‘not important’ to ‘important’. However, the
estimate stroke and embolism risk AF patientsprescription of antithrombotic medication estimate stroke and embolism riskPriority Question 1 (rating) Question 2 (ranking)
1 Apixaban, rivaroxaban or dabigatran etexilate
(anticoagulants) vs. warfarin as thromboprophylaxis
Apixaban, rivaroxaban or dabigatran etexilate
(anticoagulants) vs. warfarin as thromboprophylaxis
2 Stratification tools to assess bleeding risk before Alternative risk factor based scoring systems toranking scale asked respondents to rank in order of preference on a scale of 1–8 (where 1 is most
important), rather than ranking in order of least preference similar to the Likert scale (where 1 is least
important). This could mean that future surveys that employ two different methods to elicit similar
information should ensure that both scales are analogous.
Qualitative data: comments from free-text boxes
The comments received from the respondents for the prostate cancer survey were analysed to determine if
they could be grouped into similar themes. However, each comment related to a different topic so it was
not possible to group the topics. Box 9 lists all the comments received from respondents to the prostate
cancer survey.
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BOX 9 Prostate cancer survey comments
There is no provision for updates; consideration of new advances, techniques; clinical data supporting
the use of HIFU as an alternative therapy for men who fall within known selection criteria.
Greater patient benefit from enhanced recovery programmes for prostate cancer, so still a mystery as to
why excluded!
Impact of long term hormonal therapy on bone health is an important item that is not being considered.
STAKEHOLDER SURVEYS
30There are a number of new drugs about to be licensed for the treatment of advanced or metastatic
prostate cancer. The current treatment pathways are unclear and will become more complicated with
the introduction of Abiraterone, cablitaxel and the desire to use these sequentially. Also there is patchy
adherence to current guidance as some patients are having re-exposure to Docetaxel. It would be
helpful to give some idea of the rationale for choosing chemotherapy and hormonal therapy and any
factors to be taken into consideration for sequential treatments.
The question concerning ‘effective techniques’ for performing radical prostatectomy MUST involve an
honest health economics review. In the absence of any clinically significant benefit for vastly more
expensive, commercially driven treatment modification argued for by eminent self interest groups, i.e.
robotic radical prostatectomy, these treatments must be ruled against unfavourably. The most pressing
question, I believe, concerns the safe advocacy of active surveillance in low-risk men.
HIFU, high-intensity-focused ultrasound.Comments received from respondents to the AF survey could be grouped under a number of similar
themes; two respondents called for the guidelines to be simple, two others referred to the use of the
stroke risk (SR) scheme and also called for clearer guidance on catheter ablation. Others were interested in
technology assessment for new drugs, whereas two others also mentioned the importance of screening
for AF. Box 10 displays the comments from the survey.
Discussion
The results indicate that most respondents agreed on the most important topic to update within each
guideline, although there were differences in priority attached to other topics. A major limitation to
achieving the initial objective of the survey was that we were unable to assess if respondents opinions
would change after viewing the modelling results. To evaluate the modelling, however, the results of the
first survey could still be used to compare the topics deemed important by the survey respondents and the
topics that the model analysis indicates are likely to be important.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
BOX 10 Atrial fibrillation survey comments
Please keep it simple.
Last document had complicated pathways – make simpler this time.
All these questions relate to specific interventions and none relate to the functional capability of
living with AF – the natural inference is the target of treatment is to control treatment rather than
promote function.
The stroke risk scheme needs to be simplified and ideally should simply align with CHADS2. If it doesn’t
then chads will be used anyway. Removal of ageist statements restricting therapy on the basis of age
should be removed unless substantial data can justify them. Catheter ablation requires very clear
guidance because a large post code variation exists in the UK because of differing behaviour
across PCTs.
AF should be reviewed and updated using CHADS2-VASc2 scoring and HAS-BLED www.afstrokerisk.org.
New anticoagulants are important but are subject to individual technology appraisals so cannot be
assessed vs. warfarin in the clinical guideline.
Atrial fibrillation needs to be a high priority on the health-care agenda.
Unable to comment on pharmacological guidelines. They are less relevant to medical devices company’s
areas of work.
It is very important to update the guidelines with up to date available information on clinical trials and
approved new alternative drugs used in the management of AF.
An MTA of all agents available for stroke prevention will be most helpful.
The cost implications [(budget impact/cost-effectiveness (Cost per LYG/QALY/DALY)] of strategies in AF
management alone are critically important and the screening of individuals for AF health checks are also
critical. The communication and engagement of patients in their own decisions is also critical. The
appropriate consenting of patients for ablations with appropriate and realistic data on ablations is
critical also. Ablation long term does not get properly discussed with patients and a failure rate of 60%
post first procedure is never discussed.
AF screening should be a high priority also.
DALY, disability-adjusted life-year; LYG, life-year gained; MTA, multiple technology appraisal; PCT, primary care trust.
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ases are
diagnosed and just over 10,500 men die of prostate cancer. It is largely a disease that affects older men
prostate
change.
The modelling approach was broadly based on the methodological framework for developing Whole
Disease Models set out by Tappenden and colleagues,49 albeit using a more restrictive model scope which
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58includes only a partial representation of disease natural history.
This case study includes economic analysis of a number of potential topics to update within the guideline,
selected using methods discussed in Chapter 3. Our aim was to investigate the ability of the full guideline
model to address such questions. The results of these analyses are not intended to provide suggestions for
new guideline recommendations, as they are not based on up-to-date systematic reviews of clinicalThe aim of this case study was to develop a health economic model to cover the scope of the
cancer guideline in sufficient depth that it could be used to evaluate various options for serviceand is rare below the age of 50 years. More than 75% of cases occur in men aged > 65 years, with the
largest number in men aged between 70 and 75 years old.68 The symptoms of prostate cancer can be easy
to misinterpret as they are not specific to the disease. They include urgency, difficulty and pain on passing
urine. Men with early stages of the disease are likely to have no symptoms at all.
There is no routine screening of men in the UK for prostate cancer;69 however, men are encouraged to
seek a consultation with their general practitioner (GP) for testing if they are concerned about or are at
higher risk of developing the disease. Risk factors for prostate cancer include age, family history (the risk
of developing prostate cancer doubles or triples for men with a family history of prostate cancer in a
first-degree relative), ethnicity (the incidence of prostate cancer in the UK is highest in black Caribbean and
black African men and lowest in Asian men) and diet (diets high in calcium may increase the risk of
developing prostate cancer).68
Prostate cancer is not always life-threatening. Over the past 10–15 years there have been a number of
significant advances in prostate cancer management but also a number of major controversies, particularly
about the clinical management of men with early, non-metastatic disease.54 Radical treatment can result in
nerve damage and cause urinary dysfunction, sexual dysfunction and bowel problems which have a
significant and lasting impact on quality of life.
Variation in practice across the UK, the significant uncertainties faced by men in making treatment
decisions and the considerable impact of prostate cancer on quality of life as well as mortality led to the
commissioning of the first CG on prostate cancer by NICE in 2005 (CG58). The guideline covered the key
aspects of prostate cancer management from the point of referral into secondary care: diagnosis and
staging, observation, radical treatment, salvage treatment, follow-up, hormone treatment and best
supportive care (BSC).54
Aims of the case studyProstate cancer is the most common cancer in men in the UK.67 Every year over 40,000 new cChapter 4 Case study 1: full guideline model for
prostate cancer
This chapter presents a case study application of the development of a full guideline model to evaluatemultiple decision problems across the prostate cancer pathway.
Introduction
Introduction to the context of the case study33
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effectiveness and they have not been informed by an expert CG group. Instead the aim of the economic
analyses is to indicate topic areas where further investigation is likely to be of value.
prices. All
costs and health outcomes were discounted at a rate of 3.5%. The headline model results are presented in
detail to ensure that we had a coherent understanding of existing recommendations and the rationale
available at
the time the recommendations were made.
CASE STUDY 1: FULL GUIDELINE MODEL FOR PROSTATE CANCER
34underpinning these, the recommended care pathway and the clinical and economic evidenceterms of the incremental cost per QALY gained within each guideline topic.
The model development process had four main stages. First, we developed a detailed understanding of the
clinical area and represented this using conceptual service pathway models. These conceptual models were
intended to be recognisable to men with prostate cancer in the UK and to clinicians working within the
NHS. This aspect of conceptual model development was based on a preliminary review of the literature
and the existing NICE guideline.54 We also developed an understanding of the key clinical events, and later
represented these within a model of the disease process. The second stage involved converting our
understanding into a model constructed to retain the key events in the clinical pathway, while taking into
account the availability of evidence and the need for simplifications and assumptions. This took the form
of a design-oriented conceptual model which set out the main interactions between the disease and
treatment pathways. This latter conceptual model was developed iteratively and was formalised only at a
late stage during model development. The third stage involved programming the simulation model.
Although it has been argued that conceptual model development and implementation should remain
largely discrete,57 the processes of designing and implementing the model overlapped considerably. The
final stage involved using the model to assess the potential cost-effectiveness of a variety of options for
service change across the prostate cancer pathway.
Preliminary literature review
We conducted a literature review of published economic models of prostate cancer from NICE (TAs) and
other HTA bodies and guideline developers. Searches were undertaken across a number of electronic
databases [Centre for Reviews and Dissemination (CRD) NHS Economic Evaluation Database, CRD HTA
Database, NHS Evidence, The Cochrane Library and G-I-N database] using general disease and patient
group search terms. This search was undertaken as a rapid means of identifying potentially appropriate
structures for certain elements of the model and to identify potentially relevant sources of evidence to
inform the model parameters. We did not conduct a formal critical appraisal of the identified economic
evaluations nor did we summarise their findings, as we were not specifically interested in the credibility
of the results of existing models. Documentation for the current NICE guideline was reviewed (comprising
the full NICE guideline, accompanying evidence review, the QRG and the implementation tools70–73) inconsequences of these, over the remaining lifetime of patients. Costs were valued at 2010–11Methods
The typical starting point for creating a health economic model involves developing an understanding of
the decision problem and setting out the basis for the comparison between a full set of relevant
alternatives. Given that one of the key objectives of the case study was to assess the flexibility of having a
full guideline model for prostate cancer, the questions that the model would need to be able to evaluate
were not known at the outset.
We developed a detailed individual-level DES to evaluate the expected cost-effectiveness of options for the
diagnosis, treatment and follow-up of prostate cancer. The model was developed using SIMUL8 software.
In line with the current NICE reference case,36 the model considers health outcomes and costs from the
perspective of the NHS and PSS and simulates key clinical and subclinical events, and the costs andNIHR Journals Library www.journalslibrary.nihr.ac.uk
The conceptual model
who do
undergo TRUS-guided biopsy, the result (which generates a Gleason score – a marker of cell differentiation
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58what we term, ‘palliative treatment’).or ‘aggressiveness’ of the cancer) is used together with PSA score and clinical disease stage to define a
patient’s prostate cancer risk (Table 5).
The ‘preferred treatment option’ for men with low-risk disease who are suitable candidates for radical
treatment is active surveillance (AS).54 We interpreted this preference as a strict recommendation, ignoring
other treatments recommended as possible alternatives.
All men with intermediate- or high-risk disease who are suitable for radical treatment are assumed to
receive imaging (MRI or CT scan) to stage the disease and plan treatment. Radical treatment options
include prostatectomy, brachytherapy (for patients with high-risk disease only), radical radiotherapy with
adjuvant hormone treatment or hormone treatment (in which case men follow the same pathway as for,will not have a diagnosis of prostate cancer at this point, some may have the disease. For menBoundary and scope of the model
The scope of the NICE prostate cancer guideline74 was used to define the boundary of the health
economic model. Entry and exit rules were defined, based on all current recommendations from NICE
including recommendations for men with hormone-refractory disease from the NICE TA101 (NICE 2006).75
Patients enter the model after having been referred to secondary care by their GP, either due to the
presence of symptoms or due to an elevated prostate-specific antigen (PSA) test. Patients exit the model
when they die or when they have an event which would fall under the remit of another guideline. For
example, although the NICE prostate cancer guideline54 refers to the referral of patients with suspected
prostate cancer from primary care, this is covered in another guideline76 and was thus deemed to be
beyond the boundary of this evaluation. A proportion of men who present with elevated PSA will not have
prostate cancer but may still undergo further tests and monitoring for prostate cancer, so these patients
were necessarily retained within the model boundary.
Conceptual service pathways
A conceptual representation of the clinical service pathways for prostate cancer services in England and
Wales was constructed based on the recommendations contained within the NICE 2008 prostate cancer
guideline.54 This was intended to represent clinical practice if the recommendations within CG58 had been
fully implemented. It is important to note that the pathway does not necessarily reflect actual practice in
the NHS, as the extent of implementation and compliance with guideline recommendations is likely to
be variable.
The NICE prostate cancer guideline has a relatively clear structure in terms of the key disease management
areas: diagnosis and staging of disease; monitoring and management options; potentially curative
treatment; and palliative treatment. However, like most CGs, it was not designed to cover every aspect of
clinical care, hence a number of assumptions were required to link individual recommendations into a
single ‘joined-up’ pathway. We sought advice from a consultant clinical oncologist who was a member of
the 2008 Prostate Cancer NICE GDG and an additional urological registrar to ensure the accuracy and
representativeness of the conceptual service pathway.
Figure 1 summarises the conceptual service pathway model; a more detailed version of this conceptual
model is presented in Appendix 4. Briefly, patients enter the pathway on referral into secondary care.
Patients may have been referred by their GP or by another secondary care physician. Repeat tests are
carried out during the initial consultation and a decision is made whether the patient should undergo a
transrectal ultrasound (TRUS)-guided biopsy. If men opt-out, or if a TRUS-guided biopsy is not considered
necessary, they have regular PSA tests carried out by their GP. Note that although men on GP monitoring35
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ffered) and
e fails, the
patient is considered castration refractory.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58If the patient is considered well enough, chemotherapy is offered as fourth-line palliative treatment, using
either docetaxel or mitoxantrone in combination with prednisone or prednisolone.75 When chemotherapy
fails, patients receive corticosteroids, such as diethylstilbestrol for pain relief. No further active treatments
are offered after this time, patients will receive BSC.
The disease process model
In addition to the service pathway model, we also developed a conceptual model of the disease process to
characterise the key clinical events, risks and subsequent prognosis (Figure 2). We assumed that prior to
diagnosis the underlying progression of prostate cancer follows a consecutive sequence of disease events,
depicted on the left-hand side of Figure 2. Men without prostate cancer are only at risk of death from
other causes. Men with localised prostate cancer are assumed to only develop metastases if they first have
local progression. The NICE prostate cancer guideline54 recommends that a clinically meaningful relapse
should be established before starting palliative treatment. Owing to the absence of reported evidencepatient has received bicalutamide previously, in which case continuous hormone treatment is o
the addition of dexamethasone is given as third-line palliative treatment. When dexamethasonMen who are considered unsuitable for radical treatment or who have a life expectancy of 10 years or less
are assumed to receive watchful waiting. This involves regular PSA tests and contact with a urologist in a
secondary care setting. If symptoms of advanced prostate cancer develop over this time, individuals are
assumed to receive palliative treatment. First-line palliative treatment was taken to mean either medical or
surgical castration (intermittent or continuous hormone treatment or bilateral orchidectomy) or
bicalutamide monotherapy (which may be chosen to retain sexual function at the expense of overall
survival). When first-line treatment fails, bicalutamide is added to the treatment regimen (unless the
TABLE 5 D’Amico risk classification70
Risk PSA (blood test) Gleason (biopsy) Clinical stage (digital rectal examination)
Low < 10 ng/ml ≤ 6 T1–T2a Localised disease
Intermediate 10–20 ng/ml 7 T2b or T2c Localised disease
High > 20 ng/ml 8–10 T3–T4 Localised or locally
advanced disease
T1, tumour too small to be seen on scans or felt during examination of the prostate; T2a, tumour in only half of one of the
lobes of the prostate gland; T2b, tumour in more than half of one of the lobes; T2c, tumour in both lobes but is still inside
the prostate gland; T3, tumour broken through the capsule (covering) of the prostate gland but not spread in other organs;
T4, tumour spread into other body organs nearby, such as the rectum, bladder, muscles or the sides of the pelvic cavity.77on documented relapse, we assumed that biochemical relapse after radical treatment is a proxy for
local progression. Similarly, we assumed that a patient cannot die of prostate cancer without first
developing metastases.
The central distinction in the clinical management of the disease (depicted on the right-hand side of
Figure 2) is between patients with disease that is potentially curable and those with disease that is not. The
distinction between localised disease and locally advanced disease is assumed to be less significant since
treatment options for patients with locally advanced disease mirror those offered to patients with high-risk
localised disease. The aim of treating patients with incurable disease is to slow the progression of the
disease and to prevent it becoming castration refractory. Patients with castration-refractory disease may be
treated with chemotherapy, which is also intended to slow the progression of the disease. Again, owing to
limitations in the available evidence on documented relapse, we assume equivalence between biochemical
relapse and local progression.
37
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Final model design
as this allows for a more complex representation of model events conditional on patient characteristics and
a cohort
approach (e.g. a Markov model). The model was developed by considering the relevant competing events
at each point in the clinical pathway (see Figures 3 and 4). The time to each event was sampled for each
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58patient, with the next event determined by whichever of these occurred first. After each event, an
individual’s prostate cancer risk profile was updated (e.g. age and disease status) and the times to the next
set of relevant events were recalculated. Other-cause mortality was sampled differently in that this was
defined on model entry and the remaining time to this event was recalculated on the occurrence of any
other non-fatal event. Costs and effects were recorded as the patient progressed through the model,
conditional on the events that they experienced. A continuous discounting approach was adopted to
account for health outcomes and costs which accrue over a particular time period. One-off costs (e.g.
surgery) were discounted using a standard periodic discounting approach. The programming approach
implemented within the final model followed the method suggested by Tappenden and colleagues.49
Detailed model description and programming logic
Patients enter the simulation model having been referred to secondary care by their GP, either due to the
presence of symptoms or due to an elevated PSA test, or by a secondary care physician who suspects the
individual might have prostate cancer. The model design is summarised in Figures 3 and 4 and the
underlying logic of each section is described below. Each box within the diagram represents a SIMUL8
‘workcentre’ in which events, costs and consequences are sampled and applied to individual patients. With
the exception of hormone and palliative treatments, all events which are modelled according to multiple
competing risks are implemented using two related workcentres; one dummy workcentre that determines
which event occurs next and another that represents the actual interaction of the patient with the prostate
cancer service.
Workcentre 1: initial characteristics
On entry into the model, patients are assigned initial characteristics. These characteristics include: the
presence or absence of prostate cancer; age; initial stage (using standard tumour node metastasis
classification); and Gleason score. Patients are assigned a risk category based on the D’Amico classification
using clinical stage and Gleason score (see Table 5). CG58 classified T2c disease as intermediate risk
prostate cancer, where the original D’Amico criteria81 classified this as high-risk disease. The assigned risk
category later dictates which treatment options are available to the patient. PSA score is then sampledprovides a greater level of flexibility in implementing and adapting the model as compared withThe final model structure did not fully mimic the conceptual service pathways model described in
Appendix 4. The main reason for this was that the 2008 NICE guideline54 relies heavily on PSA score as an
indicator of underlying disease progression and as a trigger for events such as follow-up tests and changes
in treatment. Some evidence was available on initial PSA and PSA changes over time according to initial
diagnosis (which we used in the GP monitoring section of the model); however, we did not find evidence
to link these changes in PSA to changes in treatment or risk of progression over time. As a consequence,
we were unable to use PSA to fully drive changes in patients’ underlying disease and the treatment
pathways that patients would follow. Instead, we assumed that the natural history of the disease follows a
linear series of conditional transitions from local progression to metastases to death from prostate cancer
(see Figure 2). We also assumed that patients would begin palliative treatment as soon as radical
treatment was considered to have failed. In this sense, the lack of evidence restricted the level of depth
with which the progression of the disease could be represented within the model. These decisions were
taken iteratively as we understood what evidence was available and were only formalised after we had
begun to implement the model.
The model was implemented as a next-event DES model. An individual-level simulation approach was taken39
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(Scandinavian) population and most did not receive any curative treatment.
ostate
cancer are assumed not to develop prostate cancer within their lifetime. For the sake of simplicity, it is
tre until
they die of other causes. Those patients who test negative, do not have BPH and were not referred for a
CASE STUDY 1: FULL GUIDELINE MODEL FOR PROSTATE CANCER
42repeat biopsy, undergo GP monitoring (these patients may have prostate cancer, but this is clinically
unknown at this stage). The model assumes that patients do not attend every GP visit to which they are
invited.92 Where applicable, the cost of TRUS-guided biopsy is added to the running total cost. A
probability of experiencing infection due to TRUS is also sampled and the cost of treating the infection, if it
occurs, is added to the running total.
Workcentre 4: undiagnosed (dummy workcentre)
Patients who enter the GP monitoring workcentre do not yet have, and may never receive, a diagnosis of
prostate cancer; these patients may or may not have underlying cancer. These patients are assumed to
undergo PSA tests every 6 months indefinitely. For these patients, the time to the next event (TTNE) is
then determined. Competing events are (1) other-cause mortality; (2) prostate cancer-specific death;
(3) local progression (unless this has already occurred); (4) metastases (unless this has already occurred);BPH are assumed to have this pathology detected at this point and remain in the BPH workcenassumed that no time elapses between the secondary care visit and the primary care attendance (either at
model entry or when the patient attends GP monitoring). The cost of the PSA test is added, but contact
between the patient and his GP is not included.
Workcentre 3: transrectal ultrasound-guided prostate needle biopsy
On entry to the biopsy workcentre, the number of biopsies is recorded as we assumed that patients could
undergo a maximum of three biopsies in their lifetime, unless they are on AS. The probability that a
patient receives a positive biopsy result is based on the sensitivity of the test given the individual’s true
underlying histology. TRUS is assumed to be perfectly specific, meaning that all men who do not have
prostate cancer will be correctly identified as not having the disease. The results of a TRUS-guided biopsy
given the presence/absence of underlying cancer are sampled and patients with a true-positive result are
sent to the ‘determine appropriate treatment’ workcentre. A proportion of patients who test negative are
assumed to be invited to attend a repeat biopsy in 6 months’ time, whereas the remainder are assumed to
return to GP monitoring and undergo a PSA test in 6 months’ time. Those patients who have undiagnosedundiagnosed prostate cancer the disease will progress untreated. Patients who do not have prThe incidence of prostate cancer is not captured in the model (whether a man has prostate cancer or not
is defined on entry to the model). If a simulated individual does not have prostate cancer on entry into the
model, it is assumed that he cannot go on to develop prostate cancer. A proportion of these patients are
assumed to have benign prostatic hyperplasia (BPH).
Workcentre 2: secondary care attendance
Following referral to secondary care, all patients are assumed to have a repeat PSA test (from a blood test)
and digital rectal examination (DRE). Patients with a very high PSA score (> 75 ng/ml), which is taken to
indicate obvious symptoms of advanced prostate cancer, are offered a bone scan without prior biopsy and
hormone treatment with palliative intent. All other patients are considered for a TRUS-guided biopsy if
they meet the Prostate Cancer Risk Management Programme (PCRMP) primary care referral guidelines,79
which are dependent on age and PSA score. Patients who do not meet the referral criteria, who have
already had three prior biopsies or who opt-out of biopsy, are sent for GP monitoring with a PSA test
every 6 months. These patients do not have a diagnosis of prostate cancer, although some may have
underlying disease which may or may not be diagnosed if they re-enter secondary care. If a patient hasand prostate cancer death). Patients included in this arm of the trial were from an unscreenedconditional on stage; this was necessary as the national registry data used to assign patients’ characteristics
did not include data on initial PSA score (see Evidence used to inform model parameters).
Published results from the observation arm of the Bill-Axelson and colleagues trial78 were used to provide
information on the natural history of prostate cancer for each disease event (local progression, metastasesNIHR Journals Library www.journalslibrary.nihr.ac.uk
In the primary care workcentre, patients who meet the PCRMP referral guidelines (dependent on age and
tients who
are unsuitable for radical treatment and are symptomatic are assumed to transit immediately to palliative
This is a ‘dummy’ workcentre which determines the next relevant event for a given patient. As noted
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58above, only patients with low- or intermediate-risk disease enter AS. On entry into AS, patients are
assumed to undergo a PSA test every 3 months for the first year after their initial diagnosis of prostate
cancer and every 6 months thereafter until they leave surveillance or die. TRUS-guided biopsy is assumed
to take place 1 year following initial diagnosis and then every 3 years thereafter until the patient leaves
surveillance or dies. Patients who experience local progression or those who opt for treatment over
surveillance go on to receive radical treatment. Although the model assumes that it is impossible for
patients to develop metastatic disease on AS, we do not believe that this is a strong assumption as in
reality metastasis is very unlikely to occur in these patients. Patients who reach the age of 80 years withoutWorkcentre 8: active surveillance (dummy workcentre)hormone treatment. Patients who are unsuitable for radical treatment and are not symptomatic are
assumed to receive watchful waiting. If the patient has metastases but has not previously had a bone scan
since developing metastases, he receives a bone scan at this point. All patients undergo a MRI scan or CT
scan prior to receiving radical treatment.AS. Patients with high-risk disease are assumed to transit immediately to radical treatment. PaIf the patient has metastases they are assumed to receive palliative hormone treatment. If the patient is
aged < 80 years, is suitable for radical treatment and has low-risk disease, he is assumed to go to
AS with the intention of later receiving radical treatment, either at the onset of symptoms or when he
chooses to undergo treatment. If the patient is aged < 80 years, is suitable for radical treatment and has
intermediate-risk disease he is assumed to either transit immediately to radical treatment or to enter intoover time (note this assumption has been made elsewhere).80current PSA score) are assumed to be sent for a biopsy. Those patients who do not meet the referral
criteria, who have already had three prior biopsies or who opt-out of biopsy, return to GP monitoring with
the next PSA test scheduled 6 months later. The cost of a primary care visit plus the cost of the PSA test is
added to the running total. The time of the PSA test is recorded.
Workcentre 6: bone scan
Bone scans are assumed to be perfectly sensitive and specific within the model; this is a simplifying
assumption due to the lack of evidence. Patients who have metastases are assumed to be identified by the
scan; these patients are diagnosed at this point and go on for treatment planning. Patients who do not
have metastases are correctly identified and, if eligible, will have a biopsy immediately or will otherwise
have GP monitoring. The cost of the bone scan is added to the running total cost.
Workcentre 7: determine appropriate treatment
At the point of diagnosis all patients enter this workcentre to determine appropriate treatment given their
age, stage of disease and suitability for radical treatment. The patient’s prostate cancer risk, according to
the CG58 classification,70 is updated at this point based on the patient’s underlying cancer stage, Gleason
score and PSA score. Disease stage is updated over time in line with the disease logic model detailed in
Figure 2. PSA score is updated only when patients receive GP monitoring. Gleason score is not updatedWorkcentre 5: primary care appointment for prostate-specific antigen test(5) next scheduled PSA test; and (6) time to next biopsy (for those with a scheduled repeat biopsy only).
If cancer-specific or other-cause death occurs during GP monitoring, patients exit the model at this point.
The remaining time to each competing event is then recalculated based on the time interval TTNE. If the
next event is local progression or metastases, this is assumed to manifest symptomatically and triggers a
GP visit and PSA test at the time of the clinical event. Most patients return to the GP for their scheduled
6-monthly PSA test (a proportion are assumed to not attend). If the patient was due to undergo a repeat
biopsy but some other event occurs first, this is assumed to result in earlier biopsy (at age + TTNE). Age is
then updated by the time to next event for all patients.43
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Workcentre 9: active surveillance visit
ible for
hormones plus radiotherapy or hormone therapy alone.
rogression
(the primary outcome from trials of radical treatment) with local disease progression. The model assumes
adverse
event is independent of other adverse events].
Workcentre 13: hormone treatment + chemotherapy + best supportive care
CASE STUDY 1: FULL GUIDELINE MODEL FOR PROSTATE CANCER
44The hormone treatment plus chemotherapy plus BSC workcentre calculates the patient’s time to prostate
cancer death and determines the proportion of this period which is ‘progression-free’; this is assumed toIf patients do not die of other causes, they will receive follow-up comprising an annual bone scan, a PSA
test every 6 months and a urology consultation. In the first 2 years following treatment, the PSA test will
be done in secondary care and the consultation as an outpatient visit. After that, the PSA test will be
undertaken in primary care and the consultation will be by telephone with a urology consultant. Follow-up
is assumed to cease at the time of local progression (or death from other causes).to be lifelong and additive [that is the impact on health-related quality of life (HRQoL) for eachthat time to prostate cancer death is not directly influenced by radical treatment. Patients having radical
prostatectomy may die perioperatively due to surgical complications, with risk increasing with age.
The three adverse events included in the model are associated with different disutilities, which we assume(RCT) evidence does not suggest otherwise. As noted earlier, the model equates biochemical pRadical treatment is assumed to have an impact on time to local progression and the frequency of three
adverse events (sexual dysfunction, urinary dysfunction and bowel dysfunction). The model assumes that
outcomes from treatment are the same for all risk categories since the available randomised controlled trialbrachytherapy. Patients with high-risk localised disease or locally advanced disease are only eligPatients enter the AS visit workcentre if their last event was non-fatal. At this point individuals can either
receive a scheduled test (PSA or biopsy) or receive radical treatment (either at the patient’s choice or
because of symptomatic disease progression). The model assumes that every patient undergoes a PSA test
on entry into the workcentre. The last event is used to update the TTNEs in the model. For example, if a
patient reached the age of 80 years and was moved onto watchful waiting, the time to the next PSA test
is dictated by the watchful waiting test schedule rather than the AS test schedule.
Workcentre 10: watchful waiting general practitioner visit
Patients on watchful waiting are assumed to undergo a PSA test every 12 months. The TTNEs are updated.
Stage is updated in the model if the disease has progressed. If a patient developed metastatic disease, the
model assumes that hormone treatment will be initiated. Otherwise, the patient will remain on watchful
waiting. The cost of the scheduled GP consultation and the PSA test is added to the running total of costs.
Workcentre 11: watchful waiting (dummy workcentre)
This dummy workcentre calculates when the next event occurs. This can be either other-cause death,
disease progression (local or metastatic) or a scheduled test. Disease progression is assumed to be
symptomatic so a patient will present outside their scheduled appointment and will be offered
hormone treatment.
Workcentre 12: radical treatment
Patients who enter the radical treatment workcentre do not have metastatic disease and their disease was
classified according to the CG58 risk criteria at diagnosis.70 All patients with low-risk disease will have
previously been on AS, but have switched onto radical treatment (thus their disease may no longer be
considered low risk). The model assumes that these patients are offered the same treatment as
patients with intermediate-risk disease: radical prostatectomy (open), radiotherapy (and hormones) orhaving radical treatment are assumed to transit to watchful waiting and are assumed to be no longer
suitable for radical treatment.NIHR Journals Library www.journalslibrary.nihr.ac.uk
be dependent on the treatment received. The remaining time to other-cause death remains unaffected by
treatment. The model assumes that first-line treatment (intermittent hormones, continuous hormones,
bilateral orchidectomy or bicalutamide monotherapy) determines overall survival and the sequence of later
lines of treatment. Progression-free survival (PFS) from each line of treatment (up to four lines of treatment
in the base-case analysis) is added, with any remaining time before prostate cancer death spent in a
progressive disease state while receiving BSC. If patients survive the first three lines of treatment,
chemotherapy is given as the fourth-line treatment (either using a docetaxel-based or mitoxantrone-based
combination regimen). A fixed proportion of patients will not receive chemotherapy (not all patients will be
fit enough). Owing to evidence limitations, mean health state sojourn times were used so all patients
allocated to the same treatment will have the same outcomes. Cause of death is determined (prostate
cancer or other cause) and PFS is adjusted to ensure the sum of progression-free intervals does not exceed
overall survival. That is, if the sum of progression-free intervals exceeds the sampled overall survival time
for an individual patient, the final PFS interval is truncated.
Workcentre 14: death
Health outcomes are calculated for each simulated patient at time of death. The cost of terminal care is
added here, if the patient has died from prostate cancer. Survival is calculated by adding together the time
43
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FIGURE 5 Time segments (numbered) used to calculate overall survival.Arrival Diagnosis Watchful waiting
Only if on ASeach patient has spent in different segments of the model. There are up to seven time segments which
reflect all possible paths through the model (Figure 5).
The numbered time segments in Figure 5 refer to the following routes through the model:
l Segment 1: initial attendance to death (non-cancer or undiagnosed cancer patients) or cancer diagnosis.
l Segment 2: from the start of radical treatment to cure, biochemical relapse or other-cause death.
l Segment 3: from the start of AS to initiating radical treatment, until death or until beginning watchful
waiting. (Note: if patients do not receive AS no time will be spent in this segment.)
l Segment 4: from the start of watchful waiting to the start of palliative treatment, or death.
l Segment 5: hormone treatment to end of PFS from third-line (palliative) treatment [i.e. men with
castration-refractory prostate cancer (CRPC)].
l Segment 6: from the start of fourth-line (palliative) treatment to beginning of BSC or death.
l Segment 7: BSC to death.
Discounted and undiscounted life-years and QALYs are calculated for all patients. The lifetime costs
of adverse events are added in the death workcentre, including the cost of screening with flexible
sigmoidoscopy every 5 years for patients who receive radical radiotherapy, in line with the
CG58 recommendation.5445
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state cancer.
SIMUL8 and fitted the model against the unconditional data from Bill-Axelson and colleagues and other-
ifferent
CASE STUDY 1: FULL GUIDELINE MODEL FOR PROSTATE CANCER
46cause mortality estimates from the UK. We ran the algorithm over four separate chains with dThere is uncertainty regarding the true disease prevalence in men referred to secondary care with
suspected prostate cancer. Owing to an absence of empirical estimates, we assumed a value of 25%
based on expert opinion which roughly reflects the results from non-UK autopsy studies (20–34%).84–86
Data on death from causes other than prostate cancer were taken from national life tables; these were
adjusted by removing all deaths attributed to prostate cancer.87
Independent survival curves for local disease progression, metastatic disease progression and prostate
cancer death were taken from the 2011 publication of the Bill-Axelson and colleagues RCT,78 which
compared radical prostatectomy with watchful waiting (this was the closest proxy to information on the
natural history of the disease without treatment). This study reported numbers of patients who
experienced local progression, metastases and prostate cancer death at 5-year and 10-year time points. It
should be noted that the Bill-Axelson and colleagues trial78 outcomes relate to the point of documented
progression and metastases rather than the true underlying time of histological change. These outcomes
are also based on a Scandinavian population of men in the pre-PSA testing/screening era hence they may
not fully reflect the UK population within the model. We used model calibration methods to derive
correlated conditional distributions for these events. We implemented a random-walk variant of the
Metropolis–Hastings algorithm88 based on the methods described by Whyte and colleagues89 directly in
78assumed that PSA scores in these patients follow the same age distribution as for men with proEvidence used to inform the model parameters
The model was populated using evidence identified within the 2008 NICE prostate cancer guideline71
supplemented with additional evidence identified through rapid literature searches and/or expert opinion.
We did not conduct systematic reviews for all of these parameters, as this was not possible within the
resources available for the study, and there are certain parameters (e.g. unit costs) whereby a conventional
systematic review approach is neither required nor preferred.57 This is likely to mirror the pragmatic
approach taken to populate health economic models during routine development of NICE CGs. The model
includes the following groups of parameters:
l disease epidemiology and baseline patient characteristics (incidence and prevalence of the condition
and subgroups, baseline risks, rates of progression of disease and mortality rates)
l test operating characteristics (e.g. sensitivity and specificity) of the tests included in the pathway
l clinical effectiveness of the treatments included in the pathway (e.g. PFS, time to biochemical relapse,
perioperative mortality)
l patient behaviour (e.g. probabilities of opting out of biopsy or of attending routine PSA tests)
l utilities associated with disease, treatment and adverse events
l resource use and
l unit costs.
Disease epidemiology and baseline patient characteristics
Data were required to define the initial characteristics of men with and without prostate cancer. We used
national cancer registry data obtained from the South West Public Health Observatory (SWPHO) to provide
information on age, clinical stage at diagnosis and Gleason score at diagnosis for patients with diagnosed
prostate cancer (SWPHO 2010, data held on file). The national registry database does not record PSA
score, hence it was necessary to calculate patients’ prostate cancer risk according to two of the three
CG58 risk criteria (see Table 5). Age-specific PSA values from men in the watchful waiting arm of the
Bill-Axelson and colleagues RCT78 were used to estimate PSA scores on model entry for men with prostate
cancer (cited by Tilling and colleagues82).
Evidence relating to age-specific PSA scores of the cancer-free population in the model was taken from the
Krimpen longitudinal community-based study.83 We have no UK data relating to this patient group so weNIHR Journals Library www.journalslibrary.nihr.ac.uk
starting vectors in order to estimate plausible distributions for each event, conditional on the population
having experienced the previous event. The joint distributions of progression parameters were used directly
in the probabilistic sensitivity analysis. Figure 6 presents a comparison of the maximum a posteriori
estimates produced by the calibration process against the observed data reported by Bill-Axelson and
colleagues;78 the figures show that the calibration provides a good fit to the observed data.
Diagnostic test accuracy
We assumed a sensitivity of 77% for TRUS-guided biopsy.90 We assumed that PSA, DRE, MRI, CT and
bone scans are perfect tests. We also assumed that the TRUS-guided biopsy is perfectly specific (i.e. no
false-positive results), whereas in reality its use as a diagnostic test may lead to overtreatment. Test
accuracy studies are difficult to undertake in this area, as pathological confirmation will not be carried out
for patients with negative biopsy results. The simplifying assumptions were necessary not only because of
the lack of gold-standard comparison studies, but also due to the complexity of including the implications
of misdiagnosis and misclassification from these tests in the model and the limited information available on
the natural history progression of prostate cancer.
A small proportion of patients will experience an infection as a result of biopsy (probability = 0.47%), and
this is represented in the model.91 Not all patients are willing to undergo biopsy; we assume 12% of men
will opt-out.92 Uncertainty surrounding these parameters was characterised using beta distributions.
Clinical effectiveness
Where more than one treatment is recommended at a particular point in the pathway, we used
proportions elicited from the Department of Health’s National Radiotherapy Implementation Group and
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FIGURE 6 Observed vs. calibrated frequencies of disease events. LP, local progression; PC, prostate cancer.180experts on the NICE Prostate Cancer GDG. The management and treatment options in the model were
grouped according to their clinical intent (e.g. delaying and/or avoiding recurrence or increasing PFS) and
the key outcome measures used in the clinical studies from which efficacy estimates were drawn. Perhaps
surprisingly, there is a lack of evidence on the comparative effectiveness of currently available radical
treatments for prostate cancer. Therefore, through necessity, evidence from different trials was used and
compared against single arms of other trials using naive indirect comparison methods (Table 6). Radical
prostatectomy is also associated with an excess mortality risk.93 As discussed above, biochemical relapse47
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TABLE 6 Radical treatment efficacy and adverse event parameters
Treatment
Model
parameter
First-order
uncertainty
Second-order
uncertainty Source
Radical
prostatectomy
Time to local
progression
Exponential
(α = 0.016)
Normal (λ = 0.016,
SE = 0.002)
Bill-Axelson and colleagues
201178 (radical
prostatectomy vs.
observation). Local
progression at 15 years
Probability of
sexual
dysfunction
Uniform (0,1) Beta (α = 168;
β = 121;
mean = 0.58)
Probability of
urinary
dysfunction
Uniform (0,1) Beta (α = 99;
β = 190;
mean = 0.34)
Probability of
bowel
dysfunction
0 0
Brachytherapy Time to local
progression
Weibull
(α = 0.846112974;
β = 2.80697845)
Multivariate normal
(log-λ = –3.83;
γ = 0.85)
Giberti and colleagues
200994 (radical
prostatectomy vs.
brachytherapy)
Probability of
sexual
dysfunction
Uniform (0,1) Beta (α = 42; β = 58;
mean = 0.42)
Probability of
urinary
dysfunction
Uniform (0,1) Beta (α = 80; β = 20;
mean = 0.8)
Probability of
bowel
dysfunction
Not reported. In base-case analysis set equal
to probability of bowel AE with radiotherapy
Assumption based on
Fransson and colleagues
200995 (quality-of-life data
from SPCG7, Widmark and
colleagues 2009 RCT96)
Adjuvant
hormones + radical
radiotherapy
Time to local
progression
Weibull
(α = 1.354431605;
β = 21.78254729)
Multivariate normal
(log-λ = –4.17;
γ = 1.35)
Widmark and colleagues
200996 (adjuvant
hormones + radiotherapy
vs. hormones alone)
Probability of
sexual
dysfunction
Uniform (0,1) Beta (α = 250;
β = 85; mean = 0.75)
Fransson and colleagues
200995
Probability of
urinary
dysfunction
Uniform (0,1) Beta (α = 64;
β = 289;
mean = 0.18)
Probability of
bowel
dysfunction
Uniform (0,1) Beta (α = 37;
β = 312; mean = 0.1)
Hormone therapy
alone
Time to
biochemical
progression
Weibull (α = 1.06,
β = 5.57)
Multivariate normal
(log-λ = –1.82;
γ = 1.06)
Widmark and colleagues
200996
Probability of
sexual
dysfunction
Uniform (0,1) Beta (α = 197;
β = 110;
mean = 0.64)
Fransson and colleagues
200995
Probability of
urinary
dysfunction
Uniform (0,1) Beta (α = 39;
β = 289;
mean = 0.12)
Probability of
bowel
dysfunction
Uniform (0,1) Beta (α = 23;
β = 312;
mean = 0.07)
AE, adverse event; SE, standard error.
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after radical treatment is used as a proxy for local progression due to a lack of direct evidence on local
progression per se. The estimates used in the model, characterised in terms of first- and second-order
uncertainty, are detailed in Table 6.
RQoL has
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58been widely acknowledged. The health utility values used in the model were drawn from recent
economic evaluations of prostate cancer (Table 8). We did not identify any HRQoL evidence published after
these studies.
We incorporated the HRQoL impact of the three most common adverse events attributable to radical
treatment (bowel function, urinary function and sexual function) as disutilities (Table 9). Owing to the
absence of data on the duration of adverse events, the model assumes that these last for the remaining
lifetime of the patient. The impact of this assumption is not tested further here; however, the flexibility of
the model allows such assumptions to be amended easily. Owing to a lack of evidence, the differential
impact of adverse events on health utilities due to specific palliative treatments was not captured.
Resource use and unit costs
In accordance with the perspective of this analysis, the only costs considered were those relevant to the UK
NHS and PSS. Costs were estimated in 2010–11 prices (Table 10). Resource use estimates for the model
were drawn from the NICE prostate cancer guideline (CG58) recommendations70 following the prostate
cancer service pathway (see Appendix 4). The cost of primary care contact before initial referral, primary
care services during prostate cancer treatment and cardiovascular screening were not included in the
model as these were difficult to ascertain from the current guideline recommendations and resource use
patterns are likely to vary. In order to reflect the additional terminal care costs incurred by patients in the
last month of life, a one-off cost of just over £4000 was applied to men who died of prostate cancer.
This cost was used in the NICE TA101 having been estimated from costing data originally supplied by
Sanofi-Aventis on men with hormone-refractory disease.108
Drug costs used in the base-case analysis were based on prices listed in the British National
Formulary (BNF).111
Handling uncertainty
With the exception of PSA trajectories which are sampled only according to first-order uncertainty, the
model is fully probabilistic. Sampling of parameter uncertainty for the probabilistic sensitivity analysis was
implemented by sampling the necessary distributions externally in Microsoft Excel® (Microsoft Corporation,
Redmond, WA, USA) and reading them into SIMUL8. This approach has the added advantage that
changes in model results reflect only the impact of changes to the pathway (e.g. new chemotherapy B vs.
current chemotherapy A) rather than randomness in the sampling of the parameters that make up the
model structure; a similar approach was also used in the second case study (see Chapter 5). A total of
1500 probabilistic samples were used to propagate parameter uncertainty through the model, and all
headline results are presented as the expectation of the mean rather than point estimates of parameters.Health utilities
The lack of published evidence relating to the impact of prostate cancer and its treatment on HPalliative treatments (Table 7) were also difficult to model, as we did not identify any RCTs that explicitly
evaluated planned sequences of treatments. Therefore, we assumed that first-line palliative treatment was
the sole determinant of overall survival due to prostate cancer. Subsequent lines of treatment are assumed
only to increase the proportion of the patient’s remaining survival time that is progression free. This
manipulation of the evidence requires that we ignore first-order uncertainty in these parameters and
therefore use mean sojourn times for estimates of overall and PFS, which is not ideal. The uncertainty in
these mean values is still, however, reflected in the probabilistic sensitivity analysis.49
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TABLE 8 Utility data
Treatment
Mean utility
value
Second-order
uncertainty Source
AS 0.81 1-beta (4, 0.0675) Hummel and colleagues105
Radical treatment 0.78 1-beta (4, 0.055) Hummel and colleagues105
Local progression 0.73 1-beta (4, 0.08) Hummel and colleagues105
Hormone-refractory prostate cancer 0.64 1-beta (4, 0.14) Hummel and colleagues105
TABLE 9 Disutility data
Treatment
Mean disutility
value
Second-order
uncertainty Source
Sexual dysfunction 0.10 1-beta (2.6, 23.40) Krahn and colleagues106 and
Chilcott and colleagues 201069
Urinary dysfunction 0.06 1-beta (2.76, 43.24) Krahn and colleagues106 and
Chilcott and colleagues 201069
Bowel dysfunction 0.11 Beta (53.46, 6.61) Krahn and colleagues106 and
Chilcott and colleagues 201069
Progression with hormone-refractory
prostate cancer
0.07 1-beta as integer (7, 93) NICE TA255, ERG report107
ERG, Evidence Review Group.
TABLE 10 Unit cost parameters
Treatment
Mean
unit cost
(£)
SE
(estimated)
(£) Distribution
Source
(NHS reference costs109
unless otherwise stated)
PSA test in primary care 11 2.20 Gamma Hummel and colleagues105
PSA test in secondary care Assumed to be the same as PSA in primary care (above)
Digital rectal examination 0 Assumed to be carried out as part of the consultation with
the urologist
TRUS-guided biopsy 200 5.30 Normal HRG code LB27Z
CT scan 100 2.40 Normal HRG code RA08Z
MRI scan 218 6.00 Normal HRG code RA01Z
Bone scan 181 5.50 Normal HRG code RA36Z
Flexible sigmoidoscopy 219 8.80 Normal HRG code FZ54Z
Appointment with GP
(including training)
36 – Fixed PSSRU110
Appointment with GP practice
nurse (including training)
13 – Fixed PSSRU110
Face-to-face consultation with urology
consultant (first)
130 3.10 Normal Outpatient attendance
Face-to-face consultation with urology
consultant (follow-up)
91 1.40 Normal Outpatient attendance
continued
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TABLE 10 Unit cost parameters (continued )
Treatment
Mean
unit cost
(£)
SE
(estimated)
(£) Distribution
Source
(NHS reference costs109
unless otherwise stated)
Face-to-face consultation with surgical
consultant (first)
148 3.20 Normal Outpatient attendance
Face-to-face consultation with surgical
consultant (follow-up)
106 2.40 Normal Outpatient attendance
Face-to-face consultation with clinical
oncology consultant (first)
180 4.60 Normal Outpatient attendance
Face-to-face consultation with clinical
oncology consultant (follow-up)
122 5.60 Normal Outpatient attendance
Face-to-face consultation with medical
oncology consultant (first)
171 5.60 Normal Outpatient attendance
Face-to-face consultation with medical
oncology consultant (follow-up)
120 4.20 Normal Outpatient attendance
Telephone follow-up with urology
consultant
54 6.20 Normal Urology consultant led
follow-up non-face-to-face
Oral administration of chemotherapy
(first)
171 7.60 Normal HRG code SB11Z
Parenteral administration of
chemotherapy (first)
265 8.50 Normal HRG code SB13Z
Administration of subsequent elements
of a chemotherapy cycle
294 9.10 Normal HRG code SB15Z
Radical prostatectomy 5119 128.40 Normal HRG code LB21Z
Bilateral orchidectomy 407 22.20 Normal HRG code LB35B
Conformal radiotherapy planning 581 81.00 Normal HRG code SC51Z
Delivery of conformal radiotherapy 111 6.20 Normal HRG code SC23Z
Delivery of external beam radiotherapy 91 4.10 Normal HRG code SC23Z
Brachytherapy planning 1123 97.10 Normal HRG code SC54Z
Delivery of brachytherapy 383 196.60 Normal HRG code SC26Z
Specialist erectile dysfunction services 179 13.90 Normal HRG code LB43Z
Incontinence containments 68 33.80 Gamma Hummel and colleagues105
Post-biopsy infection requiring
hospitalisation
2623 79.90 Normal HRG code PA16B
Strontium (Protelos®, Servier)
(one dose)
1070 0.55 Normal HRG code SC29Z
Transurethral resection of the prostate
(ablative procedure for BPH)
2405 37.80 Normal HRG code LB25B
Terminal care 4142 Fixed Collins and colleagues 2007,108
inflated to 2010–11 prices
HRG, Healthcare Resource Group; PSSRU, Personal Social Services Research Unit; SE, standard error.
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Verification and validation
Errors and inconsistencies in the model were checked for throughout the model development process,
following the methods set out by Chilcott and colleagues.23 The model was verified internally (to ensure
correct programming) and validated externally (to ensure consistency with expected results, e.g. that
survival times and levels of service use were realistic). A variety of methods were used including black box
testing (testing the behaviour of the model) and white box testing (scrutinising the programming code). In
addition, the model was programmed to record intermediate model outcomes (e.g. survival contributions
attributable to particular segments of the pathway and costs associated with specific workcentres) in order
to assess whether changes to the pathway impacted on those parts of the model as expected.
Once we were satisfied that the model was behaving as intended, we then assessed the number of
patients required to achieve stability in the model results. We adopted a pragmatic approach to this using
the results of the base-case model only. We ran the model with the base-case service configuration with
different numbers of patients and compared the results from each section to the results for 1,000,000
simulated men. Figure 7 indicates that the costs and QALYs become fairly stable (< 2% deviation) at
around 100,000 simulated patients. Conservatively, we adopted a cohort of 200,000 simulated individuals
for the economic analysis.
Modelling decision options across the service pathway
Nine topics were shortlisted from topics highlighted by NICE for possible inclusion in an update of the
2008 prostate cancer guideline (see Box 7 in Chapter 3). Details of how the nine topics were shortlisted
are discussed in Chapter 3.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Each topic implied an alternative clinical pathway, incorporating one or more changes to the
recommendations made in CG58.54
Figure 8 shows where these alternative recommendations are located in the clinical pathway. Each topic
was transformed into a population, intervention, comparator, outcome (PICO)-style review question,
described below.
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Topic A: pelvic radiotherapy with adjuvant hormone therapy for men
with localised prostate cancer
The stated patient population for this topic – men with localised prostate cancer – is broad but reference is
made to the SPCG-7 trial,96 which included men with locally advanced or high-risk localised prostate
cancer. The NICE prostate cancer guideline54 recommended that these patients should be offered either
radiotherapy with hormone treatment or hormone treatment alone. In practice, many men will only be
offered hormone treatment, without the option of additional radiotherapy. A focused literature search
comparisons,
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58We limited our analysis to RCT evidence only. The systematic reviews suggested some problems with the
reliability of the observational evidence and in some cases the methods of synthesis do not appear to be
robust. Of the three RCTs, only the trial reported by Martis and colleagues114 provided longer-term
outcome data (biochemical recurrence); the others focussed on perioperative outcomes.115,116 The time to
biochemical recurrence survival curves reported for PRP and RRP in Martis and colleagues114 are almost
identical, hence we assumed no difference in biochemical recurrence-free survival between the two
procedures. We sampled biochemical recurrence-free survival from the curve used in the base-case
model.78 It seems reasonable, given the absence of evidence to suggest otherwise, that LRP and RALRP are
also associated with the same biochemical recurrence rate.
Differential perioperative mortality outcomes associated with specific techniques are not captured within
the model. However, differences in the frequency of adverse events associated with each surgical
Asimakopoulos
2011116
Guazzoni
2006115
Martis
2007114
PRP RRP LRP RALRP
FIGURE 9 Randomised controlled trial evidence network of surgical techniques for localised prostate cancer.Eleven studies were identified by NICE, including three systematic reviews of observational stu
additional observational studies and three RCTs. The three RCTs investigate different pairwise
as shown in Figure 9.conducted by NICE112 identified three published papers from two new RCTs.95,113 Only one paper had
published full results of the trial at the time of analysis (the SPCG-7 trial96). Six RCTs identified in the NICE
prostate cancer guideline71 have published additional follow-up results with findings in support of
combined radiotherapy and hormone therapy. Additionally, two observational studies that compared
quality of life following radiotherapy plus hormone therapy to that following radiotherapy alone
were identified.
The PICO question was formulated to mimic the clinical question addressed in the only additional RCT
published in full since 2008; an update to the SPCG-7 trial. Combined hormone treatment plus
radiotherapy was compared with hormone treatment alone for men with locally advanced or high-risk
localised prostate cancer. As the SPCG-7 trial was used to populate the base-case model, this economic
question was evaluated without needing to modify the model structure.
Topic B: surgical techniques for localised prostate cancer: open radical
retropubic prostatectomy, transperineal prostatectomy, laparoscopic
prostatectomy or robot-assisted laparoscopic prostatectomy
This topic suggests four alternative surgical techniques [radical retropubic prostatectomy (RRP),
transperineal prostatectomy (PRP), laparoscopic prostatectomy (LRP) and robot-assisted laparoscopic
prostatectomy (RALRP)] for men with localised prostate cancer undergoing surgery. The NICE prostate
cancer guideline54 did not recommend a specific procedure for radical prostatectomy. The base-case model
was populated with data from Bill-Axelson and colleagues.78 Accordingly, the cost used was the NHS
reference cost for a standard open procedure.
dies, three55
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dures.
eam
119,120 and
five were observational studies. We restricted our analysis to use only the RCT data on biochemical
adiotherapy.
e events.
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56Topic E: degarelix (a luteinising hormone-releasing hormone antagonist)
for men with locally advanced or metastatic prostate cancer
No luteinising hormone-releasing hormone (LHRH) antagonists were recommended in the NICE prostate
cancer guideline.54 Degarelix is now licensed in the UK and was recently recommended by the Scottish
Medicines Consortium under a patient access scheme. One non-inferiority RCT comparing low-dose
degarelix (240/80 mg), high-dose degarelix (240/160mg) and standard 7.5-mg monthly dose of leuprorelin
(Prostap®, Takeda) was identified.127 The primary outcome measure in this study was the cumulative
probability of testosterone with other outcomes including the incidence of PSA failure. As this study only
had 12-month follow-up data and did not report outcomes according to those used in the full guideline
model, some assumption about impact on overall and PFS was required.
Since Klotz and colleagues127 showed equivalence of both doses of degarelix compared with leuprorelin at
12 months, we could (tentatively) assume equivalence in terms of progression-free and overall survival, in
which case the cost-effectiveness will be determined by differences in cost alone. The trial does indicate
some differences between the three arms in terms of the frequency of adverse events; however, these arefollow-up of 223 patients given iodine-125 or palladium-103 brachytherapy plus neoadjuvant r
These data were used to estimate biochemical relapse-free survival and the frequency of adversrelapse and frequency of adverse events.
Topic D: low-dose-rate brachytherapy + external beam radiotherapy for
men with localised or locally advanced prostate cancer
Low-dose-rate brachytherapy (LDR) combination therapy was not considered in the NICE prostate
cancer guideline.54
No comparative data on the clinical effectiveness of LDR and external beam radiotherapy was identified.
One US cohort study, reported by Sylvester and colleagues,126 was identified. This study reported 15-yearSeven papers investigating high-dose-rate brachytherapy (HDR) in combination with external b
radiotherapy were identified in a focussed search conducted by NICE; two of these were RCTs
121–125Topic C: high-dose-rate brachytherapy + external beam radiotherapy for
men with localised or locally advanced prostate cancer
Brachytherapy alone is currently recommended by NICE as an option for the treatment of men with
intermediate- or low-risk disease, but is not recommended for patients with high-risk disease.
Brachytherapy combination therapy was not considered in CG58. The patient population overlaps with
topic D, hence we evaluated topics C and D together.PRP procedures. LRP is costed separately, but bundled with other laparoscopic urological proce
Full details are given in Appendix 5.procedure are captured; RALRP is associated with fewer sexual and urinary problems than LRP, which has a
similar adverse event profile to RRP and PRP (although LRP results in slightly more urinary problems than
RRP and PRP).114–116
Another notable difference between the procedures is the difference in length of hospital stay for LRP or
RALRP. We account for a shorter hospital stay for PRP (one-third less than for RRP) as reported in Martis
and colleagues.114 RALRP is also associated with a shorter length of stay, estimated to be 1 day less than
for the standard open procedure in a recent UK business case analysis (Oxford Radcliffe Hospitals NHS
Trust).117 RALRP requires a significant capital investment which we include as an approximate figure
of £3000 per patient in addition to the non-capital costs, based on the most expensive robot system
and assuming a fairly large centre with a throughput of around 150 patients per year (Ramsay and
colleagues118). RALRP is also associated with more costly consumables and a longer operating time (Oxford
Radcliffe Hospitals NHS Trust). The current NHS reference cost for prostatectomy includes both RRP andNIHR Journals Library www.journalslibrary.nihr.ac.uk
shown
s hormones
arm. At the time of analysis only one RCT had published its results in full, and these data were used in
rence
t price and
was scheduled for review by NICE, this topic was not evaluated using the full guideline model. The
luated by
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58A recent HTA report conducted a thorough review of the clinical evidence and found eight studies
reported across 13 publications.105 The authors concluded that ‘the studies are too heterogeneous both
for meta-analysis and to attempt to identify variation in effects by dose’. Given the limitations described,
the authors restricted their economic analysis to those studies that reported biochemical relapse-free
survival. They used the outcomes from each study as a different scenario in evaluate in their economic
model (Table 11).
We replicated the third modelling scenario (based on data from Morgan and colleagues132) from Hummel
and colleagues105 using biochemical recurrence data, frequency of sexual function and urinary adverse
events from Widmark and colleagues.96 We also included an increased frequency of bowel adverse events
with intensity-modulated radiation therapy (IMRT), as reported in Vora and colleagues.133the Department of Health National Radiotherapy Advisory Group. Neither intervention was eva
NICE in CG58.54structure of the model would easily allow such an evaluation in the future.
Topic H: intensity-modulated radiation therapy and image-guided radiation
therapy versus conformal radiotherapy
Intensity-modulated radiotherapy and image-guided radiation therapy (IGRT) have been recommended byto allow for the small survival improvement at the end of the pathway, using the survival diffe
reported in the ALSYMPCA trial.129 However, as the radium-223 chloride did not yet have a listhe base-case model. No changes to the base-case model were required to evaluate this topic.
Topic G: radium-223 chloride versus strontium-89 for men with
castration-refractory prostate cancer and painful bone metastases
This topic was suggested because of the promising results shown in a Phase III RCT, ALSYMPCA
(Alpharadin in Symptomatic Prostate Cancer Patients).129 This study suggests that radium-223 chloride
compared with placebo plus BSC, including strontium-89, significantly improves overall survival in patients
with CRPC that has spread to the bone. Roughly 90% of men with castration-refractory disease suffer
from painful bone metastases which are currently not treated directly; these patients receive ‘best
supportive care’, which includes strontium-89 to relieve pain.
Strontium-89 is included in the base-case model as an additional cost near the end of life; however, the
health benefit of pain relief is not accounted for in the model. The model structure was therefore adaptedcontinuous hormone therapy for patients with metastatic prostate cancer. Two RCTs97,128 have
almost identical survival outcomes, with a slighter longer time to progression in the continuou
97not statistically significant, and the base-case model does not reflect differences between interventions in
terms of adverse events in the palliative treatment section of the model. Thus, we assumed that any
potential difference in adverse events has no impact on either survival or HRQoL. The drug schedules are
the same (a starting dose at time 0, and monthly injections thereafter). Thus the drug cost for the
first year of treatment (using BNF prices) will be £3352, £1812 and £903 for the high-dose degarelix
(240 mg/160mg thereafter), low-dose degarelix (240mg/80 mg thereafter) and leuprorelin
(7.5 mg monthly) respectively.
Given the above assumptions, formal modelling is not required to show that leuprorelin would be
dominant (i.e. cheaper and equally effective). Therefore, given the limitations in the available evidence, this
topic was not evaluated using the full guideline model.
Topic F: intermittent hormone therapy versus continuous hormone therapy
for men with metastatic prostate cancer
The NICE prostate cancer guideline (CG58)54 did not address the question of intermittent compared with57
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given
eceive some
TABLE 11 Modelling scenarios in Hummel and colleagues 2010105
CASE STUDY 1: FULL GUIDELINE MODEL FOR PROSTATE CANCER
58On average, around one in three men diagnosed with prostate cancer will receive ‘watchful w
1 in 10 men will receive AS. Approximately 60% of men diagnosed with prostate cancer will rin Appendix 5.
Results
Base-case estimates of costs and health outcomes
The results of the base-case model provide a mean estimate of the numbers of patients in each section of
the pathway and the associated mean costs and mean health effects (life-years and QALYs gained) for the
total cohort of patients in the model. Table 13 shows the estimated number of men in each section of the
base-case (current service) model, reported for a cohort of 1000 men referred into secondary care with
suspected prostate cancer. The analysis suggests that just over 20% of men presenting to secondary care
with symptoms suspicious of prostate cancer will be diagnosed with prostate cancer.
aiting’ andTable 12 summarises the modelling undertaken for each update topic, the structural impact on
base-case model and the data requirements for each scenario. Full details of the data used areTopic I: active surveillance in previously unscreened ‘low-risk’ men
This topic suggestion indicates that men with low-risk disease according to the D’Amico classification are a
heterogeneous group and implies ‘Active Surveillance’ may not be the optimal treatment strategy for some
of these patients. However, the question is vague as it does not propose an alternative risk classification
system or an alternative treatment pathway to evaluate. Although both of these options could in principle
be evaluated using the pathway model, no modelling was attempted for this topic as further work would
be needed to define an answerable clinical and economic question.
the
Study Group Dose (Gy) Scenario
Vora and colleagues 2007133 IMRT 75.6 Difference in biochemical
recurrence-free survival
3DRT 68
Kupelian and colleagues 2002/5130,131 IMRT 70a Difference in biochemical
recurrence-free survival
3DRT 78a
Morgan and colleagues 2007132 IMRT/3DRT 80/81 No difference in biochemical
recurrence-free survival
3DRT, 3D-conformal radiotherapy; IMRT, Intensity-modulated radiation therapy.
a Considered biologically equivalent.form of radical treatment, including those men who switch to treatment after some time of AS.
Approximately half of all men diagnosed with prostate cancer will at some point in their lives receive
hormone treatment. Around one-third of men diagnosed with prostate cancer are expected to receive
palliative chemotherapy.
Table 14 shows the contribution of each segment of the model to overall life-years gained and QALYs
gained. The results show that, on average, each man referred into secondary care with suspected prostate
cancer can expect to live for 13.96 years and will accrue around 11.18 QALYs (undiscounted).
The costs associated with each workcentre within the model are shown in Table 15. The model suggests
that over the lifetimes of a cohort of 1000 men, expenditure on radical treatment is almost three times
that of palliative treatment. For the 1000 men referred, the expected discounted lifetime cost associated
with the base-case configuration of UK services is around £6.5M (£6500 for each man referred).
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TABLE 13 Intermediate results (per 1000 men referred)
Intermediate results Mean 2.5th percentile 97.5th percentile
Number patients diagnosed 215.88 146.95 292.67
Number patients never diagnosed 784.12 707.33 853.05
Number patients entering watchful waiting 63.14 40.16 91.24
Number patients entering AS 23.31 15.22 33.10
Number patients undergoing radical treatment 125.02 85.32 172.25
Number patients cured by radical treatment 14.93 9.75 21.20
Number patients getting hormone treatment 101.69 68.92 136.80
Results from probabilistic base-case model.
TABLE 14 Health outcomes by base-case model segment (per 1000 men referred)
Model segment
Undiscounted Discounted
LYG QALYs LYG QALYs
From model entry to death or diagnosis 11,070.54 9008.60 7934.80 6456.90
From start of radical treatment to cure, relapse or other-cause death 1196.35 973.21 893.90 727.17
AS to radical treatment, death or watchful waiting 181.03 147.28 145.29 118.20
Watchful waiting to palliative treatment or death 545.72 443.89 415.21 337.73
Palliative treatment to the end of PFS (third line) 330.45 242.68 258.11 189.55
Fourth-line palliative treatment: chemotherapy 39.92 25.30 28.95 18.35
From end of PFS from fourth-line treatment to death 605.45 341.43 374.36 211.12
LYG, life-year gained.
Results from probabilistic base-case model.
TABLE 15 Costs from the base-case model (per 1000 men referred)
Workcentre Undiscounted costs (£) Discounted costs (£)
PSA secondary care 2,342,422 1,682,779
GP PSA test 374,922 268,588
Biopsy 390,979 354,920
Bone scan 1158 967
BPH 272,793 247,392
Determine treatment 74,712 73,978
Watchful waiting 25,928 19,466
AS 58,094 47,257
Radical treatment 3,759,894 2,893,291
Palliative treatment 1,072,554 896,817
Total 8,373,456 6,485,454
Results from probabilistic base-case model.
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Incremental cost-effectiveness analysis
Table 16 presents the mean service costs and health outcomes for all 13 possible variations to the
pathway, based on 1000 patients. A full incremental analysis was undertaken within each guideline topic;
these results are described below.
Topic A: pelvic radiotherapy with adjuvant hormone therapy for men with
localised prostate cancer
Three possible alternatives were compared in topic A. In the base-case model we assumed that 50% of
men with high-risk or locally advanced disease would receive radiotherapy with adjuvant hormone
treatment, whereas the remaining 50% would receive hormone treatment alone. Option A2 assumed that
all eligible men would receive radiotherapy with adjuvant hormone treatment. Option A3 assumed that all
eligible men would receive hormone treatment alone.
TABLE 16 Summary of mean costs and outcomes for all options tested (per 1000 men referred)
Options Description
Undiscounted Discounted
Mean
LYG
Mean
QALYs
Mean
cost (£)
Mean
LYG
Mean
QALYs
Mean
cost (£)
Base
case
Current recommended service
pathway
13,969 11,012 8,373,456 10,051 7937 6,485,454
A2 All patients with high-risk
disease receive
radiotherapy + hormone therapy
14,038 11,090 8,537,561 10,084 7981 6,551,211
A3 All patients with high-risk
disease receive hormone therapy
only
13,902 10,937 8,210,568 10,018 7894 6,419,836
B2 All patients suitable for surgery
have PRP
13,969 11,010 8,410,989 10,051 7936 6,510,380
B3 All patients suitable for surgery
have LRP
13,969 11,011 8,437,810 10,051 7936 6,533,648
B4 All patients suitable for surgery
have RALRP
13,969 11,021 8,309,678 10,051 7943 6,458,066
CD2 All patients not suitable for
surgery have HDR + radiotherapy
13,954 11,017 9,043,842 10,041 7939 7,141,438
CD3 All patients not suitable for
surgery have LDR + radiotherapy
14,017 11,092 8,771,330 10,074 7985 6,812,138
CD4 All patients not suitable for
surgery have brachytherapy
14,075 11,165 7,407,755 10,099 8021 5,720,469
CD5 All patients not suitable for
surgery have
14,031 11,076 8,738,726 10,081 7974 6,694,736
CASE STUDY 1: FULL GUIDELINE MODEL FOR PROSTATE CANCER
62palliative treatment
H2 All patients receive IMRT instead
of conformal
radiotherapy + hormone therapy
13,969 11,004 8,540,108 10,051 7932 6,602,819
LYG, life-year gained.hormone therapy as first-lineradiotherapy + hormone therapy
F2 All patients receive continuous
hormone therapy as first-line
palliative treatment
14,026 11,043 8,453,604 10,085 7956 6,535,322
F3 All patients receive intermittent 13,901 10,970 8,400,305 10,020 7916 6,496,847NIHR Journals Library www.journalslibrary.nihr.ac.uk
The results of the analysis are shown in Table 17. This suggests that offering all men with high-risk or
locally advanced disease radiotherapy in addition to hormone treatment, rather than hormone treatment
alone, is expected to be the most effective and the most expensive option. Offering hormone therapy
alone is expected to produce the fewest QALYs and the lowest overall cost. The base-case service, which
involves a combination of the other two options, is ruled out due to extended dominance. Radiotherapy
plus hormone therapy compared with hormone therapy alone is expected to yield a discounted ICER of
around £1522 per QALY gained.
Figure 10 presents cost-effectiveness acceptability curves for the three options compared in topic A.
At very low values of λ (when health is valued less) hormone therapy alone is expected to produce the
greatest net benefit (NB). At threshold values of around ≥ £5000, radiotherapy plus hormone therapy is
expected to produce the most NB. Assuming a willingness-to-pay threshold of £20,000 per QALY gained,
the probability that radiotherapy plus hormone therapy produces the greatest NB is approximately 1.0.
Topic B: surgical techniques for localised prostate cancer
Topic B involves a comparison of four alternative surgical procedures for men eligible to undergo radical
prostatectomy. The base-case strategy assumed all men would undergo a standard open procedure.
Option B2 assumed that all men would have a PRP. Option B3 assumed men would have a LRP. Option B4
assumed that all men would receive a RALRP.
The results of the economic analysis of this topic are presented in Table 18. Unsurprisingly, the model results
indicate very little difference in terms of incremental health gains between the evaluated options. The
model suggests that RALRP (option B4) is associated with a slight increase in QALYs compared with the
other options. This is also the least expensive option, hence it is expected to dominate all other options.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Figure 11 presents cost-effectiveness acceptability curves for the four options compared in topic B.
Assuming a willingness-to-pay threshold of £20,000 per QALY gained, the analysis shows that RALRP is
always likely to produce the greatest NB, compared with the standard RRP open procedure. However,
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FIGURE 10 Cost-effectiveness acceptability curves: topic A.
TABLE 17 Incremental cost-effectiveness results: topic A (per 1000 men referred)
Option
Total
QALYs Total cost (£)
Incremental
QALYs
Incremental
cost
ICER
(£ per QALY)
Radiotherapy + hormone therapy (A2) 7980.68 6,551,211 86.34 131,375 1522
Base case (combination) 7937.14 6,485,454 – – –
Hormone therapy only (A3) 7894.34 6,419,836 – – –63
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B4RALRP (B4) 7943 6,458,066 – –TABLE 18 Incremental cost-effectiveness results: topic B (per 1000 men referred)
Option
Total
QALYs
Total cost
(£)
Incremental
QALYs
Incremental cost
(£)
ICER
(£ per QALY)
Dominatingthere is still considerable structural uncertainty with respect to the duration of adverse events and the costs
of managing these, which are not addressed with probabilistic sensitivity analysis.
Topic C/D: brachytherapy + external beam radiotherapy for men with localised
or locally advanced prostate cancer
The evaluation of topic C/D involved a comparison of five alternative options. The base-case model assumes
that patients with intermediate-risk disease will receive radiotherapy plus hormone treatment and those
with high-risk disease may receive radiotherapy plus hormones or brachytherapy monotherapy. Option CD2
involve brachytherapy in combination with external beam radiation as high dose. Option CD3 involves
brachytherapy in combination with external beam radiation as low dose. Option CD4 represents
brachytherapy monotherapy. Option CD5 represents radiotherapy plus adjuvant hormone treatment.
Table 19 presents the results for the economic analysis of topic C/D. The results suggest that brachytherapy
monotherapy (option CD4) is associated with the highest expected QALY gain and the lowest cost.
All other options, including the current base case, are dominated by this strategy.
Figure 12 presents the cost-effectiveness acceptability curves for topic C/D. Assuming a willingness-to-pay
threshold of £20,000 per QALY gained, the probability that brachytherapy monotherapy produces the
greatest NB is approximately 0.84.
Topic F: intermittent hormone therapy versus continuous hormone therapy
for men with metastatic prostate cancer
Topic F involved the economic comparison of three options. The base-case model assumed 90%
of men who received either continuous or intermittent hormone treatment would receive luteinising
hormone-releasing hormone analogue (LHRHa) continuously, with 10% receiving LHRHa intermittently.
Option F2 represents continuous hormone therapy and option F3 represents intermittent hormone therapy.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 19 Incremental cost-effectiveness results: topic C/D (per 1000 men referred)
Option
Total
QALYs
Total
cost (£)
Incremental
QALYs
Incremental
costs
ICER
(£ per QALY)
Brachytherapy monotherapy (CD4) 8021 5,720,469 – – Dominating
Brachytherapy + LD external beam
radiotherapy (CD3)
7985 6,812,138 – – Dominated
Radiotherapy + adjuvant hormone therapy
(CD5)
7974 6,694,736 – – Dominated
Brachytherapy + HD external beam
radiotherapy (CD2)
7939 7,141,438 – – Dominated
Base case 7937 6,485,454 – – Dominated
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58HD, high dose; LD, low dose.
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hormone treatment is expected to produce the greatest number of QALYs at the highest cost. Option F3
(intermittent hormones) is expected to be dominated by the base-case service. Continuous hormone therapy
is expected to cost approximately £2700 per QALY gained when compared with the base-case service.
Figure 13 presents the cost-effectiveness acceptability curves for topic F. Assuming a willingness-to-pay
threshold of £20,000 per QALY gained, the probability that continuous hormone therapy produces the
greatest expected NB is approximately 0.87.
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FIGURE 12 Cost-effectiveness acceptability curve: topic C/D.
TABLE 20 Incremental cost-effectiveness results: topic F (per 1000 men referred)
Option
Total
QALYs
Total cost
(£)
Incremental
QALYs
Incremental
costs
ICER
(£ per QALY)
Continuous hormone
therapy (F2)
7956 6,535,322 18.47 49,868 2700
Base case 7937 6,485,454 – – –
Intermittent hormone
therapy (F3)
7916 6,496,847 – – Dominated
65
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Topic H: intensity-modulated radiation therapy versus conformal radiotherapy
Topic H compares IMRT (option H2) against the base-case strategy (3D-conformal radiotherapy). The
headline economic results are presented in Table 21. The economic analysis suggests that IMRT is expected
to result in fewer QALYs and a greater expected cost than 3D-conformal radiotherapy.
Figure 14 presents cost-effectiveness acceptability curves for topic H. Assuming a willingness-to-pay
threshold of £20,000 per QALY gained, the probability that 3D-conformal radiotherapy produces more
NB than IMRT is approximately 0.99.
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FIGURE 13 Cost-effectiveness acceptability curve for topic F.
TABLE 21 Incremental cost-effectiveness results: topic H (per 1000 men referred)
Option
Total
QALYs
Total cost
(£)
Incremental
QALYs
Incremental
costs
ICER
(£ per QALY)
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IMRT (H2) 7932 6,602,819 – – Dominated
3DRT, 3D-conformal radiotherapy.
1.000.00
0.20
0.40
0.60
0.80
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
0 20 40 60 80 100
Cost-effectiveness threshold (£000s) (λ)
Baseline
H2
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Summary of economic results and implications for updating
guideline topics
Table 22 summarises the results of the economic analyses in terms of the expected absolute net benefit
for each option and the probability that each option produces the greatest net benefit as compared with
other options within each guideline topic. The option which is preferred on the grounds of expected
cost-effectiveness within each topic is highlighted in bold.
For topics A, B, C/D and F, the economic analysis indicates that the current base-case service is not
expected to produce the greatest amount of net benefit. In each of these circumstances, additional
health benefits may be attainable by pursuing other treatment options. This would indicate that these
topics should be considered for update in the guideline. On the basis of the magnitude of expected
INB lost between each option as compared with the base-case service, topics A, C/D and F represent
the top three priorities for update on economic grounds. Topic B is also associated with lost net
benefit, although this is less than that for the other topics.
TABLE 22 Summary of NB results (per 1000 men referred)
Topic Option
At £20,000 per QALY
gained At £30,000 per QALY gained
INBa (£)
Probability
optimal INBa (£)
Probability
optimal
A Base case 0 0.00 0 0.00
A2 – radiotherapy + hormone therapy 804,983 1.00 1,240,353 1.00
A3 – hormone therapy only –790,423 0.00 –1,218,444 0.00
B Base case 0 0.00 0 0.00
B2 – PRP –57,590 0.00 –73,923 0.00
B3 – LRP –74,465 0.00 –87,600 0.00
B4 – RALRP 149,966 1.00 211,255 1.00
C/D Base case 0 0.00 0 0.00
C2 – brachytherapy + HD external
beam radiotherapy
–623,607 0.00 –607,419 0.00
C3 – brachytherapy + LD external
beam radiotherapy
635,095 0.07 1,115,984 0.11
C4 – brachytherapy monotherapy 2,443,541 0.92 3,282,819 0.87
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58C5 – radiotherapy + adjuvant
hormone therapy
521,177 0.02 886,407 0.02
F Base case 0 0.00 0 0.00
E2 – continuous hormone therapy 319,543 0.87 504,248 0.86
E3 – intermittent hormone therapy –437,557 0.13 –650,639 0.14
H Base case 0 0.99 0 0.99
H2 – IMRT –213,792 0.01 –262,005 0.01
HD, high dose; LD, low dose.
a The potential NB gain from changing the pathway compared with baseline model (per 1000 men referred).67
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up care and
palliative treatments. The full guideline model differs from conventional piecewise models in that it adopts
Topic F: Intermittent hormone therapy compared with continuous hormone therapy for men with
recognise that most of these problems are not a result of the modelling methodology itself; rather, the
, irrespective
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68same problems with evidence would apply to the development of any health economic modelmetastatic prostate cancer.
Evidently, there is disagreement between the topics which would be prioritised on economic grounds and
those which would be prioritised by the stakeholders who responded to our survey (see Chapter 3).
Although both the economic analysis and the surveys indicate that some benefit may be obtained by
prioritising topic B (surgical techniques), this is associated with a comparatively small amount of net benefit
lost relative to the base-case service.
Limitations of the analysis
As with any health economic model, the credibility of this model and its results are largely dependent on
the quality of the evidence used to inform it. There are a number of limitations of the economic analyses
presented here, the majority of which derive from limitations in the evidence base. It is important toprostate cancer.
la broader pathway-level scope while retaining a high level of depth across the individual pathway
components. Although most conventional models are developed to address a single decision problem at a
specific decision point in a care pathway, this full guideline model provides a platform for the evaluation of
multiple options for service change across the whole service pathway. Although these are presented solely
as analyses of individual guideline topics, the model also has the functionality to evaluate multiple topics
simultaneously. This represents a more powerful decision-making tool than has been used in the majority
of existing CGs.
Headline probabilistic model results
We evaluated six of the nine selected guideline topics. Our analysis indicates that for five of these topics
the current guideline recommendations are not expected to produce the greatest NB. Although these
results are not definitive – as, for example, they are not based on systematic reviews of the evidence – they
are indicative of areas where further investigation is likely to be of value. In particular, the economic
analysis indicates that:
l offering all men with high-risk or locally advanced disease radiotherapy plus hormone treatment is
expected to have an ICER of around £1500 per QALY gained when compared with hormone
therapy alone
l RALRP is expected to dominate all other surgical options for localised prostate cancer
l brachytherapy monotherapy is expected to dominate alternative radiotherapy options for men with
localised or locally advanced prostate cancer
l continuous hormone treatment is expected to yield an ICER of around £2700 compared with the
current mix of continuous and intermittent hormone treatments
l 3D-conformal radiotherapy is expected to dominate intensity-modulated radiotherapy.
In terms of net benefit lost (by choosing the base-case service over other potentially more cost-effective
decision alternatives), the following three topics represent the highest priorities for update:
l Topic A: Pelvic radiotherapy with adjuvant hormone therapy for men with localised prostate cancer.
l Topic C/D: Brachytherapy plus external beam radiotherapy for men with localised or locally advancedimaging, GP monitoring, treatment planning, watchful waiting, AS, radical treatments, follow-Discussion
The full guideline model presented within this chapter captures the key events, costs and health outcomes
associated with the main elements of care for men referred into secondary care with suspected prostate
cancer. The model reflects the broad range of components of the care pathway including diagnosis andNIHR Journals Library www.journalslibrary.nihr.ac.uk
reatment.
We also necessarily assumed that Gleason score was fixed from the point of diagnosis as we found no
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58evidence to reflect the potential trajectory of change in Gleason score over time. Given these issues, the
lack of evidence invariably limits the level of depth (or detail) reflected in the pre-diagnostic portion of the
model. The consequence of this lack of evidence led to certain elements of the model becoming ‘blunt’
and in some instances to a separation between our conceptual understanding of how diagnostic and
treatment decisions are made in practice and the extent to which the model can reflect these decisions.
As a consequence, we were unable to capture any of the NICE prostate cancer guideline CG58
recommendations based on observed changes in PSA score, doubling time or velocity.
In addition, the simulation model includes only a partial representation of the natural history of prostate
cancer. As a result, the portion of the model dealing with the underlying natural history and diagnosis is
fairly simplistic. This set of simplifications was driven by significant limitations in the available evidence base
with respect to underlying natural history progression and the lack of good-quality evidence relating to the
probabilities and consequences of incorrect diagnostic decision-making. We did not assess the impact of
the error associated with PSA testing, MRI or bone scans. We also assumed TRUS-guided biopsy was
associated with perfect specificity and the evidence used to estimate the false-negative rate is dated.90 As
with the evaluation of any diagnostic intervention, the lack of evidence regarding the costs and
consequences of counterfactual pathways that would be followed by patients with misclassified disease
presents a further challenge which we chose not to fully address within the model.
Our estimation of the natural history of prostate cancer was crude, calibrated using data on patients in the
watchful waiting arm of the Bill-Axelson and colleagues RCT78 and UK-specific life tables using theevidence concerning the relationship between PSA score, underlying disease progression and tof its scope. One of the key values of mathematical modelling, in particular modelling on this scale, is its
ability to draw out the key gaps and uncertainties in the evidence base. The following key simplifications
should be borne in mind when interpreting the results of the economic analysis:
l The available registry data did not include the PSA score at diagnosis. Gleason score is assumed to be
fixed from the point of diagnosis when in reality this could change following a repeat biopsy.
l PSA-based criteria for informing treatment decisions were not fully captured in the active treatment
portions of the model.
l The potential impact of misclassification of diagnostic tests was not reflected in the model because of
the inherent difficulties of modelling inaccurate diagnoses and the impact on outcomes. In addition,
test operating characteristics were captured only for TRUS.
l The model includes only a partial representation of disease natural history – the model does not
include the incidence of prostate cancer over time – that is, all patients either have or do not have
prostate cancer on model entry.
l Much of the evidence used to inform the treatment portions of the model required naive indirect
comparisons due to a lack of randomised evidence.
l We assumed that biochemical progression and disease recurrence have an equivalent impact on clinical
decision-making and subsequent prognosis.
l Survival benefits for sequences of palliative treatments were assumed to be driven by the first-line
treatment in the sequence. In addition, sequences of palliative treatments are modelled according to
an overall mean time and do not fully reflect treatment variations between patients.
Key evidence limitations and model simplifications
The adoption of an individual patient-level simulation approach can place heavy demands on a model in
terms of data. In the absence of well reported summary statistics, such as variance-covariance matrices
across multiple patient characteristics, access to individual-level data on patient characteristics at model
entry is essential to fully characterise the correlations between the key patient characteristics. We used UK
cancer registry data on age, clinical stage and Gleason score from the SWPHO registry. This registry data
set did not however include information on patients’ PSA scores; instead these were ‘back-calculated’
conditional on the characteristics for which we had data. Furthermore, we did not identify any robust69
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70Usefulness of the broader modelling approach
Volume of economic evidence generated
A total of nine topics were selected for evaluation. Two of these topics dealt with potentially competing
interventions at the same point in the pathway (topics C and D). Six topics were subjected to formal
CEAs using the full guideline model. The economic analysis of three topics was not attempted. Topic E
was not evaluated due to a total lack of evidence, topic G because the intervention did not have a list
price (and is not being actively marketed), and topic I was not undertaken as the question was not
sufficiently defined to identify the relevant comparator(s).
It is reasonable to suggest that the full guideline model provides considerably more economic information
than would otherwise be available from the conventional piecewise approach. It remains unclear, however,
whether or not the resources and effort required to develop the full guideline model exceeds what would
be required to undertake the same economic analyses using five individual de novo piecewise models.
With the exception of topic I (AS strategies for previously unscreened men), all of the topics selected for
the case study reflect active treatments for diagnosed disease. In principle, the full guideline model could
also be used to address a wide range of other decision problems across the prostate cancer service which
were not selected for inclusion in the update (e.g. assessing the optimal frequency of GP monitoring visits
or assessing alternative biopsy techniques).
Development time
The time and resource required to develop the model were considerable. Model development began in
August 2010 and the final results were produced in November 2012. Two modellers were involved in
designing and implementing the model. It is reasonable to suggest that a considerable proportion of thisfor the sequence, with subsequent treatments influencing the amount of time for which the p
progression-free. This is a common problem in cancer evaluations and is again not specific to t
modelling methodology. In addition, because PFS includes survival as an event, we were unaband resource. Given that none of the topics selected for evaluation actually related to diagnostic
interventions or screening, this additional effort would have had, at best, a limited payoff for the context
of the case study. However, it is acknowledged that the value of explicitly modelling epidemiology and
natural history progression may be greater in guidelines for other diseases. Further extension of this
component of the model may increase the utility of the model in addressing other decision problems
elsewhere in the prostate cancer pathway.
The treatment portion of the model is also subject to a number of problems relating to the availability and
quality of evidence. No modelling approach can reconcile the absence of head-to-head trials comparing all
relevant radical treatment options and a comprehensive evidence network. In most instances, we had little
choice but to use naive indirect comparisons to capture the relative effects of radical and palliative
treatments. This breaks randomisation between studies and can lead to significant bias and confounding.
However, again, we believe this problem lies in the evidence base rather than the modelling approach per
se. In other instances, we were also limited by relevant trials reporting less relevant or useful outcomes.
The palliative treatment portion of the model is intended to reflect the impact of different sequences of
treatments on HRQoL and survival. However, we did not identify any studies which assessed planned
sequences of treatment. As such we assumed that the first-line treatment determines the survival benefitmonitoring studies. The design and implementation of a more comprehensive calibration procMetropolis–Hastings algorithm. Although we believe the calibration method is appropriate, undoubtedly
other information sources would tell us something about these unobservable parameters. This could
include evidence from screening trials, autopsy studies or evidence from prostate cancer surveillance andNIHR Journals Library www.journalslibrary.nihr.ac.uk
time involved developing familiarity with the software package and the inevitable learning curve associated
with developing models on this scale. It may have been possible to develop the same model within the
timescales of a ‘live’ CG, although this could represent a risk to the delivery of the guideline. The
magnitude of this risk will inevitably vary across different guidelines and different disease areas.
Alternatively, it may be possible to develop this type of model before the CG development process begins.
Problems of the approach
Although the adoption of a broad model scope is attractive in terms of the volume and consistency of
economic evidence that can be generated using a single model, it does carry with it a number of potential
risks and costs. For example, one could argue that the scope was too broad – we modelled the breadth of
the whole pathway from secondary care referral yet only topics related to treatment were evaluated using
the model. Thus, considerable development time was devoted to developing parts of the model for which
topics were not actually prioritised. Of course, the case study was not undertaken as part of a live
guideline process and the model may have potential for evaluating a wider range of topics than those
selected for inclusion in the case study.
The development of a single model may offer consistency but also carries a cost in terms of running
the evaluation. It remains debateable whether simulation models are easier or harder to check than
cohort-based models. However, when an error is identified, either in the conceptual or quantitative basis
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58of the model, this error will influence all decision problems addressed using that model. Where errors are
spotted, this can mean rerunning all analyses, potentially multiple times. Where errors are not spotted,
these may permeate through the evaluation of multiple topics (although the precise nature of the error will
determine whether or not this makes a difference to the conclusions of any individual topic). Given the
likely computational burden associated with this type of model, this can represent a negative aspect of the
approach. In this case study, all analyses were rerun five times each of which required approximately
1200 computation hours. Although this was not ideal, it was possible by spreading the model runs across
multiple computers using multithreading; while not substantial in this case, pursuing this type of modelling
approach may have implications for purchasing both hardware and software.
A final potential problem relates to how this type of large-scale complex model would be interpreted by a
GDG. We did not have access to the GDG itself and so we were unable to gauge whether they would find
this type of model more or less useful than conventional piecewise models. Testing of the approach, and
the qualitative elicitation of the views of GDG members should be considered a priority for future research.71
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Chapter 5 Case study 2: full guideline model for
can
sometimes present as a critical condition with haemodynamic instability requiring urgent treatment,
cidence of
to address a
ed economic
evaluations of some changes to the current pathway related to the potential update topics identified in
Chapter 3. The purpose of this analysis was to illustrate the process of developing a full guideline model,
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58and to test its ability to evaluate cost-effectiveness questions. The results are indicative of topic areas
where further investigation is likely to be of value. We did not conduct systematic reviews to inform
estimates of effectiveness or other model parameters, and so the results should not be used directly to
inform clinical policy or practice.diagnosed and treated in accordance with CG36.136 The model was designed to predict the in
AF-related risks and associated health outcomes and expenditure, so as to provide a platform
range of cost-effectiveness questions across the care pathway. To test the model, we conductalthough in contrast some patients do not experience symptoms at all and might be unaware of their
condition. AF is associated with a greatly increased risk of death from stroke and other thromboembolic
events, heart failure and cardiovascular disease. Three types of AF have been distinguished: paroxysmal,
persistent and permanent AF. Paroxysmal AF is characterised by short episodes of irregular heart rhythm
lasting < 7 days, normally < 48 hours. Persistent AF is associated with longer episodes, which do not
terminate without intervention. In permanent AF there is a perpetual fibrillation of the atria. The ‘natural’
course of AF is generally progressive, with the frequency and duration of symptomatic episodes usually
increasing over time.
Atrial fibrillation is common, affecting 1–2% of the general population, and is associated with age
(a European study estimated the prevalence at 0.7% for people aged 55–59 years, rising to 17.8% for
people aged ≥ 85 years).135 Recent increases in AF prevalence have been attributed to improvements in
survival for cardiovascular conditions associated with AF, and the ageing population. Resources consumed
in the treatment of AF are estimated to account for nearly 1% of the UK NHS expenditure. The impact of
AF on mortality and quality of life, and the associated economic burden led to the commissioning of a CG
by NICE.
The scope for the NICE CG (CG36),136 published in 2006, covered the processes of patient care including
identification and diagnosis, treatment for the prevention of stroke and TE, electrical and pharmacological
methods to correct heart rhythm (‘cardioversion’ to achieve sinus rhythm), drugs to maintain heart rhythm
or to control heart rate, monitoring and referral for specialist electrophysiological interventions such as
pacing or ablation.137 The guideline also covered acute treatment for haemodynamically unstable patients,
and the prevention and treatment of AF in patients undergoing cardiac surgery.
Aims of the case study
The aim of this case study was to develop a model to reflect the course of AF for a cohort of patientsof symptoms including chest pains, palpitations, angina, shortness of breath and fatigue, andatrial fibrillation
This chapter presents a case study showing the development of a full guideline model to evaluatemultiple decision problems across the AF pathway.
Introduction
Introduction to the context of the case study
Atrial fibrillation is a condition characterised by irregular and rapid heart rhythm.134,135 It can cause a range73
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74documentation for CG36 to develop an understanding of the recommendations, the available
and the GDG rationale for decisions.135 The NICE QRG document was also useful, as this conta
flow charts and other illustrations that put the recommendations together into a connected paSeveral documents were identified that were very influential in the development of our model structure.
These included economic evaluations and models that covered different aspects of the diagnosis and
treatment of AF that we sought to bring together in a model of the whole service pathway and
disease process:
l Case finding: A HTA-funded project by Hobbs and colleagues138 included a clinical trial and economic
evaluation of methods for screening for AF. This provided data on the accuracy of diagnostic methods,
as well as informing the design of the decision tree in the diagnostic section of our model.
l Antithrombotic therapy: Various models have been developed to evaluate the cost-effectiveness of
antithrombotic therapy.139–144 Drug treatments include antiplatelet agents (aspirin and clopidogrel) and
anticoagulants (warfarin, dabigatran, rivaroxaban and apixaban). These drugs are all effective at
reducing the risk of TE, but at the risk of causing dangerous bleeds. In addition, the mainstay of oral
anticoagulation (OAC), warfarin, requires regular monitoring which is difficult, inconvenient for the
patient and expensive. The available models estimate the balance between these various risks and their
health and financial consequences. For this element of our model, we drew particularly on the models
developed for the recent NICE TAs of dabigatran and rivaroxaban, and the critique of these models
provided by the Evidence Review Groups and the Appraisal Committee considerations.139,140,145–148
The NICE TA of another OAC drug (apixaban, Eliquis®, Bristol-Myers Squibb) was published after
completion of our model (www.nice.org.uk/TA275), and so did not influence our work.
l Antiarrhythmic therapy: Another recent NICE TA that provided valuable information for the
construction of our model was TA197, which compared dronedarone (Multaq®, Sanofi-Aventis) with
other drugs for the maintenance of sinus rhythm [amiodarone and the class 1c antiarrhythmic drugs
(AADs)].149–151 The report of the sponsor’s model was particularly useful, as they used a DES technique.
The detailed critique provided by the Evidence Review Group and by the Appraisal Committee was also
very helpful in identifying important factors to include in our model.
l Ablation: Finally, we considered an HTA review and economic evaluation that compared antiarrhythmic
drug (AAD) therapy with radio frequency catheter ablation for the curative treatment of AF
and flutter.152
This list illustrates the wide range of models evaluating different parts of the AF service pathway, but we
did not find any models that brought together all of these elements in sufficient detail to provide a
platform for economic evaluation across the whole pathway.
Conceptual model development
Before constructing the computer model, a conceptual understanding and definition of the problem area
was developed. This comprised two key elements: (1) a model of the service pathway defined in CG36 and
(2) a model of the disease processes.
The design of the service pathway model began with detailed consideration of the full guidelinesources of data. We did not conduct formal critical appraisal of published economic evaluationMethods
Preliminary literature review
To inform model development, we conducted an initial review of literature on published economic models
for the disease area, related models from NICE guidance (e.g. TAs) and other HTA bodies and guideline
developers. We searched the following secondary databases, using general disease/patient group search
terms: (a) CRD NHS Economic Evaluation Database; (b) CRD HTA Database; (c) NHS Evidence; and (d) the
G-I-N database. This search was intended as a rapid means of identifying appropriate model structures andNIHR Journals Library www.journalslibrary.nihr.ac.uk
also
longitudinally broad, covering the spectrum of care for patients with all stages of the condition and
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58associated adverse events in primary and secondary NHS health-care settings, as well as referral to tertiary
care. The guideline group considered evidence and made recommendations on:
l identification of AF, including active case finding but not population screening
l investigations required to confirm diagnosis and to assess comorbidity
l treatment of acute-onset AF episodes with haemodynamic instability
l prevention and treatment of post-operative AF
l risk stratification and prophylactic antithrombotic treatment
l electrical and pharmacological interventions to promote and maintain heart rhythm
l pharmacological methods to control heart rate
l referral for specialist assessment
l reviewing and monitoring of patients with AF.
The model was also broad in scope, including most of the patient groups and interventions covered in the
guideline, although there were some exceptions. Owing to a lack of clarity and evidence about atrial
flutter this was not explicitly modelled as a separate group. We also chose not to model post-operative AF.
This was a pragmatic decision, due to anticipated difficulties in reviewing a separate body of
epidemiological and clinical evidence with limited time and resources. To evaluate preventative treatments
for post-operative AF would also have meant introducing a very different cohort of patients into the
model, including patients undergoing cardiac surgery who did not go on to develop AF.and atrial flutter that is indistinguishable from AF in terms of aim of treatment. The scope wasFor CG36, this included: an overview of the whole process from diagnosis to follow-up; strategies for
cardioversion in acute and non-acute situations; a decision tree defining the criteria for selecting rate or
rhythm control strategies; risk stratification and choice of drugs for prevention of stroke; and sequencing
of rhythm and rate control drugs. These QRG ‘algorithms’ were developed into much more detailed and
formalised flow charts necessary to provide a foundation for the simulation model. This involved in-depth
review of the full guideline and of the precise wording of the recommendations.
The conceptual service pathway model was drafted using flow charts, which were then checked with
clinical experts to identify errors or lack of clarity. Four clinicians, including a GP, two cardiologists
specialising in AF and an interventional electro-physiologist provided advice. The purpose of consulting
experts was to help the modellers to understand and interpret the pathway of care defined in CG36,
rather than to elicit information about how services are organised in practice, or the experts’ views on how
services should be organised. This process was essential to resolve some ‘gaps’ and ambiguities in the
guideline algorithms and documentation. We also sought information from the experts on sources of data
to inform the model parameters.
Another essential component of the conceptual model was an understanding of the disease course, how
this varies between individuals and how it can be modified over time by interventions and events. The
initial design of this disease process model for this guideline was informed by the preliminary literature
review described above, and again clinical experts were invited to comment on this approach.
Boundary and scope of the model
The aim of this case study was to model the service pathway recommended in the NICE AF CG
(CG36)136 to estimate associated patient flows, health outcomes and cost, to assess the incremental
cost-effectiveness of possible changes in the service pathway, and to estimate the value of updating
selected topics within the guideline. We therefore took the scope of CG36 as the starting point for
defining the model boundaries.137 However, there were some differences between the scope and model
boundaries which are described below.
The CG scope137 included people with new-onset or acute AF, chronic AF (CAF; including recurrent
paroxysmal, persistent and permanent/sustained AF), comorbidities that impact on AF, post-operative AF,75
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Although we considered adopting a population approach to modelling, to reflect costs and outcomes for
both prevalent and incident cases across time, this was not possible in the time available. Instead, the
model took a more conventional incident cohort approach, starting with a group of individuals being
tested for suspected AF, and following these individuals through until death. Information about the
demographic and clinical characteristics of individuals entering the model, which governs their risks of
adverse events and health outcomes, was taken from a primary care database (described below). A data
set of patients not diagnosed with AF was also obtained to allow modelling of case finding approaches
and to capture consequences of false-positive and false-negative test results. (In the event, these data were
not used as we did not identify sufficient information on the effectiveness of case finding or diagnostic
test accuracy to model these questions.) Extension of the model to post-operative AF would require a
similar individual-patient data set for this population, or sufficient information to generate such a data set.
CG36 did not review evidence relating to specialist interventions to identify and correct structural heart
abnormalities or electrophysiological problems, which might be the underlying cause of AF for some
individuals. Evaluation of implantable devices was explicitly excluded from the scope, as was evaluation of
tients were
Another common boundary issue for guideline models is the evolution of adjacent and sometimes overlapping
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76NICE guidance. During the course of this project, three NICE TAs within the model boundary were published:
two related to new OACs (dabigatran146 and rivaroxaban147) and one to a new AAD (dronedarone150). As NICE
CGs are expected to integrate current NICE TAs unchanged, we reviewed the evidence from these published
appraisals and attempted to integrate their recommendations in the CG36 pathway. However, we did not
include apixaban because the NICE TA on this drug was not published until after completion of our model.
The service pathway
Outline of pathway
Figure 15 gives a broad view of the flow of patients through the service pathway.
To enable an evaluation of case finding and screening strategies, two cohorts of patients can be fed into
the model (a cohort with AF and a cohort without AF). The proportion of patients with AF (p) can be
manipulated to represent more or less targeted case finding strategies, with different rates of prevalence in
AF
Diagnostic
pathway
Treatment
pathway
TN
Non-AF
FN Death
Ongoing
management
Routine review
Post-event review
Event
p
TP
(1–p)
FIGURE 15 Overview of AF service pathway model. FN, false-negative; p, prevalence of AF in patients tested for
suspected AF; TN, true-negative; TP, true-positive.outside the scope. The model therefore stopped, as did the guideline, at the point at which pa
referred to a tertiary specialist. This issue is discussed further below.‘novel/experimental’ arrhythmia surgery. The guideline group did recommend referral to a specialist if
symptoms could not be adequately controlled with conventional rate or rhythm control strategies, but they
did not recommend which further treatment options should be considered for which patients. There is
currently a lot of interest in various ablation techniques that are potentially curative of AF refractory to
AAD treatment.152–157 However, we did not explicitly include this within the model as it was consideredNIHR Journals Library www.journalslibrary.nihr.ac.uk
the population being tested. In the analyses presented below, however, we model results only for patients
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58presenting with ‘true’ AF.
Patients enter via the diagnostic module where they undergo a series of tests. If the tests are negative,
patients leave the diagnostic module and wait for the next event. Patients with false-negative results,
undiagnosed AF, are then at risk of another symptomatic AF episode or an AF-related event, such as a
stroke or TE. If this event is not fatal, they will then present again and return to the diagnostic module.
Patients with false-negative results who do not experience a symptomatic episode or AF-related event wait
in the model until they die from other causes.
Patients diagnosed with AF enter the treatment pathway, where they have their risk assessed and are
allocated treatments based on their personal characteristics and the guideline recommendations. These
treatments may include antithrombotic drugs, interventions to promote and maintain sinus rhythm, and/or
drugs to control their heart rate. These options are discussed below.
After treatment allocation, patients enter the ongoing management (OM) module, where they wait for the
next event. This can be a routine follow-up appointment, in which case they will cycle back through the
treatment pathway, and possibly have their treatment changed. Alternatively, they may experience an
event, which may include recurrence of arrhythmia, stroke or TE or an increase in another risk factor, such
as onset of hypertension or diabetes. Unless the event is fatal, the patient then returns to the treatment
pathway, and his or her treatment is reassessed.
Patients may cycle between the treatment pathway and OM modules many times over their lifetime,
reflecting the chronic nature of AF. The rate at which patients experience events and return for
reassessment is governed by their initial characteristics on model entry, their history of events within the
model, and the treatments that they receive. Patients can also leave the model at any time, due to death
from non-AF related causes.
Figure 16 expands on the contents of the diagnostic and treatment pathways. This contains eight blocks
related to eight main aspects of the pathway, and each linked to a chapter in CG36. Each block is also
further expanded into a detailed flow chart (see Appendix 6).
Diagnosis
Patients can enter the model through two routes: (1) primary care referral and (2) emergency attendance
due to an acute onset of AF. The acute onset pathway is described later. Patients presenting routinely may
be symptomatic, or they may have asymptomatic AF detected incidentally (e.g. by pulse palpitation in a
consultation for another purpose). AF symptoms range from breathlessness or palpitations through to
acute medical problems such as heart failure, stroke or TE. The precipitating trigger for an AF test is not
modelled, although patients may arrive with a history of AF-related conditions and an average utility
reduction is applied to reflect other symptoms.
Patients entering the model with suspected AF are referred to a specialist for an electrocardiogram (ECG)
(D1). AF can be missed by an ECG test, as it is often intermittent in nature (paroxysmal AF). If AF is not
confirmed by the ECG and the patient is not suspected of having paroxysmal AF, they will be discharged
(D13). However, a negative ECG might be accompanied by suspicion of paroxysmal AF (e.g. if the patient
reports symptoms such a fast heartbeat). In this case, an ambulatory ECG test might be performed, either:
(a) event-recorder related electrocardiogram ECG (ER ECG) (D8); or (b) a 24-hour ambulatory ECG (D9).
In general, the 24-hour ambulatory ECG would be used in patients with suspected asymptomatic episodes
or symptomatic episodes < 24 hours apart, whereas the ER ECG would be used in those with symptomatic
episodes > 24 hours apart. If an ambulatory ECG test is negative, and the doctor has a high index of
suspicion, a further ER ECG might be requested. The model assumes that patients can receive up to three
negative ambulatory ECG tests before being discharged from the system (D13).77
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FIGURE 16 Overview of AF service pathway model. BB, beta blocker; i.v., intravenous; N, no; Y, yes.
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f data on the
ed to AADs.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Regardless of the strategy for treating AF, it is recommended that all patients should have their
SR assessed.
Assess stroke risk
If patients are contraindicated to the OACs (SR1), then they are prescribed aspirin (SR4). Patients not
contraindicated to an OAC (SR1) have their SR assessed (SR2). There are three levels of risk defined
in CG36:
(a) low risk (aged < 65 years with no moderate- or high-risk factors)
(b) moderate risk (aged ≥ 65 years with no high-risk factors or aged < 75 years with hypertension,
diabetes or vascular disease)
(c) high risk [previous ischaemic stroke/transient ischaemic attack (TIA) or thromboembolic event, aged
≥ 75 years with hypertension, diabetes, vascular disease, heart failure, or impaired left ventricular
function on echocardiography].
Patients at low risk are recommended for aspirin (SR4). Patients at moderate SR may be treated with either
aspirin (SR4) or warfarin (SR6). If patients are assessed as high risk then they will get treated either with
warfarin (SR6) or dabigatran/rivaroxaban (SR7).
After SR assessment, patients proceed to either rate or rhythm control treatment.
Rhythm control for paroxysmal atrial fibrillation
Patients assigned to a rhythm control strategy for paroxysmal AF (RYpx) might choose at first not to receive
any AAD treatment (RY1b) or to use a ‘pill-in-the pocket’ approach (RY1c) if this is suitable. The first line of
regular AAD treatment is a standard beta blocker (BB) (RY2). After failure of treatment with a BB, the next
line of treatment is either a class 1c agent (RY5), sotalol (RY6), or amiodarone (RY9), depending on
whether the patient has a history of coronary heart failure or coronary artery disease. In addition, NICEinform this choice based on the patient’s age, whether they have a history of coronary arte
left ventricular dysfunction (LVD), or if they are unsuitable for cardioversion or contraindicatdiagnostic accuracy of ECG from the HTA report by Hobbs and colleagues,138 although data to populate
this decision tree were sparse.
Classification
After diagnosis, patients are classified into the three types of AF: paroxysmal (spontaneous termination
< 7 days and most often < 48 hours); persistent (not self-terminating and lasting > 7 days or prior
cardioversion); or permanent (not terminated, terminated but relapsed, or failed cardioversion attempt).
The main significance of this classification is that it is used, along with other criteria, to choose the AF
treatment strategy.
(a) Patients with paroxysmal AF will usually follow a rhythm control strategy, with AADs used to reduce
the frequency of subsequent AF episodes.
(b) Patients with permanent AF will follow a rate control strategy, in which no attempt is made to regain
sinus rhythm, but instead drugs are used to control heart rate and avoid symptoms and potentially
dangerous tachycardia.
(c) Patients with persistent AF may follow either a rate or rhythm control strategy: CG36 defined criteria to
ry disease orThe diagnostic pathway is further illustrated in the decision tree in Figure 17. This made use oAfter diagnosis of AF (by standard or ambulatory ECG), the patient might be referred for additional
tests, including a transthoracic echocardiogram (TTE) (D4) and possibly also a transoesophageal
echocardiogram (TOE) (D6). TTE and TOE may be used to diagnose structural heart defects or to plan
cardioversion. However, these treatments were not included in the model, as this was outside the
scope of CG36.79
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TA197150 recommends dronedarone as a second-line treatment for patients with additional risk factors.
Once AAD treatment has failed, the guideline recommends that patients are referred to a tertiary specialist
(RY11) for consideration for ablative treatment.
The rate control strategy contains three lines of drug treatment, followed by referral to a tertiary specialist
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58After treatment, patients with onset of AF < 48 hours previously or at high risk of recurrence will be
offered 4 weeks of warfarin, before being routed to further treatment.amiodarone otherwise.Acute-onset atrial fibrillation
Patients presenting with an acute arrhythmia associated with haemodynamic instability will first undergo
ECG, radiography and check of electrolytes (A1) to establish the cause of the haemodynamic instability
if possible. If the situation is life-threatening, an emergency ECV will be performed (A13). If the
haemodynamic instability is not life-threatening, patients not already taking anticoagulants will be given
heparin (if not contraindicated) before proceeding to treatment.
For patients known to have permanent AF, then urgent treatment with an intravenous rate-control drug
will be used to reduce the heart rate. This will usually be either a BB (A17) or RLCA (A18), although
amiodarone (A24) may also be tried. If the AF is not known to be permanent, then urgent rhythm control
with cardioversion will be tried (A9). ECV (A14) is recommended in this context, although PCV (A15
and A16) may be used if there is a delay in organising ECV. For PCV, the guideline recommends
intravenous flecainide if the patient is known to have Wolff–Parkinson–White syndrome, or intravenousfollowed by amiodarone (RA10).if the heart rate remains uncontrolled [> 80 beats per minute (b.p.m.)]. The first line is a rate-limiting
calcium antagonist (RLCA) (RA3) if heart rate control during exercise is required, or otherwise BBs (RA2).
If these treatments are unsuccessful at controlling the heart rate, digoxin is added (RA6 and RA7),Rate control for persistent and permanent atrial fibrillationRhythm control for persistent atrial fibrillation
The sequencing of AADs for patients with persistent AF following a rhythm control strategy is similar to
that for patients with paroxysmal AF, except that a pill-in-the-pocket approach or no treatment is not
usually considered appropriate. After initiation of an AAD, patients enter the OM strategy.rhythm control modules.When patients have been allocated to an AAD treatment, they progress to OM.
Cardioversion
Patients with persistent AF following a rhythm control strategy will undergo a trial of cardioversion. If the
onset of AF was > 48 hours before the cardioversion (C1), electrical cardioversion (ECV) is recommended
(C7), preceded by 3 weeks of warfarin and/or TOE-guided ECV to reduce the risk of TE (C3). Patients with
a high risk of cardioversion failure will also receive 4 weeks of sotalol or amiodarone (C8) before ECV.
Patients with AF onset < 48 hours ago would benefit from speedier treatment, so prophylaxis with heparin
administered by injection (C2) is used prior to cardioversion. In these patients, the guideline recommends
use of either ECV or pharmacological cardioversion (PCV). Patients with structural heart disease (SHD;
coronary artery disease or left ventricular dysfunction) undergoing PCV will be treated with intravenous
amiodarone, otherwise a class 1c agent is recommended. If cardioversion (PCV or ECV) is not successful,
the procedure can be repeated. The model assumes a maximum of two cardioversion attempts.
After an attempt at cardioversion, patients will have their SR assessed, before proceeding to the rate or81
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or for some
other reason. After a drug withdrawal, patients are sent to classification (CL), and will pass again
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
82Patients who survive also incur additional treatment costs. We did not include costs or QALY lothrough the pathway to have alternative treatment considered.
(e) Routine follow-up (OM7). It is assumed that previously undocumented AF recurrence will be detected
at this time, when patients are asked about symptoms and have further tests. In such cases, patients
are returned to classification (CL) and have their treatment reconsidered. Otherwise, patients have their
next routine visit scheduled, and then wait for the next event (OM2).
The disease process model
The above rules were based on a model of the risks associated with AF, as illustrated in Figure 18. This is
built around the five types of outcome shown in the column on the far right:
l Loss of AF control. This was defined as loss of sinus rhythm for patients being treated with a rhythm
control strategy (paroxysmal and some persistent). In patients with paroxysmal AF, this loss of sinus
rhythm could be documented or undocumented, depending on whether or not the symptoms were
sufficient for the patient to seek medical attention. For patients being treated under a rate control
strategy, AF control was defined as maintenance of a resting heart rate < 80 b.p.m.
l TE events. These were defined to include ischaemic strokes, TIAs and other major thromboembolic
events. The risk of TE is greatly increased with AF, and so it is an important outcome to include within
the model.
l Bleeds. Including haemorrhagic strokes and other major bleeds. These events are included as an
outcome, because drug treatment to prevent TE increases the risk of bleeding.
l Other related risks. The incidences of several other conditions (hypertension, diabetes, CHD and heart
failure) were modelled as risk factors for the above directly AF-related outcomes.
l Death. Mortality unrelated to AF was modelled independently of the other risk factors (other than age
and sex). Mortality related to AF was modelled by applying case-fatality rates to acute-onset
arrhythmias, thromboembolic events and bleeds.
Loss of AF control, TEs and bleeds impact directly on health status (and hence on QALYs) in two ways:
(1) they can be fatal; and (2) in patients who survive the event, they can reduce quality of life (utility).
sses for(d) Drug withdrawal (OM6). Patients might stop taking a drug, either due to an adverse effectOngoing management
On entering the OM module, an appointment with the GP or specialist (OM1) is scheduled, according to
the recommended follow-up frequencies from the guideline (CG36, chapter 12).135 Patients then wait
(OM2) until the next one of five types of event occurs:
(a) Loss of AF control (OM3). For patients on a rhythm control strategy, this will be an AF recurrence (loss
of sinus rhythm). A recurrence may be ‘undocumented’, which is not sufficiently serious to trigger a
consultation and the patient continues to wait until the next event, or ‘documented’ which causes the
patient to seek medical attention. Documented recurrences can be acute, in which case the patient is
routed to the acute onset module (A). Otherwise, patients are routed to classification (CL) to be
allocated to the appropriate treatment strategy. In patients on a rate control strategy, loss of control is
defined as having a resting heart rate > 80 b.p.m., which may be of acute onset (route to module A) or
non-acute (route to CL).
(b) Major adverse event (OM4). Events included in the model are thromboembolic events (ischaemic
stroke, TIA or other) and bleeds (haemorrhagic stroke or major bleed). These events may be fatal.
If the patient survives, they will be routed to the classification module (CL), where their treatment will
be reassessed.
(c) New risk factor (OM5): The onset of new risk factors, such as hypertension, diabetes or passing an age
threshold, can have two effects. First, it can increase individuals’ risk of major events, reducing the time
to their next major event within the OM module. Second, additional risk factors might trigger a change
in treatment, as patients meet criteria that they would have previously failed. In this case patients are
routed back to classification (CL) to have their treatment adjusted.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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84Atrial fibrillation progression and control
The process by which patients pass through the different types of AF is illustrated in Figure 19. If the first
diagnosed episode terminates without intervention within 7 days, patients are classified as having
‘paroxysmal’ AF. They pass through the service pathway, as described above, are prescribed appropriate
antithrombotic and antiarrhythmic therapy, and move into the OM module. If they have an AF recurrence,
this will be one of three types: an ‘undocumented’ recurrence for which they do not seek medical
attention and remain in OM; a documented recurrence that is self-terminating within 7 days but leads to a
reassessment of their antithrombotic and antiarrhythmic medication; or onset of CAF that does not
self-terminate within 7 days. The latter defines a transition from paroxysmal to persistent AF.
Patients with an episode of AF that is not self-terminating in 7 days (either a first episode or a CAF
recurrence of paroxysmal AF) are considered for cardioversion. If they are suitable for this procedure, it is
scheduled, and if successful the patient is classified as having ‘persistent’ AF. Patients with persistent AF
are prescribed appropriate antithrombotic and antiarrhythmic therapy, before going to OM. If they have a
recurrence, it is assumed that they would require cardioversion to move back into sinus rhythm. This is a
simplification, as in reality patients with persistent AF may also experience paroxysmal episodes.
A patient with AF that has not terminated within 7 days, who is not suitable for cardioversion, or for
whom cardioversion has failed, is classified as having ‘permanent’ AF. Patients with permanent AF are
given appropriate antithrombotic and rate control drugs, before going to OM. If the rate control drugs are
insufficient to bring their resting heart rate below the threshold of 80 b.p.m., their treatment will be
reassessed at their next scheduled appointment.
When patients experience an AF recurrence (paroxysmal or persistent) or uncontrolled heart rate
(permanent), this may be of acute onset, necessitating an emergency cardioversion or rate
control intervention.withdrawal rate was defined for each drug.other conditions modelled as risk factors (hypertension, diabetes, CHD and heart failure). We assumed that
ischaemic and haemorrhagic strokes would have a lasting impact on utility and health-care costs, owing to
the high potential for disability. Other events were assumed to have more transient consequences,
incurring costs and utility decrements over a short initial period.
The risk equations or algorithms listed in the second column of Figure 18 were used to calculate
individuals’ risks of the included outcomes in the absence of treatment. There are five main classes of risk
calculation used in the model, based on the five types of outcome. The risks of loss of AF control and
progression between the types of AF (paroxysmal, persistent and permanent) were defined according a
model that we developed. The risks of TEs and bleeds were defined by published risk algorithms for
patients with AF: CHA2DS2-VASc and HAS-BLED respectively.158–160 Rates of incidence for the other risk
factors were also based on published sources: Framingham equations for CHD, type 2 diabetes and
hypertension.161–163 and simple age- and sex-based incidence from a cohort study for heart failure.164
Mortality rates from non-AF-related causes were based on national life table data.87
The inputs required for these risk calculations define the set of individual risk factor information that is
required for the model (listed in the first column of Figure 18). The risk factors in bold were defined in advance
of model entry, as variables from our individual-patient data set from The Health Improvement Network (THIN)
(see Table 23). The factors in grey are assigned as patients move through the simulation model.
Finally, the third column in Figure 18 lists the treatment effects that are used to modify individuals’
baseline risks in accordance with any treatments that they receive. Treatments are grouped into four
classes, defined by their major outcome targets: cardioversion (aim to regain sinus rhythm); rhythm control
drugs (aim to prevent AF recurrence); rate control (aim to achieve control of heart rate); and
antithrombotic (aim to reduce the risk of TE, while minimising impacts on bleeding). In addition, aNIHR Journals Library www.journalslibrary.nihr.ac.uk
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Risk of thromboembolism (CHA2DS2-VASc)
Atrial fibrillation is associated with a substantial risk of stroke and other TE. This risk is not homogeneous
and various risk factors have been identified that are predictive of stroke in AF.165 These risk factors have
rmalised
l
ions exclude
data on labile INR as they were not available for the cohort. We also excluded antiplatelet therapy when
calculating individual HAS-BLED scores in the model, to avoid double-counting the effect of aspirin on
as estimated
based on age/sex specific rates from a general population cohort. These sources are not ideal for our
e as the
model runs.
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
86The patients travel through the model accruing costs and QALYs as they receive treatment and experience
events. The patient’s route may be determined by the values stored in their labels (criteria-based routing),
or by sampling from a defined distribution (probability-based routing). For instance, in the classification
module the decision to adopt a rate or rhythm control strategy for a particular patient is informed by the
contents of the label that records whether they have paroxysmal, persistent or permanent AF, whereas in
the diagnosis module, the choice between a 24-hour or ER ECG is randomly decided according to defined
probabilities. In this way, each patient’s route through the model is tailored to their individual
characteristics, but also depends to some extent on chance.event history that accumulates within the model. The values assigned to each label may changpurpose, as they are estimated from a general population cohort, rather than from people with AF.
Model design
Discrete event simulation model
The DES model combines the conceptual service pathway (see Figure 16) and the disease process model
(see Figure 18) into a single dynamic incident cohort model that incorporates time. The patients are
modelled as individual entities. Each has labels attached, which record their personal characteristics,
including the risk factors listed in the first column of Figure 18, as well as a record of their treatment andestimated from the Framingham cohort study.161–163 Finally, the risk of onset of heart failure w
164bleeding rates (as we applied relative risks of bleeding with aspirin and OACs).
Other related risks
The risks of new-onset CHD, hypertension and diabetes were calculated using multivariate risk equationsabnormal renal/liver function, stroke, bleeding history or predisposition, labile international no
ratio (INR), elderly (aged > 65 years), drugs that increase the risk of bleeding [e.g. non-steroida
anti-inflammatory drugs (NSAIDs) or aspirin], and alcohol (≥ 8 units/week). Coefficient calculatbeen formulated into various SR stratification schemes.159,165–170
A well-known and simple risk assessment scheme is the CHADS2 score.171 This evolved from the AF
investigators’ and Stroke Prevention in Atrial Fibrillation Investigators’ criteria,172 and is based on a point
system, in which two points are assigned for a history of stroke or TIA and one point each is assigned for
age > 75 years and a history of hypertension, diabetes, or recent cardiac failure. The CHA2DS2-VASc
extends the CHADS2 scheme by adding vascular disease (MI, peripheral arterial disease or aortic plaque) as
a risk factor.159 The score is calculated by adding one for each risk factor, and an additional point each for
age > 75 years and prior stroke.
Risk of bleeding (HAS-BLED)
Various risk stratification systems have been proposed for the assessment of the risk of bleeding.160,173,174
Individuals’ risk of bleeding in the model is assigned on the basis of the HAS-BLED risk algorithm.160
This was developed from a cohort study of 3978 European subjects with AF from the Euro Heart Survey.
The HAS-BLED score is calculated by adding one for each of the following risk factors: hypertension,NIHR Journals Library www.journalslibrary.nihr.ac.uk
Selection of the patient cohort
The model contains information on 12,776 patients with newly diagnosed AF, drawn from THIN primary
care database (see Data sources below). The database contains the characteristics listed in Table 23 for
each patient.
TABLE 23 Risk factors drawn from THIN data
Variable Risk factorsa Values SIMUL8 label
id Unique identifier for patients Integer
sex Sex 0 =male, 1 = female i_Sex
age Age Years i_CurrentAge
diagaf Incident AF case 0 = no, 1 = yes i_DrawnFromKnownAFpatientsDatabase
fhchd Family history of CHDb 0 = no, 1 = yes h_ParentalDiabetes,
h_ParentalHypertension
sbp Systolic blood pressure mmHg i_BloodPressureSystolic
dbp Diastolic blood pressure mmHg i_BloodPressureDiastolic
bmi BMI (height/weight squared) kg/m2 i_BMI
smoker Current smoker 0 = no, 1 = yes h_smoker
tsc Total serum cholesterol mmol/l i_Cholesterol_Total
hdl High-density lipoprotein cholesterol mmol/l i_Cholesterol_HDL
antipl Antiplatelet drugs (BNF 2.9) 0 = no, 1 = yes m_AntiplateletDrugs
nsaid NSAIDs (BNF 10.1.1) 0 = no, 1 = yes m_NSAID
vasc Vascular disease: MI (I21, I252)
or peripheral artery disease (170–73)
0 = no, 1 = yes h_VascularDisease_MI_PAD
chd CHD: angina, MI, coronary
insufficiency
0 = no, 1 = yes h_CHD_ Angina,_MI_coronary
insufficiency
te TE: IS (I63–4), TIA (G45) or
other TE (I74, I26)
0 = no, 1 = yes h_ThromboembolicEvent
haem Bleed: intracranial (I160–2) or other
major bleed [I850, I983,
K25–28 (0–2,4–6), K625, K922, D629]
0 = no, 1 = yes h_BleedingHistory
hf Heart failure: CHF/LVD (I50) 0 = no, 1 = yes h_HeartFailure_LVD_CHF
lvh Left ventricular hypertrophy 0 = no, 1 = yes h_LVHypertrophy
ht Hypertension
(I10–15) – CHA2DS2-VASc definition
0 = no, 1 = yes h_Hypertension
diab Diabetes (E10–14) 0 = no, 1 = yes h_Diabetes
alcohol Alcoholic disease 0 = no, 1 = yes h_AlcoholConsumption
kidney Renal disease
(N17–19, transplant or dialysis)
0 = no, 1 = yes h_RenalFunction
liver Liver disease
(K70–77, transplant or resection)
0 = no, 1 = yes h_LiverFunction
BMI, body mass index; CHF, congestive heart failure.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58a International Classification of Diseases, Tenth Edition codes given in brackets.
b Family history of CHD was used as a proxy for family history of diabetes and hypertension, which were not available from
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When the model is run, it is possible to randomly select patients from a subset based on their initial
nal life table
f AF so
occur.
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
88If these patients experience an arrhythmic event then, depending on the severity, they will either present
again for an ECG (effectively restarting this process after a delay), or they will present at the accident and
emergency department for cardioversion. As these patients will not be taking medication for their AF, they
do not receive any protective benefit from antithrombotic or rhythm or rate control drugs.(described below). These untreated AF patients have their risk factors and characteristics upda
same way as treated patients, and incur the costs and consequences of any major events thateither 24-hour ambulatory ECG or ER ECG is required; or (4) ECG is negative and there is no suspicion
of AF (false-negatives). Patients in whom ambulatory ECG is necessary are randomly allocated to either
24-hour or ER ECG. Those patients in whom results are negative may then undergo ER ECG or be
incorrectly discharged (false-negatives); again this is randomly allocated.
After a positive diagnosis, patients are randomly allocated to have paroxysmal or persistent AF, in
accordance with a defined probability, and their CurrentAFstatus label is updated to 1 (paroxysmal),
or 2 (persistent). It is assumed that no patients present for the first time with permanent AF.
False-negatives
The patients who receive a false-negative diagnosis remain in the system to ensure a penalty for missing
cases is incorporated. These patients loop through a similar (but reduced version) of the OM module
ted in thethere is no need for more tests; (2) the patient has confirmed AF but TTE/TOE is required to as
underlying physical problems; (3) the patient’s ECG was negative but there is still a suspicion odata were used to generate probability distributions for life expectancy, based on the patient’s initial age
and sex. Patients’ starting utility is assigned (CurrentUtility) based on their age and sex. This is obtained
from a look-up table, so all patients of the same age and sex will have the same starting utility. Labels are
also set to indicate that patients are not initially taking any medication. Each patient has a random number
(U) assigned for each of the events to be modelled (e.g. U_bleed, U_diabetes). These are used when
calculating, and updating, the time to each event. Finally all patients arriving have a label i_NextEvent
initialised to ‘First Event’. This next event label is used to control the routing of the patient through the OM
section of the model.
Diagnosis
The diagnostic section of the model contains more probability-based decisions than the rest of the model.
This reflects the difficulty that we experienced in obtaining data for this module. The intermittent nature of
AF makes it impossible to establish false-negative rates for the diagnostic tests, and there is no ‘gold
standard’ for assessment of diagnostic accuracy. The model does include the facility to add patients
without AF, and to include false-positive test results for these patients, incurring unnecessary expenditure.
However, this was not applied in the analyses presented below.
Diagnosis is one of the two sections of the pathway in which time elapses as the patient progresses.
Patients arrive and have to wait a number of days for their ECG based on a defined distribution [mean
14 days, standard deviation (SD) 3 days]. Costs associated with ECG are added to the patient’s tally of
costs. For patients with AF, there are four possible routes after ECG: (1) the patient has confirmed AF and
sessthat is currently undiagnosed (CurrentAFstate = 5). All patients are also assigned a label (Non_
which specifies their age of death, unless they die from an AF-related cause prior to this. Natiocharacteristics. For example, it would be possible to select a group of patients within a specific age range
who have a history of hypertension. Sampling from the list of eligible patients is random ‘with
replacement’. The cohort of patients arrives in the system at time zero, and the model runs until all
patients from the cohort have died.
Set up attributes
When the sampled patients arrive in the system, information about their starting state is read from the
database and copied to the appropriate labels. Patients are assigned a label to specify that they have AF
AFdeathAge)NIHR Journals Library www.journalslibrary.nihr.ac.uk
Classification
All patients arriving in the classification section of the model will have the CurrentAFstate label set to
1 (paroxysmal), 2 (persistent), or 3 (permanent). Only those who have cycled through the system at least
once can be classified as having permanent AF. Patients with paroxysmal AF are assigned to a rhythm
control treatment strategy, patients with permanent AF are assigned to rate control treatment strategy and
patients with persistent AF are assigned to either a rate control or rhythm control strategy depending on
their attributes in accordance with the guidelines. Patients have their TreatmentOption label updated to
reflect the strategy that is adopted, and are directed to cardioversion or SR classification as appropriate.
Cardioversion
Patients with persistent AF who are assigned to a rhythm control strategy, and who are not in sinus
rhythm when they pass through the classification process, receive non-emergency cardioversion. The
number of cardioversion attempts per episode is limited, currently set to a maximum of two attempts,
though this parameter may be changed. If cardioversion is unsuccessful, then the patient is considered to
be in permanent AF, their i_CurrentAFstatus label is updated and they are assigned to a rate control
strategy. If cardioversion is successful then they remain on a rhythm control strategy and remain labelled as
at a
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 582 – 50 25 25
> 2 – 50 25 25
Previous stroke – 50 25 25
LVD or CHF – 50 25 25
CHF, congestive heart failure.1 33 33 17 17later stage.
TABLE 24 Choice of antithrombotic drugs by risk factors: 65–74-year-old age group
Aspirin (%) Warfarin (%) Dabigatran (%) Rivaroxaban (%)
Risk factors 0 50 50 – –drug, as shown in Table 25. The order of the rows for all the tables associated with the drugs
utilities, costs, etc.) is the same throughout the model. This allows the addition of other drugshaving persistent AF. Following cardioversion, patients are routed to have their SR assessed.
Stroke risk assessment and antithrombotic therapy
When patients enter this module, their SR scores are recalculated (CHADS2 and CHA2DS2-VASc) and their
antithrombotic therapy is reassessed on the basis of criteria set out in the NICE AF CG.
The NICE criteria for assignment of anticoagulation depend on age and various other risk factors (CG36,136
TA249146 and TA256147). In many cases patients are eligible for more than one drug, so some assumptions
are needed to determine the split of patients between these options. An example of the percentage split
between assumptions used for the 65–74-year-old age group is shown in Table 24. This shows the
assumed percentage split between the eligible drugs for each risk group. If a patient is contraindicated to
a drug or has previously withdrawn from taking it, the percentages are revised to ensure that the total
equals 100% across all eligible options. The patient is then randomly allocated a suitable anticoagulant
based on these revised percentages.
Rate and rhythm control
Each patient has two labels in which their current medication is recorded, one for antithrombotic drugs
and one for rate or rhythm control drugs. These record the row number associated with the particular
(such as89
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2 First visit (medication not yet considered)
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
903 No drug treatment prescribed
4 Aspirin
5 Warfarin
6 Heparin
7 Dabigatran
8 Rivaroxaban
9 Pill in pocket
10 Standard BB (rhythm)
11 BBs (rate)
12 BBs (rate) + digoxin
13 Calcium-channel antagonist
14 Calcium-channel antagonist + digoxinRow MedicationTABLE 25 Drugs currently included in the modelThe selection of the next line of rate or rhythm control treatment is dictated partially by the guideline and,
where there is a choice of medication, by a similar random process as described above for anticoagulants.
There are three tables – one each for paroxysmal, persistent (rhythm control), and rate control – that
record the recommended sequencing of medications. These tables contain 21 medications on both the
horizontal and vertical axes. The cells within the tables detail the percentage chance of changing from any
given drug (vertical axis) to another (horizontal axis). Similarly to the anticoagulants, the percentages are
read from the table and adjusted to take account of any existing contraindications for the patient, before
patients are randomly assigned to one of the remaining drugs for which they are eligible. On a change of
medication, the previous drug is marked as contraindicated to prevent selection again in the future
Once a patient has been prescribed a new drug they are routed to the OM section of the model. Patients
may pass through the rate and rhythm control sections of the model many times, as their AF progresses,
or if they withdraw from a drug. A similar process of drug selection is followed for each line of treatment.
Once patients have exhausted all lines of treatment they are referred to the tertiary specialist for
consideration for an interventional procedure. We assume that they will continue to take the final line of
treatment following referral.
Ongoing management
Patients travel through the model and after being diagnosed and receiving their first-line treatment
options, arrive in the OM section of the model (Figure 20). This section is the main driver behind the
15 Digoxin
16 Class 1c drug
17 Sotalol
18 Dronedarone
19 Amiodarone
20 Intravenous BB
21 Intravenous calcium-channel antagonist
22 Intravenous amiodarone
NIHR Journals Library www.journalslibrary.nihr.ac.uk
rate/rhythm
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Change
treatment
options
Event
occurs
Die
AF-related event
Non-AF-
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Assess/
update risks
Diagnosis
Classification/
emergencies/
Ongoing
managementmodel. When patients enter, all of their risk scores and risk values are updated based on their current
characteristics and any treatment effects. From these updated risks, a ‘time-to-event’ is calculated for each
event of interest. These times, and the time to non-AF death, are compared to find the minimum, and this
event is designated as the next event. The patient then waits until the time designated for this event to
occur. This means that each patient moves through the model in time increments defined by the events
that they experience, as opposed to all moving at pre-defined time intervals.
If the event is not related to AF, and would not cause a change in rate or rhythm control treatment, the
patient’s antithrombotic risk is reassessed and changed if appropriate. The patient’s risk factors are
updated, the effects of the new anticoagulant applied, and the ‘time-to-event’ recalculated. If, however,
the patient’s AF has progressed, they are routed back through the classification module, from where they
may change from rhythm control to rate control, be referred for cardioversion, and/or move to the next
line of treatment. Following this, they return to the OM, where the process repeats.
Modelling risk
The chance of not having a particular event until a time t, given an adjusted hazard rate of λ is modelled
by an exponential survival function (F(t;λ) = 1 – e–λt). This assumes that the hazard remains constant over
the period of time modelled. However, as patients move through the model, their risk of a particular type
of event may change in response to other associated risks, or as they age. We modelled this using a
piecemeal exponential distribution, in which the hazard changes at defined points in time (when an event
has occurred), but is constant in between events.
The times at which events occur are determined by random numbers. At model entry, each patient is
assigned a random number for each of the main types of event in the model. This could be considered as
a proxy for unknown factors that influence a patient’s propensity for that particular type of event.
FIGURE 20 Illustration of OM process.
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TE events, bleeds and AF recurrences are composite events, each consisting of a number of subtypes of
event. TE events comprise ischaemic strokes, TIAs and other thromboembolic events, bleeds comprise
2 1 uld appear
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
92to have been increased by the occurrence of a TE. To avoid this, instead of drawing a new random
number for bleeding, the original number UB1 is adjusted to reflect the remaining probability of a bleed,
conditional on no bleed having occurred up to time T T1 : U
B
2 ¼ ðUB1−aÞ/ð1−aÞ, where a ¼ FðT T1 ,λB1Þ. The time
of the next bleed is then calculated as T B2 ¼ T T1 þ F−1ðUB2,λB2Þ. Thus the random number used to calculate
the time to an event is only resampled when that particular type of event has occurred. This procedure is
easily extended to include other types and subtypes of events, and also age thresholds that increase
estimated risks or trigger new treatments.
Calculating costs and quality-adjusted life-years
For each outcome event there may be short- and long-term consequences, affecting costs and QALYs. For
instance, an ischaemic stroke incurs a mean cost of £11,646 associated with the initial hospitalisation and
treatment during the first 90 days, followed by an ongoing cost of £22.61 per day for continuing health
and social care. The model assumes that a patient experiencing the event incurs the initial cost at the time
of the event (regardless of whether or not they survive for the whole 90 days), and schedules the daily cost
to start after the initial period, if they survive that long. The ongoing cost continues for the remaining
lifetime of the patient.
A similar method is used to apply short- and long-term modifications to patient’s utility values. A
short-term utility multiplier is applied during a defined initial period after the event, followed by a
long-term multiplier. The adjusted utilities are used to estimate patients’ QALYs for as long as they survive.
The duration of the initial period can differ between events, and between the costs and utilities. Some
types of event are assumed not to incur any lasting cost or utility effect after the initial period.
Costs and QALYs are updated every time the patient passes through a section of the pathway where a
cost is applied, as well as whenever a change in treatment occurs. In addition, if the TTNE is more
than the ‘Frequency of Update’ variable (currently 90 days) then an update of costs and QALYs is
scheduled. Costs and QALYs are discounted using a continuous time approach to the time of model
entry for each patient.there is a chance that we could draw a random number such that the first bleed would occur
had been originally expected: T B>T B. This would be counterintuitive, as the time to a bleed wohaemorrhagic strokes and other major bleeds, and recurrence events comprise undocumented
events, self-terminating events, non-terminating events requiring cardioversion, and acute arrhythmic
events requiring emergency cardioversion. For each composite event, patients are assigned another
random number, which determines which subtype of event will occur next. This approach ensures that
related groups of events are not treated as independent.61
Once an event has occurred, care is needed in adjusting the times for competing events to avoid
counterintuitive effects. The process for sampling time to event is illustrated in Figure 21. For simplicity,
suppose initially that there are only two types of event, TEs and bleeds. On entry to the model, an
individual is assigned two random numbers between zero and one: one for TEs UT1 and one for bleeding
UB1. The person’s starting attributes are used to calculate CHA2DS2-VASc and HAS-BLED and initial hazard
rates for TE λT1 and bleeding λ
B
1 are estimated.
The times to events are calculated using the inverse of the exponential survival function: T k1 ¼ F−1ðUk1,λk1Þ ¼
−lnð1−Uk1Þ/λk1, where k = T,B. Suppose that T T1 ¼ 10 and T B1 ¼ 20, so that a TE is the first event to occur. At
year 10, having had one TE, the person is now at higher risk of a second TE and also at higher risk of a
bleed. The CHA2DS2-VASc and HAS-BLED scores are updated, the patient is assessed for any changes in
treatment and revised estimates of the hazard rates: λT2 and λ
B
2 are obtained. The time of the next TE T
T
2 is
calculated as before, using a new random number UT2 . However, if we were to do the same for bleeding,
later thanNIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 21 Illustration of the sampling process for the AF model. (a) TE first event; (b) TE second event; (c) bleeding
first event; (d) bleeding second event.
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Data sources
hort of
patients to feed into the model. Individual patient data were obtained for a cohort of patients newly
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94diagnosed with AF from a primary care database. These data are described below.
Individual patient data set
The Health Improvement Network (THIN) is a research database comprising anonymised patient records
uploaded from primary care information systems. THIN data collection began in 2003, and the database
currently contains data from 479 practices with a total of 9.1 million patients. We obtained an extract of
data for patients registered on an index date (1 May 2008), aged ≥ 30 years, without any record of an AF
diagnosis during the 2-year period prior to the index date. Individuals within this group with a record of an
AF diagnosis during the 2-year period after the index date were then identified, defining an incident
cohort of 12,776 patients who were used to populate the model. Demographic and medical information
was collated for these patients for the 2 years before and 2 years after the index date (from 1 May 2006
to 30 April 2010), although some patients left the system during the 2 years after the index date. The list
of patient-level variables used in the model is shown in Table 23.
Some variables were recorded more than once over the 4-year follow-up period (e.g. blood pressure and
lipid levels had often been measured several times during this time). In such cases, we took the average of
the three readings closest to the date of diagnosis. Some individuals did not have a record of blood
pressure, body mass index (BMI), lipids (total or high-density lipoprotein cholesterol) or smoking status.
These missing data were imputed using a multivariate regression approach, to provide a full data set for
use in the model. Before imputation, the incident cases of AF were on average 73.6 years old, and
47% female. Around 5% had a family history of CHD. Their average blood pressure was 78/137mmHg,
their average BMI was 28.5 kg/m2 and 12% were current smokers. In terms of medication, around
40% were on antiplatelet or lipid lowering medication and 65% were on antihypertensive medication.
Twenty-one per cent had a history of haemorrhage, such as an ulcer or bleed. Imputed values for missing
data items had very similar means and SDs to those in the non-imputed data.The other major data requirement for the model was information to define a representative coA list of all parameters needed to populate the model was compiled. Potentially relevant sources of
information to define these parameters were first identified from the searches conducted for CG36.135
This provided a base of evidence of clinical effectiveness, which we knew had been identified through
systematic searches and quality appraised. In extracting this evidence, we paid particular attention to the
commentary on the quality and interpretation of the evidence base in the ‘from evidence to
recommendations’ sections of the full guideline. Clinical papers that had informed GDG decisions were
obtained and relevant data were extracted.
However, a recurring problem with CG36135 as a source of data for modelling was the lack of meta-
analysis in this document. When multiple studies related to a question were identified, the results were
presented in a narrative fashion, with no attempt to statistically pool the available data. We were also
aware that for some interventions the evidence base reported in CG36135 was significantly out of date. It
was not possible to conduct our own systematic reviews within the resources available, so where necessary
we relied on other published systematic reviews and meta-analyses. Reviews conducted for NICE TA
reviews were prioritised as sources of evidence for the model, as we knew that they will have undergone
rigorous review and public consultation. Where NICE TA reviews were not available, we sought to identify
information from other HTA reports, Cochrane reviews or other high-quality sources. However, it should
be emphasised that effectiveness estimates were not all based on up-to-date systematic reviews, and that
the results should therefore not be used to inform clinical decisions.
In addition to evidence about clinical effectiveness, we needed data to inform other model parameters,
including background rates of the adverse events defined in the disease process model, utilities and costs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
Risks of bleeding and thromboembolism
The model uses data from the Swedish AF cohort study to estimate incidence rates for thromboembolic and
haemorrhagic events.158 This was a nationwide cohort study containing 182,678 individuals with a diagnosis
of AF [International Classification of Diseases, Tenth Edition (ICD-10; code I489:A–F)] who were treated as an
inpatient or outpatient at Swedish hospitals between July 2005 and December 2008. Average follow-up was
1.5 years. This is a very large cohort, likely to be reflective of the general Swedish population with AF
(although the sampling methods did exclude patients with ‘silent AF’ and patients managed only in primary
care and open clinics). The other advantage of this study as a source of data for the model was that
thromboembolic and bleeding events were reported for the same cohort, providing coherent estimates of
these two related risks. The applicability of these data to the UK AF population is discussed below.
One-year incidence rates for TE (stroke/TIA/peripheral embolism) stratified by CHA2DS2-VASc scores were
reported for 90,490 patients not treated with warfarin (Table 26). Figures used in the model were adjusted
for aspirin use to provide estimate rates for an untreated cohort. Figures for CHA2DS2-VASc scores ≥ 7
were pooled, as estimated rates were uncertain above this value due to small numbers of events.
Similarly, incidence rates of major bleeds (intracranial and major extracranial) were reported by HAS-BLED
scores (Table 27). Rates used in the model were for 33,486 patients who were not on oral anticoagulation
or aspirin at baseline. Event rates for HAS-BLED scores ≥ 4 were pooled, due to small numbers of events.
TABLE 26 Rates of TE from the Swedish AF cohort study158
CHA2DS2-VASc score n
Stroke/TIA/peripheral embolism
per 100 person-years at risk
(no warfarin, adjusted for aspirina)
0 5343 0.3
1 6770 1.0
2 11,240 3.3
3 17,689 5.3
4 19,091 7.8
5 14,488 11.7
6 9577 15.9
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58a Estimated from distribution of HAS-BLED scores in the whole cohort (170,291) and number not on prophylTABLE 27 Rates of bleeding from the Swedish AF cohort study158
HAS-BLED score na
Major bleeds per 100 person-years at risk
(no oral anticoagulation or aspirin)
0 1754 0.5
1 6871 2.1
2 12,219 3.6
3 9127 5.5
4–7 3513 10.9
Total 33,486 2.1
axis (33,486).
7–9 6292 18.4
Total 90,490 7.0
a Estimates for patients not prescribed warfarin during follow-up, and adjusted for aspirin use.95
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We assumed that the incidence of different types of thromboembolic event would be in the same
proportions as observed in the Swedish AF cohort: 70% ischaemic strokes, 25% TIA, and 5% other
embolisms. Similarly, the relative incidence of bleeds was also based on the observed rates in the Swedish
AF cohort: 28% intracranial and 72% major extracranial. Minor bleeds were excluded from the model.
Atrial fibrillation control and cardioversion
Data to populate the AF progression and control model (see Figure 19) were drawn from two main
sources. Euro Heart Survey data175 were used to derive estimates of the proportion of first episodes that
are paroxysmal (42%), recurrence rates for paroxysmal AF (54% per year), rates of progression from
paroxysmal to persistent AF (20% of recurrences), and the proportion of AF recurrences that are of acute
onset (64%). The proportion of recurrences for patients with paroxysmal AF that are undocumented (68%)
was taken from the Canadian Registry of Atrial Fibrillation study.176
Rates of recurrence for patients with persistent AF and progression from persistent to permanent AF were
determined by effectiveness data for cardioversion (CG36, chapter 5).135 These studies reported on the
initial success rate of cardioversion (reversion to sinus rhythm within 24 hours) (Table 28), early recurrences
(up to 1 month) and late recurrences (> 1 month) (Table 29).
Diagnostic accuracy
Sensitivity of the initial 12-lead ECG (78%) was based on the HTA trial by Hobbs and colleagues,138 and it
rivaroxaban)
andard error
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
96Early recurrence (< 1 month) 171 53 0.31 0.0635
Late recurrence (> 1 month) 1023 502 0.49 0.0223
Estimated from studies reported in CG36 (p. 35).135Outcome n Recurrence Recurrence rate Stwere taken from a network meta-analysis conducted by the British Medical Journal Technology
Assessment Group for the NICE TA on rivaroxaban.145 This study estimated odds ratios for thromboembolic
events (ischaemic stroke and systemic embolisms), bleeding (intracranial and major extracranial bleeds) and
treatment withdrawals in comparison with warfarin. As inputs to the model, we estimated relative risks
compared with placebo (Table 30), using assumed control risks from the warfarin arm of the ROCKET AF
TABLE 29 Atrial fibrillation recurrence after cardioversion
TABLE 28 Cardioversion success rates
Outcome n Sinus rhythm Success rate Standard error
PCV (first attempt) 158 123 0.78 0.0374
ECV (first attempt) 211 160 0.76 0.0338
PCV or ECV (second attempt) 37 23 0.62 0.1011
Estimated from studies reported in CG36 (p. 35).135Treatment effectiveness
Estimates of the effectiveness of antithrombotic medications (aspirin, warfarin, dabigatran andwas assumed that 5–24% of patients with suspected paroxysmal AF would be diagnosed following a
positive 24-hour or ER ECG.177 Other probabilities within the diagnostic pathway (including the proportion
of patients with a negative ECG referred for ambulatory assessment on the basis of suspicion of
paroxysmal AF, the ratio of 24-hour to ER ambulatory ECGs, referral rates for TTE and TOE) were
estimated by informal elicitation from experts.NIHR Journals Library www.journalslibrary.nihr.ac.uk
trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonist for
Prevention of Stroke and Embolism Trial in Atrial Fibrillation).178
Treatment effects for the rhythm control drugs were taken from a published network meta-analysis,
funded by Sanofi-Aventis to inform their submission to NICE for the appraisal of dronedarone.179 For the
model, we estimated relative risks for AF recurrence and treatment withdrawals (Table 31).
The effectiveness of the rate control drugs was estimated by simulating an initial resting heart rate for each
individual patient (sampled from a normal distribution with a mean of 109 and SD of 31).180 Mean
reductions in heart rate with rate control drugs (Table 32) were estimated from four randomised cross-over
studies reported in CG36 (p. 59).180–183 Data were pooled using a simple inverse-variance method of
meta-analysis. Estimates of the standardised mean difference were obtained for first-line treatment (BB or
RLCA) compared with no treatment, and for second-line treatment (BB and digoxin or RLCA and digoxin)
compared with first-line treatment. No data were found to estimate the effect of the third-line of
treatment recommended in CG36 (amiodarone). We therefore assumed that this gives the same additional
TABLE 30 Treatment effects of antithrombotic drugs145
Outcome Aspirin Warfarin Dabigatran Rivaroxaban
Relative risk of TEa 0.45 0.30 0.23 0.25
Relative risk of bleedinga 1.12 1.76 1.63 1.81
Withdrawal rate (per person per year) 0.10 0.18 0.24 0.19
a Compared with placebo.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58reduction in heart rate as second-line treatment.
TABLE 31 Treatment effects of AADs179
Outcome Dronedarone Amiodarone Sotalol Flecainide
Propafenone
hydrochloridea
Relative risk of AF recurrenceb 0.7938 0.4906 0.6948 0.6054 0.6576
Withdrawal rate (per person per year) 0.2847 0.2829 0.2453 0.3047 0.3047
a Arthmol®, Abbott Healthcare.
b Compared with placebo.
TABLE 32 Treatment effects of rate control drugs180–183Comparison
Standardised mean difference
n Meana SEa
First line (BB or RLCA) vs. no treatment 34 0.87 0.20
Second line (BB + digoxin or RLCA + digoxin) vs. first line 55 0.70 0.15
Amiodarone vs. second line No data identified, assumed equal to second line
SE, standard error.
a Compared with placebo.
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Case fatality rates
The proportion of patients admitted for acute AF dying within 30 days of admission was estimated at
2.56% (147 out of 5735 cases in a study of all patients admitted with a diagnosis of AF in Scotland in
1996).184 The case fatality for ischaemic stroke was estimated from a large population-based cohort study
(the Oxford Vascular Study; OXVASC).185 Fatality rates for bleeding were estimated from a pooled analysis
of data from the Sport Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) III and V
trials of ximelagatran compared with warfarin for treatment of non-valvular AF.186 This estimated a
case-fatality rate for major bleeding of 8.1% (very similar for the two study arms). The fatality rate among
patients experiencing an intracranial bleed was much higher (10 out of 18 cases, 56%). A similar
case-fatality rate was observed for haemorrhagic strokes in the OXVASC (8 out of 17 cases, 47%).
Utilities
Health utility estimates were drawn from three sources. First, baseline utility values for members of the
public with no history of heart problems by 5-year age band were taken from the analysis of Health Survey
for England data reported by Ara and Wailoo187 (Table 33).
Utilities were then adjusted for patient’s AF status, using data from the Real-life global survey evaluating
patients with Atrial Fibrillation (RealiseAF) study,188 which is an international observation cross-sectional
study of patients with any history of AF in the previous year. Out of 9665 patients evaluated, 26.5% were
in sinus rhythm, 32.5% had an arrhythmia but with a heart rate of ≤ 80 b.p.m. and 41% had uncontrolled
AF (neither in sinus rhythm nor heart rate ≤ 80 b.p.m.). EQ-5D™ scores were available for 9644 of these
.854 to 0.877
50 to < 55 3089 0.8376 0.828 to 0.847
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9855 to < 60 3173 0.8269 0.815 to 0.837
60 to < 65 2580 0.8189 0.805 to 0.832
65 to < 70 2784 0.8132 0.799 to 0.827
70 to < 75 2276 0.7892 0.766 to 0.802
75 to < 80 1709 0.7602 0.745 to 0.774
80 to < 85 1072 0.7070 0.684 to 0.729
≥ 85 572 0.6692 0.642 to 0.69545 to < 50 3243 0.8664 0patients. We used these data to estimate utility multipliers for AF status (Table 34).
Finally, we needed estimates of utility losses for the thromboembolic and bleeding events included in the
model. These were obtained from the Medical Expenditure Panel Survey,189 which collected EQ-5D scores for a
nationally representative sample of 38,678 non-institutionalised adults between 2000 and 2002. These data
were analysed using regression methods to estimate the marginal disutilities associated with 95 chronic
conditions. Estimates of utility multipliers for adverse events included in the model are listed in Table 35.
Costs
Finally, estimates of costs for tests and treatments administered in the service pathway, drug costs, and
costs for adverse events are shown in Tables 36, 37 and 38 respectively.
TABLE 33 General population utility by age (no other heart problems)187
Age group (years) n Mean utility 95% CI
< 30 8040 0.9389 0.935 to 0.942
30 to < 35 3592 0.9148 0.907 to 0.922
35 to < 40 3992 0.9075 0.901 to 0.913
40 to < 45 3703 0.8855 0.876 to 0.894NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 34 Utility multipliers for AF health states, RealiseAF188
Comparison n Mean utility Baseline Multiplier
AF rhythm controlled (sinus rhythm)
vs. no AF
2576 0.75 0.8132a 0.922
AF rate controlled (≤ 80 b.p.m.)
vs. AF (sinus rhythm)
3123 0.72 0.7500 0.960
AF not in sinus rhythm
vs. AF (sinus rhythm)
1014 0.67 0.7500 0.893
AF rate not controlled
vs. AF rate controlled
2931 0.67 0.7200 0.931
a Assumed average (Health Survey for England mean for 65–70 year olds).179
TABLE 35 Utility multipliers for adverse events, Medical Expenditure Panel Survey189
Adverse event n Mean utility Baseline Multiplier
Ischaemic stroke 38,678 0.67 0.81 0.829
TIAa 38,678 0.71 0.81 0.873
Systemic embolisma 38,678 0.69 0.81 0.852
Haemorrhagic stroke 38,678 0.67 0.81 0.829
Major bleedinga 38,678 0.63 0.81 0.776
a TIA, other systemic embolism and major bleeds assumed to be transient (acute period only).
TABLE 36 Costs for consultations and tests on the pathway
Health-care resource 2011 (£) Source
GP visit 36.00 PSSRU110
Cardiologist first visit 175.00 DoH Reference Costs109
Cardiologist follow-up visit 122.00 DoH Reference Costs109
Tertiary specialist visit 177.58 DoH Reference Costs109
Emergency attendance 158.69 DoH Reference Costs109
ECG 31.00 DoH Reference Costs109
ER ECG 45.00 DoH Reference Costs109
24-hour monitor ECG 56.00 DoH Reference Costs109
TTE or TOE 185.00 DoH Reference Costs109
Cardioversion (PCV/ECV) 773.00 DoH Reference Costs109
DoH, Department of Health; PSSRU, Personal Social Services Research Unit.
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100TABLE 37 Daily drug costs (NHS net price, BNF111)
Class Drug 2011 (£) (per day)
Antiplatelet Aspirin 0.02
Anticoagulant Warfarin 0.25
Warfarin initiation (one-off) 0.00
Warfarin administration (per day) 0.66
Dabigatran 2.52
Rivaroxaban 3.03
Heparin 6.96Verification and validation
The model was coded using SIMUL8 software by one of the authors (JE). The data spreadsheet was
prepared by another author (MTB), who worked closely with JE to ensure that the data interface worked
correctly. Data entry was checked by another author (JL), by comparison of data from the original papers
with the numbers in the spread sheet. The modelling team (MTB, JE and JL) met regularly to discuss and
resolve problems arising. At several stages in development, the model was discussed at meetings of the
wider MAPGuide team, and issues about model structure, coding and data sources were considered.
Various steps were taken during model development to avoid potential errors. This included double coding
of some of the more complicated formulae in Excel and SIMUL8, to check that they were being applied
correctly. This included: the method for sampling time to event and for dealing with competing risks;
Antiarrhythmic class 1c Flecainide 0.12
Propafenone 0.35
Flecainide (intravenous) 11.00
Antiarrhythmic class II Atenolol 0.05
Labetalol 0.46
Labetalol (intravenous) 2.94
Esmolol hyrochloride (Brevibloc®, Baxter) (intravenous) 4.98
Atenolol (intravenous) 3.60
Esmolol + digoxin 5.47
Atenolol + digoxin 0.54
Labetalol + digoxin 0.95
Bisoprolol 0.03
Metoprolol 0.13
Antiarrhythmic class III Sotalol 0.18
Amiodarone 0.18
Amiodarone (intravenous) 7.13
Dronedarone 2.25
Class IV (RLCA) Diltiazem 0.16
Verapamil 0.26
Verapamil (intravenous) 1.64
Positive inotropic drug Digoxin 0.49
NIHR Journals Library www.journalslibrary.nihr.ac.uk
ormulae ); and the formula for continuous discounting of costs and QALYs. A patient diary was also
reated to collect information about the events and timelines for individual patients running through the
odel, and to present this in the form of individual ‘case histories’. These diaries were used throughout
evelopment, and towards the end of this process case histories were checked for 500 patients by
embers of the modelling team, and any apparent inconsistencies or errors were identified, discussed and
necessary investigated.
erification of the coding was commissioned to an external modeller based at the University of Sheffield.
his comprised three tasks:
. checking that the SIMUL8 logic correctly reflected the AF pathway
. checking the coding of costs, QALYs and discounting calculations
. checking the model logic via the patient diaries.
inally, the model outputs were compared with the model inputs to ensure that the rates of
hromboembolic events and bleeds observed for a modelled cohort matched the input data (‘internal
alidation’). The results of the model were also analysed to verify that the relative risks for different
ntithrombotic drugs correctly reflected the data built into the model.
he following list summarises the set of assumptions that were agreed during model development.
ummary of model simplifications
. Patients’ individual blood pressure and cholesterol levels remain constant throughout.
. Patients have hypertension if they are taking antihypertensive drugs at the start (regardless of their
blood pressure).
colleagues185
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Acute period (days) 90 Luengo-Fernandez and colleagues185
TIA Event cost (one-off) 402 DoH Reference Costs109
Ongoing cost (per day) 0 Assumption
Acute period (days) 1 Mean length of stay
Other TE Event cost (one-off) 1705 DoH Reference Costs109
Ongoing cost (per day) 0 Assumption
Acute period (days) 6 Mean length of stay
Haemorrhagic stroke Event cost (one-off) 16,228 Luengo-Fernandez and colleagues185
Ongoing cost (per day) 15.75 Luengo-Fernandez and colleagues185
Acute period (days) 90 Luengo-Fernandez and colleagues185
Other major bleed Event cost (one-off) 725 DoH Reference Costs109
Ongoing cost (per day) 0 Assumption
Acute period (days) 5 Mean length of stay
DoH, Department of Health.Ongoing cost (per day) 23.48 Luengo-Fernandez andTABLE 38 Cost of adverse events included in model
Adverse event Type of cost 2011 (£) Source
Ischaemic stroke Event cost (one-off) 14,426 Luengo-Fernandez and colleagues185101
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continue in
of the
guideline, but it was felt that the costs and QALYs should be included in the analysis.
ophylactic
, intra- or
post-operative), and subsequent treatment.
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102However, the modelling team did not include post-operative AF in the base-case model because the
clinical and demographic characteristics of patients undergoing cardiothoracic surgery and their risks of
adverse events differ from those of the general AF population. Although the base-case model could be
adapted to reflect post-operative AF, this would require further consultation with experts, identification of
suitable evidence sources for both baseline risks and treatment effects and possibly restructuring of the
model. Consequently, this topic was not evaluated.
Topic B: drugs for pharmacological cardioversion
Background to topic
CG36135 made recommendations for the cardioversion of patients in AF, including patients presenting as
an emergency with haemodynamic instability (chapter 7) and stable patients for whom a rhythm control
strategy is being pursued (chapter 5). For the latter more common situation, the evidence suggested that
ECV and PCV were of comparable efficacy. Based on clinical practice and opinion, the guideline group
recommended ECV for prolonged AF (episode lasting for ≥ 48 hours), and either PCV or ECV for AF of
more recent onset. Evidence on the relative effectiveness of drugs for PCV suggested that although the
class 1c AADs (flecainide and propafenone) are more effective than amiodarone in the short term, they
achieve a similar rate of conversion to sinus rhythm by 24 hours. The guideline group noted concerns overstrategy (chapter 10). The 2011 review195 highlighted new evidence related to the choice of pr
treatment (including statins and corticosteroids as well as AADs), the timing of prophylaxis (pre8. No time passes while patients pass through the classification, SR classification, acute onset,
cardioversion, rate control and rhythm control sections of the model. The reason for this assumption is
that we are not currently modelling resources explicitly, and as costs are accumulated on a daily basis,
times of < 1 day will not change the results.
9. We are not considering the costs, impact and effects of medications for comorbidities within the
model, so only the medications and anticoagulants that are prescribed as part of the treatment for AF
are considered.
Modelling pathway changes
The approach to evaluating the selected topics by the AF model are outlined in Table 39, and discussed in
more detail below.
Topic A: prophylaxis for prevention of post-operative atrial fibrillation
Onset of AF following cardiothoracic surgery is a common problem. This is sometimes transient, but AF
can persist and, if so, is associated with potentially serious effects (including haemodynamic instability,
ischaemia, heart failure and stroke and TE).135 CG36135 recommends the use of prophylaxis to prevent
post-operative AF (amiodarone, BBs, sotalol or RLCA) and management with an initial rhythm-controlincludes reactions, treatment failure, and ineligibility due to personal characteristics.
7. Patients continue with the final line of treatment after referral to the tertiary specialist, but
the model accumulating costs and QALYs until their death. This section is outside the scope3. As the Office for National Statistics data only cover ages up to 100 years, patients aged > 99 years are
not considered eligible for this model.
4. ER and 24-hour ambulatory ECG tests have a specificity of 1 (i.e. no false-positives as it is unlikely
that an arrhythmia will be picked up if it does not exist), but have varying sensitivities to allow
for false-negatives.
5. By definition, no one can be classified as in permanent AF state on initial diagnosis as they will not have
had the opportunity to try cardioversion at this point.
6. The contraindicated label encapsulates any reason that the patient cannot take the particular drug, soNIHR Journals Library www.journalslibrary.nihr.ac.uk
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In addition to the efficacy and speed of cardioversion, the risk of adverse events is a major factor that
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58influences clinicians’ choice of drugs for PCV. In particular, with antiarrhythmic therapy there is the risk
of proarrythmia, where the treatment itself can precipitate the onset of a new arrhythmia, including
bradycardia, tachycardia or prolongation of the QRS or QT interval. As with any drugs, AADs may be
associated with a range of other adverse events, including headache, nausea, dizziness and ocular
disturbances. Though most adverse events have no long-term consequences, they can be unpleasant and
are potentially harmful. As is often the case, modelling of adverse events is difficult because of the wide
variety of types and severity of events associated with the rhythm control drugs. Data on adverse events is
also sparse and difficult to collate due to variations in how it is reported. Nevertheless, it is important that
they can be included in evaluations of AADs, both in the context of short-term use for PCV (as in this
topic) and in ongoing treatment (as in the following two topics). In the illustrative analysis presented
below, we included an additional cost to reflect a longer length of stay for patients experiencing a
complication during PCV. We did not include any QALY loss for complications, as none of the
complications observed in the identified trials had any lasting effect.
We are not aware of any evidence to suggest that the choice of drug for PCV would influence the risk of
recurrence in patients successfully converted to sinus rhythm, and so did not include this in our illustrative
evaluation on this question. CG36 did present evidence that concomitant use of AADs alongside ECVthe safety of class 1c drugs in patients with SHD (coronary artery disease or LVD). They therefore
recommended amiodarone for PCV in patients with SHD, and a class 1c drug for other patients. The group
also reviewed evidence relating to adjuncts to ECV, including concomitant use of AADs to increase the
chance of success and reduce recurrence, and anticoagulation and TOE to reduce the risk of stroke and TE
associated with the ECV procedure.
The 2011 review195 identified new evidence relating to the choice of methods for cardioversion as part of a
rhythm control strategy. This included studies comparing drugs for PCV, ECV with concomitant AAD
treatment and different ECV techniques. Four RCTs were found relating to a new class III agent,
vernakalant (Brinavess®, Cardiome), which is licensed for cardioversion of AF episodes lasting for ≤ 7 days.
This drug was referred to NICE as a Single Technology Appraisal, but the process was suspended due to
information about the timing of launch in the UK. Vernakalant is not yet available in the UK and does not
have an NHS price, so evaluation is not currently possible. None of the new evidence relating to other
drugs for PCV identified in the review document provides a suitable basis for economic evaluation, as it
has have not demonstrated superiority over current recommendations. Similarly, it is difficult to identify a
clear evidence base to test potential changes in CG36 recommendations on concomitant AAD treatment
with ECV, or strategies to prevent TE associated with ECV.
Approach to economic evaluation
We therefore decided to use existing evidence included in CG36 to illustrate how the model could be
adapted for evaluation of different methods of cardioversion. As an example, we focus on the choice of PCV
drugs in patients with AF onset of < 48 hours, without haemodynamic instability or SHD (recommendation
R8, p. 40, CG36135): comparing the use of class 1c drugs (as is currently recommended) with amiodarone.
Key factors likely to drive the cost-effectiveness of different methods of cardioversion are: the frequency
and speed of conversion to sinus rhythm; the frequency and severity of adverse events; the risks of future
recurrence; and the cost of the procedure, consumables and associated hospital stay. The efficacy and
speed of cardioversion is clearly important for patients (as faster resolution of symptoms will alleviate
discomfort, distress and anxiety). The short duration of this benefit and the lack of quality-of-life data
make it difficult to capture in a QALY metric. However, speed of cardioversion is likely to impact on the
use of NHS resources and costs, which should be easier to estimate. Although we have not identified any
direct evidence that more rapid cardioversion translates to a shorter hospital stay, this is a reasonable
inference. We therefore modelled this effect by applying an additional cost for patients not converted to
sinus rhythm by a given time, to reflect the likelihood of an extra bed-day.105
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vernakalant,
gs, as well
2 patients),
and a serious adverse event rate of 4% (25 of 637). Four deaths were reported during this initial period
The GDG highlighted difficulties in interpreting the evidence base in this field because of confounding
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106with antithrombotic therapy. Trials comparing rate and rhythm control suffered from an imbalance
between the arms in the proportion of patients treated with an OAC, as patients allocated to rhythm
control were often withdrawn from OAC treatment if they remained in sinus rhythm. The use ofand a further eight after 24 hours, although it was reported that none of these deaths were related to
treatment. There were insufficient data to estimate relative adverse event rates for different drugs.
For the PCV evaluation, we assumed that 4% of patients undergoing PCV would experience a serious
complication, incurring an additional 1.78 days in hospital at a cost of £338 per day (total cost £602 per
complication). This estimate is based on the difference in average length of stay for elective inpatient
episodes for arrhythmia or conduction disorders (EB07) for patients with/without complications, and the
cost of an excess bed-day for these patients.109 For simplicity we assumed that other more minor side
effects would not have any significant health or resource impact. A relative risk parameter was added to
the model to allow sensitivity analysis of the impact of a difference in the percentage of patients
experiencing complications with different drugs.
We ran the model twice, once assuming that patients without SHD undergoing PCV would receive an
intravenous class 1c drug, and once assuming that they would receive intravenous amiodarone.
The difference in NB between these strategies illustrates the potential for gain from identifying faster
acting PCV drugs for use in this context.
Topic C: rhythm versus rate control for persistent atrial fibrillation
Background to topic
The choice of treatment strategy for patients with persistent AF is controversial. There is no clear evidence
that patients with persistent AF benefit from attempts at regaining and maintaining sinus rhythm through
cardioversion and use of AADs, or whether or not they would achieve better outcomes by moving straight
to a rate control strategy. CG36 reported that no study had demonstrated rhythm control to be superior to
rate control (or vice versa) for the outcomes of mortality or quality of life, although the GDG concluded
that there was ‘generally consistent’ evidence that rates of adverse events and hospital admissions were
higher with a rhythm control strategy. The GDG also considered subgroup analyses of the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM) trial,193 which identified some factors associated
with a lower risk of death with rate control. More recent Cochrane reviews197,198 have reached similar
overall conclusions.data to quantify the risks. Another review191 conducted by the manufacturer of the new drug
collated safety data from 22 trials of a range of PCV drugs, including amiodarone, class 1c dru
as vernakalant. They reported an overall adverse event rate within 2 hours of 40% (188 of 47can reduce the rate of relapse to AF (tables 5.5 and 5.6, p. 42).135 It would be easy to incorporate any
such impacts by applying appropriate relative risks to the early and late recurrence rates following
successful cardioversion.
Sources of data
The guideline recommendations on the choice of PCV drug were informed by a meta-analysis190
comparing amiodarone, class 1c drugs (propafenone or flecainide) and placebo. This review concluded
that the class 1c drugs were more effective than amiodarone at achieving sinus rhythm by 8 hours (63%
vs. 42%; p< 0.001), but that there was no significant difference by 24 hours (71% vs. 66%; p = 0.50).
We assumed that after 8 hours, one extra bed-day would be incurred at a cost of £338 [the excess
bed-day cost for an elective inpatient stay for Healthcare Resource Group (HRG) EB07I109]. For comparison,
a randomised trial of cardioversion196 reported a mean length of stay of 1 day (SD = 2) for 72 patients
randomised to an initial PCV strategy, and 2 days (SD = 2) for 67 randomised to initial ECV.
The review by Chevalier and colleagues190 also considered reports of adverse events, but found insufficientNIHR Journals Library www.journalslibrary.nihr.ac.uk
for
cardioversion and AADs. Additional criteria for rhythm control were symptomatic AF, first presentation of
rates
non-AF-related mortality, which is defined at model entry and independent of interventions and events in the
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58pathway, and AF-related mortality, which is defined as a case-fatality rate, consequent on the occurrence of
certain events (acute arrhythmia, TE or bleeding), as shown in Figure 18. The model is therefore incompatible
with data on all-cause mortality effects. Similar problems apply to data on rates of hospitalisation when it is
not possible to separate the reasons for admissions. This problem applies to the subgroup analyses
highlighted in the guideline review, as well as to the overall comparison of rate versus rhythm control.
There are two mechanisms through which rhythm and rate control interventions impact on health
outcomes in the model: through acute arrhythmic episodes that can be fatal and through the reduced
quality of life associated with uncontrolled AF (lack of sinus rhythm or heart rate > 80 b.p.m.). It is
straightforward to use these existing modelled mechanisms to compare the overall cost and QALY impact
of directing all patients with persistent AF to rhythm control or to rate control. The results of this analysis
are reported below. However, this analysis suffers from some important limitations, particularly the rather
limited incorporation of adverse drug effects within the current base-case model. These issues are
addressed in the Discussion section below.
Topic D: antiarrhythmic drugs
CG36136 recommended an escalating sequence of drugs, starting treatment with a standard BB. In patients
without SHD for whom a BB is ineffective, contraindicated or not tolerated, the GDG recommended use of
a class 1c agent or sotalol. For patients with SHD, or in patients for whom other treatment options have
failed, amiodarone was recommended. This sequence was largely based on concerns over adverse effects,
rather than on efficacy or cost. Evidence suggests that amiodarone is the most effective drug for
maintaining sinus rhythm, but it is associated with some potentially serious adverse effects, including
pulmonary, hepatic, ophthalmic and thyroid toxicity. The guideline review195 highlighted recent evidence
relating to new and existing antiarrhythmic agents. New treatments included dronedarone, which hadproblems of confounding with OAC treatment and composite outcomes. The model design sepalone AF, and AF secondary to a treated/corrected precipitant.
The review of CG36195 identified some evidence that could potentially be used to revise criteria for rate
versus rhythm control in defined patient groups:
l An analysis of data from the Rate Control versus Electrical cardioversion for atrial fibrillation (RACE)
trial199 reported that hypertensive patients randomised to rhythm control were at greater risk of
cardiovascular morbidity and mortality than those randomised to rate control. This difference was not
seen for non-hypertensive patients.
l The AF-CHF trial200 reported that patients with heart failure randomised to rhythm control had a similar
risk of death from cardiovascular causes compared with those randomised to rate control.
l The VALsartan In Acute myocardial iNfarcTion (VALIANT) study201 compared rate or rhythm control
strategies in patients following a MI. This found an excess mortality associated with AADs over the first
45 days, but no increased mortality after this initial period.
Approach to economic evaluation
It is not possible to use the direct rate versus rhythm evidence in the MAPGuide model, because of the(≥ 65 years), coronary artery disease, absence of congestive heart failure (CHF), and suitabilitycomposite outcome measures makes it difficult to tease out the effects of rate/rhythm control from the
effects of antithrombotic therapy. The primary outcome for most rate versus rhythm trials has been
all-cause mortality, which includes deaths from thrombotic, haemorrhagic and arrhythmic events.
Rates of hospitalisation are also confounded, since they often included admissions for cardioversion, as
well as for treatment of adverse events and treatment-related side effects.
Given this equivocal evidence, CG36 recommended that the choice of strategy should be tailored for
individual patients, and suggested criteria to guide this choice. The criteria for initial rate control were age107
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, they
recommend more detailed assessment with the CHA2DS2-VASc scoring system.
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108Topic G: anticoagulant drugs
Since publication of CG36, two new OACs have been recommended by NICE TAs: dabigatran (TA249)
issued in March 2012146 and rivaroxaban (TA256) issued in May 2012.147 Both drugs were recommended
with certain restrictions. Rivaroxaban was recommended as a treatment option for AF without underlying
heart valve disease and at least one of the following additional risk factors:
l CHF
l high blood pressure
l aged ≥ 75 years
l diabetes
l or history of stroke or TIA.thresholds to limit the use of oral anticoagulation in patients at high risk of a bleed.The base-case model incorporated CHA2DS2-VASc as the means of stratifying stroke and TE risk, and applied
the NICE criteria as the means of identifying patients suitable for OACs. The model also included calculation
of CHADS2 scores in order that they could be used for comparison. It is therefore straightforward to
compare these different scoring systems, and to compare different thresholds for prescription of OACs.
Topic F: stratification tools to assess bleeding risk
The review group also considered systems for assessing patients’ risk of bleeding, which could be used to
identify patients who would not be suitable for OACs. CG36136 listed criteria for assessing the risk of
bleeding including age, use of antiplatelet drugs or NSAIDs, multiple other drugs treatments, uncontrolled
hypertension, history of bleeding or poorly controlled anticoagulation therapy. However, recommendations
about how these factors should be combined or evaluated were unclear. Since publication of the NICE
guideline, more formal systems for assessing individuals’ risk of bleeding have been developed, including
the HAS-BLED scoring system, which was used in the model.
As with SR assessment, it is straightforward to use the model to evaluate the application of HAS-BLEDscoring ≥ 2 recommended for oral anticoagulation. For patients with a CHADS2 score of 0 or 1Topic E: risk factor scoring systems for stroke and embolism risk
CG36135 includes a SR stratification algorithm that prioritises patients for oral anticoagulation. It groups
patients into high-, medium- and low-risk groups on the basis of their age and history of ischaemic stroke/
TIA or other thromboembolic event, hypertension, diabetes, vascular disease, valve disease, heart failure
or LVD. This was based on a review of evidence on individual risk factors, and of existing risk
stratification algorithms.
The guideline review195 identified various new studies defining and testing different SR stratification
schemes for patients with AF. The European Society of Cardiology (ESC) published its guideline on AF in
2010.134 This recommended the CHADS2 scheme as a simple initial method for assessing SR, with patientsthe model to evaluate this topic.been the subject of a NICE TA,150 angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers (ARBs), and rosuvastatin (Crestor®, AstraZeneca).
Similar issues arise for the evaluation of particular AADs as for the comparison of rate with rhythm control
strategies discussed above. In particular, adverse effects are expected to have an important influence on
the choice of AAD. However, although the current version of the base-case model includes treatment
withdrawals, it does not account for any significant or lasting costs or health impacts for adverse effects.
We therefore consider that the base-case version of the model is not a suitable platform for evaluation of
this topic. Adaptation of the model to incorporate these effects is possible (see Discussion), but there was
insufficient time in this project to make the necessary changes. Consequently, we did not attempt to useNIHR Journals Library www.journalslibrary.nihr.ac.uk
The model already includes the above criteria, so the addition of dabigatran and rivaroxaban in line with
NICE TA recommendations to the CG36 treatment pathway is straightforward, and does not require any
of the
technique in patients with persistent or permanent AF. The HTA economic analysis found that treatment
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58would be cost-effective if quality-of-life improvements are maintained over the remaining lifetime of the
patient, but that cost-effectiveness is unclear if the benefits are only maintained for 5 years. Other
uncertainties relate to the effect of ablation on the risk of TE.
The costs and outcomes of ablation were not included in the base-case model – as this was outside the
original scope of CG36. Adaptation of the model to evaluate this procedure would be relatively
straightforward, and would involve the addition of a pathway for selection of individuals for treatment,
inclusion of the costs of treatment and follow-up, the costs and QALY impacts of complications, and
adaptation of the AF recurrence rate calculations. As noted above, there might be some difficulty in
identifying evidence of the longer-term impact of ablation on AF recurrence and TE risk.
Results
Base-case scenario: deterministic results
Results for 10,000 patients sampled from the THIN AF cohort are shown in Table 40 and in Figures 22–26.
At diagnosis, this sample had an average age of 74 years, a mean CHA2DS2-VASc score of 3.3 and a mean
HAS-BLED score of 2.3. The health outcomes and costs shown are the results of one run of the base-case
simulation model, following the CG36 recommendations and using point estimates for all modelto 12 months. However, evidence beyond 12 months is lacking, as is evidence relating to useadditional data. The model makes certain assumptions about the proportion of patients receiving the
different antithrombotic drugs when they are eligible for more than one drug (as illustrated in Table 24).
In particular, it assumes equal use of aspirin and warfarin when both are recommended (e.g. for patients
at medium risk), it assumes equal use of warfarin and of either dabigatran or rivaroxaban when all three
are recommended, and it assumes equal use of rivaroxaban and dabigatran when both are appropriate.
These criteria are easily changed, and a wide range of other strategies for the use of OACs could be tested
within the current model structure.
We did not attempt to model apixaban for use as an OAC for AF, as the NICE TA on this indication202 was
not published until April 2013, after completion of our research.
Topic H: catheter ablation for paroxysmal and persistent atrial fibrillation
CG36135 includes recommendations for the referral of patients for consideration for various interventional
procedures after failure of medical therapies for rate or rhythm control. This included referral for
pulmonary vein isolation, which includes catheter-based procedures. However, the guideline did not review
evidence for the clinical effectiveness or cost-effectiveness of any specialist invasive procedures, or make
recommendations for their use per se.
The guideline review identified new evidence relating to a range of ablation techniques, indicating an
increased interest in this approach. Ablation is potentially curative of AF, although it is associated with a
range of complications, including cardiac tamponade, pulmonary stenosis and thrombotic and
haemorrhagic events. The HTA systematic review and CEA152 concluded that radio frequency catheter
ablation is more effective than AAD therapy in patients with refractory paroxysmal AF over a period of upl aged ≥ 75 years
l aged ≥ 65 years with diabetes, coronary artery disease or high blood pressure.Criteria for access to dabigatran were similar, non-valvular AF and at least one of the following:
l stroke, TIA or embolism in the past
l heart failure of class 2 or above109
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110TABLE 40 Results for 10,000 patients: base-case model, deterministic
Characteristic Duration Mean SD Min. Median Max.
Age at arrival 74 12 31 75 99
Initial CHA2DS2-VASc score 3.3 1.7 0 3 9
Initial HAS-BLED score 2.3 1.2 0 2 9
Life-years Lifetime total 11.2 9.2 0.0 9.0 65.8
QALYs Lifetime total 7.15 5.88 0.00 5.69 38.02parameters. These illustrate the magnitude and range of key outputs under the base-case scenario. Mean
predicted survival was 11 years, with a range from 0 to 66 years. Adjusting for utility during this time
(mean 0.64), resulted in an estimated mean lifetime accumulation of around 7 QALYs (undiscounted).
Over their lifetime, the simulated patients experienced a mean 0.31 thromboembolic events and 0.79
haemorrhagic events. Their AF treatment included a mean of 0.36 attempts at cardioversion, 0.16 acute
admissions, and 2.68 tertiary consultations. The model predicted wide variations in costs, with the overall
lifetime cost of AF-related care amounting to a mean of £28,230 per patient, rising to a maximum of
£678,741. The cost of medication made up around 21% of this total cost. On an annual basis, the mean
cost of medications was £538 per patient and the mean cost of other health care was £1856 per patient
Mean per year 0.64 0.06 0.35 0.64 0.84
Thromboembolic events Lifetime total 0.31 0.68 0 0 7
Haemorrhagic events Lifetime total 0.79 1.06 0 0 8
Cardioversions Lifetime total 0.36 0.80 0 0 12
Acute AF episodes Lifetime total 0.16 0.44 0 0 7
Tertiary reviews Lifetime total 2.68 6.59 0 0 73
Medication costs (£) Lifetime total 5989 6762 0 3817 70,293
Mean per year 538 400 0 411 1931
Other health-care costs (£) Lifetime total 22,240 49,291 0 3204 671,148
Mean per year 1856 3431 0 360 94,386
Total cost (£) Lifetime total 28,230 50,823 0 10,709 678,741
Mean per year 2395 3421 0 1143 95,154
Max., maximum; min., minimum.
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FIGURE 22 Age at diagnosis: 10,000 patients from THIN AF cohort.
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FIGURE 23 Simulated life-years: 10,000 patients from THIN AF cohort.
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FIGURE 24 Simulated QALYs: 10,000 patients from THIN AF cohort.
Medication cost, undiscounted (£000 per person)
0 2 4 6 8 1210 14 16 18 20 22
Fr
eq
u
en
cy
0
500
1000
1500
2000
2500
3000
FIGURE 25 Simulated medication costs: 10,000 patients from THIN AF cohort.
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(including costs for AF admissions and consultations, and treatment and care following AF-related
adverse events).
To inform the decision over the number of patients to include per iteration in the probabilistic sensitivity
analysis, we estimated the cumulative means of key output parameters for increasing numbers of patients.
Figure 27 shows how the volatility of the estimated NB per patient decreases as the number of patients is
Health-care cost, undiscounted (£000 per person)
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FIGURE 26 Simulated health-care costs: 10,000 patients from THIN AF cohort.
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112increased to 10,000. The estimate is reasonably stable at 1000 patients and there is very little change in
the estimate above 2000 patients. For the analyses below, we used 1000 patients per probabilistic
iteration to limit the runtime of the model, as we wanted to compare a large number of scenarios.
Base-case scenario: probabilistic results
Table 41 compares the deterministic and probabilistic results for the base-case scenario. With 500
probabilistic iterations and 1000 patients per iteration, the results of the probabilistic and deterministic
analyses were quite similar. The probabilistic sensitivity analysis produced an estimate of 5.22 QALYs per
patient (discounted), compared with 5.20 QALYs from the deterministic analysis. There was rather more of
a difference in estimated costs (£21,048 from the probabilistic analysis, compared with £19,494 from the
deterministic analysis). This is not unexpected, as a large proportion of costs in the model related to
treatment of relatively rare but expensive events (mainly ischaemic and haemorrhagic strokes). Overall NBs
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FIGURE 27 Cumulative NB per patient with increasing sample size.
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TABLE 41 Base-case model results (per 1000 incident cases)
Outcome
Deterministic Probabilistic
1000 patients 1000 patients/500 probabilistic
Mean SD 95% CI Mean 95% CI
Thromboembolic events 0.31 0.71 0.24 to 0.37 0.35 0.33 to 0.36
Haemorrhagic events 0.84 1.09 0.74 to 0.94 1.03 0.99 to 1.07
Life-years 10.68 8.97 10.12 to 11.25 10.76 10.66 to 10.85
QALYs (undiscounted) 6.76 5.58 6.41 to 7.11 6.83 6.77 to 6.90
QALYs (discounted at 3.5% pa) 5.20 3.51 4.98 to 5.42 5.22 5.19 to 5.26
Medication costs (undiscounted) 5778 6152 5389 to 6167 5787 5684 to 5891
Medication costs (discounted) 4466 4227 4198 to 4733 4386 4317 to 4455
Other costs (undiscounted) 23,269 51,681 20,001 to 26,538 24,867 24,353 to 25,380
Other costs (discounted) 15,028 28,702 13,213 to 16,843 16,662 16,315 to 17,010
Total costs (undiscounted) 29,048 53,822 25,644 to 32,452 30,654 30,169 to 31,139
Total costs (discounted at 3.5% pa) 19,494 29,857 17,605 to 21,382 21,048 20,729 to 21,367
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58NB (undiscounted)a 106,176 99,704 99,871 to 112,482 106,026 104,633 to 107,419
NB (discounted)a 84,497 65,099 80,380 to 88,615 83,441 82,517 to 84,365
pa, per annum.
a At £20,000 per QALY.were similar when estimated from the probabilistic and deterministic analyses: £83,441 compared with
£84,497 respectively (assuming a cost-effectiveness threshold of £20,000 per QALY).
The number of probabilistic iterations used for the analyses presented below was based on observation of
the volatility of key output estimates with increasing numbers of iterations. Figure 28 shows how the
expected NB per patient changed as the number of probabilistic iterations was increased from 0 to 500 for
90
88
86
84
82
80
78
76
74
72
70
0 100 200 300
Number of PSA iterations
400
Aspirin
for all patients
Base-case strategy
for OAC
No antithrombotic
medication
N
et
 b
en
ef
it
 (
£0
00
) 
p
er
 p
at
ie
n
t
(d
is
co
u
n
te
d
, a
t 
£2
0,
00
0 
p
er
 Q
A
LY
)
FIGURE 28 Cumulative NB by probabilistic iteration (1000 patients per iteration).
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three illustrative strategies for antithrombotic therapy. It can be seen that the expected NB per patient is
lowest with no antithrombotic treatment, the base-case NICE strategy gives the next highest expected NB,
and prescription of aspirin for all patients gives the highest expected NB. The ranking and relative
differences between these strategies are very stable after only 100 probabilistic iterations. Unnecessary
variation between strategies was removed by the following procedures:
l For each probabilistic iteration, the same patient sample was used across all of the scenarios compared.
Thus the set of patients used in probabilistic loop n for the base-case scenario, was the same as for
probabilistic loop n for the no antithrombotic and aspirin scenarios. For probabilistic loop n + 1, the
patient sample was different from that in loop n, but again the same across all three scenarios.
l Similarly, the n’th probabilistic iteration used the same set of values for all of the population parameters
that did not differ between the scenarios. So, for example, the cost of treating a TE was the same for
the n’th probabilistic loop under the base-case scenario and for the no thromboprophylaxis and aspirin
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114These suggest that referring all patients with persistent AF straight to rate control dominates both the
current guideline recommendations and the strategy of rhythm control. Overall, the model estimates that
rate control would save £256 and yield an additional 0.017 life-years and 0.133 QALYs on average per
patient. The estimated differences in NB between the strategies are large. For example, rate control gives
an expected INB of £2908 per patient compared with the base case at a cost-effectiveness threshold of
TABLE 42 Model results: PCV drugs for patients without SHD (per 1000 patients)
Treatment option Life-years QALYs Cost (£M) NB (£M) ICER
Probability
cost-effective (%)
B0 class 1c 10,758 5225 21.044 83.453 Dominant 57
B1 amiodarone 10,756 5223 21.054 83.407 Dominated 43
INB (B1 – B0) –2.5 –1.8 0.010 –0.046
Mean results from 500 probabilistic iterations, 1000 patients per iteration.
Cost-effectiveness threshold = £20,000 per QALY.
INB compared with base case.AF are shown in Table 43.more cost-effective than amiodarone. Amiodarone is dominated as it gives a higher expected cost (£10 per
patient) and fewer expected QALYs (–0.0018 per patient). At a cost-effectiveness threshold of £20,000 per
QALY, this gave an expected INB of £46 more per patient with class 1c drugs than with amiodarone.
However, there is a high degree of uncertainty over this result. The estimated probability that class 1c
drugs are more cost-effective than amiodarone is 57% at a cost-effectiveness threshold of £20,000 per
QALY. The results were very similar at a cost-effectiveness threshold of £30,000 per QALY. Sensitivity
analysis over the relative incidence of complications also made very little difference to these results.
Topic C: rate versus rhythm control for patients with persistent
atrial fibrillation
The results for the illustrative comparison of rate and rhythm control strategies for patients with persistentshown in Table 42. These suggest that the current guideline recommendation (class 1c drugs)scenarios. The only parameters that differed between the scenarios for a given iteration were the cost of
the antithrombotic treatment and the relative risk reductions on rates of TE and bleeds.
The analyses reported below used 500 probabilistic iterations with 1000 patients per iteration.
Topic B: pharmacological cardioversion for patients without structural
heart disease
The results of the analysis comparing amiodarone with class 1c drugs for PCV in patients without SHD is
is likely to beNIHR Journals Library www.journalslibrary.nihr.ac.uk
£20,000 per QALY. This estimate increases to £4223 at £30,000 per QALY. The model also suggests that
there is a high degree of certainty over this result: in all 500 probabilistic iterations, rate control was more
cost-effective than either of the other strategies. However, as noted above, it is not clear that this analysis
properly accounts for the full range of adverse effects associated with both rate and rhythm control drugs.
TABLE 43 Model results: rate vs. rhythm control for persistent AF (per 1000 incident cases)
Strategy Life-years QALYs Cost (£M) NB (£M) ICER
Probability
cost-effective (%)
C0 base case 10,758 5224 21.05 83.44 Dominated 0
C1 rhythm 10,684 5004 22.42 77.67 Dominated 0
C2 rate 10,775 5357 20.79 86.35 Dominant 100
INB (C1 –C0) –74 –220 1.37 –5.78
INB (C2 –C0) 17 133 –0.26 2.91
Mean results from 500 probabilistic iterations, 1000 patients per iteration.
Cost-effectiveness threshold = £20,000 per QALY.
INB compared with base case.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58It can be seen that as the threshold for warfarin is increased (restricting use of anticoagulation), the mean
number of thromboembolic events rises, and the mean number of bleeds falls. Both life-years and QALYs
TABLE 44 Model results: CHA2DS2-VASc thresholds for warfarin (per 1000 incident cases)
Strategy Threshold TEs Bleeds Life-years QALYs Cost (£M) INB (£M)
E0 Warfarin 354 1058 10,663 5189 20.329 0.001presented are means across 500 probabilistic iterations, each including 1000 patients.Further analysis is required before conclusions should be drawn regarding the relative clinical effectiveness
or cost-effectiveness of rate and rhythm control.
Topic E: thromboembolism risk thresholds for oral anticoagulation
The results of the comparison of CHA2DS2-VASc thresholds for warfarin are shown in Table 44. For this
analysis, we assumed that patients would receive warfarin if their CHA2DS2-VASc score was greater than
or equal to a defined threshold X and aspirin if their CHA2DS2-VASc score was less than X. With X = 0, all
patients would be prescribed warfarin. As X is increased fewer patients are prescribed warfarin, until with
X = 10 all patients are prescribed aspirin. The model assumes that patients who have a bleed while on
warfarin will switch to aspirin. All other model parameters are held at their base-case values. The resultsE1 CHA2DS2-VASc ≥ 1 355 1059 10,677 5193 20.318 0.109
E2 CHA2DS2-VASc ≥ 2 357 1049 10,707 5205 20.076 0.591
E3 CHA2DS2-VASc ≥ 3 365 1033 10,766 5229 19.932 1.201
E4 CHA2DS2-VASc ≥ 4 384 994 10,827 5252 19.668 1.936
E5 CHA2DS2-VASc ≥ 5 411 952 10,885 5272 19.640 2.369
E6 CHA2DS2-VASc ≥ 6 432 925 10,924 5284 19.732 2.510
E7 CHA2DS2-VASc ≥ 7 455 896 10,943 5289 19.875 2.459
E13 Aspirin 470 884 10,962 5293 20.031 2.395
Mean results from 500 probabilistic iterations, 1000 patients per iteration.
Cost-effectiveness threshold = £20,000 per QALY.
INB compared with base case.
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are at a maximum when all patients are prescribed aspirin. This is because of the relatively high health loss
associated with bleeds. However, costs are at a minimum with a CHA2DS2-VASc threshold of 5, and at a
cost-effectiveness threshold of £20,000 per QALY gained, NBs reach a maximum at a CHA2DS2-VASc
threshold of 6.
The results of a similar analysis using CHADS2 thresholds for warfarin are shown in Table 45. Here the
maximum NB is reached at a CHADS2 threshold of 4.
The above results are illustrated in Figure 29. This shows estimated costs and QALYs relative to the
base-case results. As the CHADS2 and CHA2DS2-VASc risk thresholds are increased, the estimated QALY
gain increases, and the estimated cost-effectiveness point moves to the right. This graph shows the
similarity of results based on CHA2DS2-VASc and on the simpler CHADS2 scoring system.
Topic F: bleeding risk thresholds for oral anticoagulation
Results for the HAS-BLED threshold analysis are shown in Table 46. This analysis assumes that a patient
would receive warfarin only if their HAS-BLED score was less than a defined threshold Y and aspirin
otherwise. As in the preceding analyses, we assumed that patients who have a bleed while on warfarin
TABLE 45 Model results: CHADS2 thresholds for warfarin (per 1000 incident cases)
Strategy Threshold TEs Bleeds Life-years QALYs Cost (£M) INB (£M)
E0 Warfarin 354 1058 10,663 5189 20.329 0.001
E8 CHADS2 ≥ 1 356 1053 10,692 5199 20.244 0.287
E9 CHADS2 ≥ 2 372 1023 10,786 5236 19.877 1.410
E10 CHADS2 ≥ 3 404 965 10,868 5267 19.666 2.231
E11 CHADS2 ≥ 4 426 936 10,911 5280 19.715 2.440
E12 CHADS2 ≥ 5 453 903 10,945 5289 19.926 2.418
E13 Aspirin 470 884 10,962 5293 20.031 2.395
Mean results from 500 probabilistic iterations, 1000 patients per iteration.
Cost-effectiveness threshold = £20,000 per QALY.
INB compared with base case.
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FIGURE 29 Costs and effects for CHADS2 and CHA2DS2-VASc thresholds for warfarin.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 46 Model results: HAS-BLED thresholds for warfarin (per 1000 incident cases)
Strategy Threshold TEs Bleeds Life-years QALYs Cost (£M) INB (£M)
F0 Warfarin 354 1058 10,663 5189 20.329 0.001
F1 HAS-BLED < 4 376 1025 10,710 5206 20.420 0.258
F2 HAS-BLED < 3 419 958 10,792 5236 20.408 0.871
F3 HAS-BLED < 2 459 899 10,897 5271 20.255 1.718
F4 HAS-BLED < 1 470 883 10,953 5290 20.100 2.262
F5 Aspirin 470 884 10,962 5293 20.031 2.395
Mean results from 500 probabilistic iterations, 1000 patients per iteration.
Cost-effectiveness threshold = £20,000 per QALY.
INB compared with base case.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Estimated health outcomes are rather better with the addition of the new drugs (with fewer
thromboembolic events and bleeds and more life-years and QALYs for G0 compared with G1). However,
as might be expected, costs are increased with dabigatran and rivaroxaban. At a cost-effectiveness
threshold of £20,000 per QALY, this results in a very similar expected NB for these two strategies and the
estimated probability that G0 is more cost-effective than G1 is only 45%. However, with NICE’s upper
threshold for cost-effectiveness (£30,000 per QALY), the expected NB is higher with dabigatran and
rivaroxaban: £135,685 for G0 and £128,712 for G1 (51% probability that G0 is more cost-effectivepatients to aspirin or warfarin, as well as TA249 criteria for access to dabigatran and TA256 fo
rivaroxaban. G1 excludes dabigatran and rivaroxaban from the treatment options.will switch to aspirin, and all other model parameters were held at their base-case values. The figures are
presented as mean values across 500 probabilistic iterations, each including 1000 patients.
As the HAS-BLED threshold is reduced, fewer patients receive warfarin and the mean rate of TEs increases,
whereas the mean rate of bleeding declines. Health outcomes (life-years and QALYs) are at a maximum
and costs are at a minimum when the bleeding risk threshold is set so that no patients receive warfarin
(all receive aspirin).
Topic G: choice of oral anticoagulation drugs
For this analysis (Table 47), we changed the oral anticoagulation drugs available within the modelled
treatment pathway. Strategy G0 is the base-case analysis, which includes CG36 criteria for allocation of
r access tothan G1).
TABLE 47 Model results: comparison of OAC drugs (per 1000 incident cases)
Strategy TEs Bleeds
Life-
years QALYs
Cost
(£M)
ICER
(£)
INB
(£M)
G0 warfarin/dabigatran/rivaroxaban/aspirin 346 1028 10,758 5224 21.048 – –
G1 warfarin/aspirin 354 1058 10,663 5189 20.329 20,038 0.001
Mean results from 500 probabilistic iterations, 1000 patients per iteration.
Cost-effectiveness threshold = £20,000 per QALY.
INB compared with base case.
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118treatment effects of antithrombotic therapy, this would have corrected to some extent for natScope of the model
This chapter has presented the methods and results of a DES model developed to estimate the costs and
health effects associated with the main processes of care for people with AF: diagnosis, cardioversion,
antithrombotic therapy, rate and rhythm control, and ongoing monitoring. The model covered most of the
service pathway in the NICE CG on AF, although we did not attempt to include the prevention and
treatment of post-operative AF, which is a rather separate clinical question. The model does not currently
include tests or interventional procedures for patients with structural heart defects, or for people with AF
refractory to medical treatment (e.g. ablation or implantable devices), though these were also excluded
from the scope of the original NICE guideline. As an individual-level simulation, the MAPGuide AF model
reflects heterogeneity in the patient population. It contains rich information about correlated risk factors
and retains information about individuals’ history as they pass through the modelled pathway, which
allows greater flexibility and realism in representing variations between patients.
Data sources
Overall, the model benefits from the availability of strong data sources to inform many of its key
parameters. The THIN database provided individual-level data on demographic and clinical risk factors for
over 12,000 individuals close to the time of their AF diagnosis. These data were derived from routine
primary care data and are broadly representative of the UK population. However, there may be flaws in
the recording of information in the database, as this was collected for primary patient management
purposes rather than for research. We also had to make a number of assumptions to associate the
recorded data with the risk factors that we required for the model.
Estimates of the rates of TE and bleeding were taken from a large population cohort study.158
The applicability of these Swedish data to the UK AF population is open to question. However, as the data
used in the model were stratified by risk score (CHA2DS2-VASc and HAS-BLED) and adjusted for estimatedDiscussionCHA2DS2-VASc, and that the optimum INB is actually greater with CHADS2 than with CHA2DS2-VASc
(£2538). This suggests that the simple CHADS2 risk scoring system is at least as good, if not better, than
the more complex alternative, CHA2DS2-VASc.
Tables 50 and 51 show estimated QALYs, costs and NBs by CHADS2 and HAS-BLED thresholds for
selection of dabigatran and rivaroxaban respectively. These matrices illustrate how the optimal treatment
thresholds can change with the anticoagulation drug: CHADS2 ≥ 4 and HAS-BLED< 4 for warfarin; CHADS2
≥ 4 with no HAS-BLED threshold for dabigatran; and CHADS2 ≥ 3 and HAS-BLED < 2 for rivaroxaban.
As might be expected, there is a high level of interaction between the choice of antithrombotic drug, and
the thromboembolic and bleeding risk thresholds for treatment.The results for a similar analysis using CHADS2 as the stratification system for stroke and thro
risk are shown in Table 49. It can be seen that the pattern of results is very similar with CHADInteractions: risk thresholds and drugs for oral anticoagulation
The model results for simultaneous changes in thresholds for stroke (CHA2DS2-VASc) and bleeding
(HAS-BLED) for allocation of patients to warfarin or aspirin are shown in Table 48. The optimum health
outcome (QALY maximum) occurs with a CHA2DS2-VASc threshold of ≥ 2 combined with a HAS-BLED
threshold of < 1 for warfarin. However, the greatest cost savings are attained with a CHA2DS2-VASc
threshold of ≥ 5 and no HAS-BLED threshold. Overall, the model predicts a maximum INB compared with
the base case of £2510 per patient (at £20,000 per QALY), which is achieved with a CHA2DS2-VASc
threshold of ≥ 6, with no HAS-BLED threshold. This finding contrasts with the separate analyses of the
HAS-BLED threshold shown above in Table 46, which suggests that a very high HAS-BLED threshold would
be optimum in the absence of a threshold for thromboembolic risk.
mboembolicNIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 49 Model results: HAS-BLED and CHADS2 thresholds for warfarin
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
120Incremental QALYs (mean per person, discounted)
Warfarin/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None –0.0359 –0.0258 0.0120 0.0424 0.0553 0.0648
< 4 –0.0185 –0.0096 0.0270 0.0566 0.0648 0.0684
< 3 0.0116 0.0214 0.0494 0.0653 0.0664 0.0700
< 2 0.0463 0.0547 0.0655 0.0682 0.0690 0.0689
< 1 0.0657 0.0703 0.0697 0.0689 0.0689 0.0689
Incremental cost (mean £ per person, discounted)
Warfarin/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None –719 –804 –1171 –1383 –1334 –1122differences in the distribution of risk factors and differences in treatment. Other key inputs to the model
were estimates of the effects of antithrombotic and antiarrhythmic therapy, which were drawn from
network meta-analyses conducted to inform recent NICE TAs.145,179 These analyses provide coherent
estimates of the relative impacts of the available medications in these two key areas of AF treatment,
although it should be noted that they do not necessarily reflect all current evidence as we have not
updated the reviews on which they were based. The cost estimates for the various interventions and
outcomes along the pathway were based on standard UK sources,109–111 and estimates of the costs of
stroke in people with AF were also supported by an unusually large and well-conducted UK
population-based study.185 The utility data underlying the QALY estimates may also be seen as a strength,
as they came from large sample surveys using the EQ-5D instrument: starting with UK population
utilities,187 with adjustment for AF status from an international cohort study of patients with AF,188 and
adjustment for adverse events from a US panel of patients with a range of chronic conditions.189 Although
their applicability to a UK population can be questioned,203 these sources provided consistent estimates of
the utility impacts of AF control, and of the AF-related adverse effects included in the model.
< 4 –628 –766 –1104 –1287 –1241 –1082
< 3 –640 –791 –1100 –1134 –1090 –1025
< 2 –793 –905 –1052 –1063 –1011 –1017
< 1 –948 –1036 –1001 –1017 –1017 –1017
INB (mean £ per person, discounted)
Warfarin/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None 1 287 1410 2231 2440 2418
< 4 258 575 1644 2420 2538 2450
< 3 871 1219 2087 2441 2417 2425
< 2 1718 1999 2361 2426 2391 2395
< 1 2262 2442 2395 2395 2395 2395
Mean results compared with the base-case strategy.
INBs calculated at a cost-effectiveness threshold of £20,000 per QALY.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
< 3 0.0659 0.0674 0.0754 0.0737 0.0710 0.0694
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58< 2 0.0652 0.0660 0.0700 0.0686 0.0690 0.0689
< 1 0.0688 0.0691 0.0698 0.0689 0.0689 0.0689
Incremental cost (mean £ per person, discounted)
Dabigatran/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None 1237 827 –33 –881 –1030 –1077< 4 0.0683 0.0709 0.0795 0.0793 0.0770TABLE 50 Model results: HAS-BLED and CHADS2 thresholds for dabigatran
Incremental QALYs (mean per person, discounted)
Dabigatran/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None 0.0594 0.0637 0.0782 0.0757 0.0741 0.0713
0.0712There are, however, some weaknesses in the quality of data in some other areas (most notably around the
accuracy of diagnostic tests for AF, the effectiveness of different methods of cardioversion and of rate
control medications). Another potentially important weakness is the sparse data on the case fatality rates
for haemorrhagic strokes and other major bleeds. The high estimated rate of mortality from bleeds
compared with mortality from TEs (21% vs. 11%) in the model, impacts on the relative cost-effectiveness
of anticoagulant drugs. The analysis would be strengthened by a more robust source of data on the
case-fatality rates associated with the modelled events.
Modelling antithrombotic treatment strategies
The model provided a good foundation for comparison of strategies for the prevention of stroke and TE. It
provided stable and consistent estimates of costs and health effects for many strategies, including changes
in SR and bleeding thresholds for anticoagulation, and the choice of anticoagulant medication. The
structure of the model offers great flexibility to model a wide variety of strategies.
As mentioned above, although the data underlying the model are of a generally good quality, there are
some model inputs in particular that require further consideration before the results should be used to
< 4 1182 760 –114 –859 –963 –1060
< 3 674 147 –512 –973 –1024 –1039
< 2 –213 –593 –1004 –1030 –1012 –1017
< 1 –785 –1034 –998 –1017 –1017 –1017
INB (mean £ per person, discounted)
Dabigatran/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None –49 448 1597 2396 2513 2502
< 4 183 657 1704 2444 2502 2484
< 3 645 1202 2021 2446 2444 2427
< 2 1517 1914 2405 2402 2392 2395
< 1 2162 2417 2394 2395 2395 2395
Mean results compared with the base-case strategy.
INBs calculated at a cost-effectiveness threshold of £20,000 per QALY.
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2CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
122Rivaroxaban/aspirin None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None 0.0129 0.0070 –0.0008 0.0264 0.0478 0.0614
< 4 0.0193 0.0121 0.0085 0.0349 0.0533 0.0631
< 3 0.0460 0.0411 0.0406 0.0573 0.0680 0.0686
< 2 0.0649 0.0611 0.0632 0.0680 0.0690 0.0689
< 1 0.0704 0.0694 0.0697 0.0689 0.0689 0.0689
Incremental cost (mean £ per person, discounted)
Rivaroxaban/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None 5576 5381 4121 1908 520 –455Incremental QALYs (mean per person, discounted)
CHADS thresholdTABLE 51 Model results: HAS-BLED and CHADS2 thresholds for rivaroxabaninform treatment decisions. Essentially, the model weighs up the relative frequency and severity of
thromboembolic and haemorrhagic events. One key factor in this equation is the mortality associated with
these different events, and the case-fatality rate for haemorrhagic strokes was only based on a very small
number of cases, so might not be reliable.
The model relies on two scoring systems to stratify individuals on the basis of the risk of TE
(CHA2DS2-VASc) and bleeding (HAS-BLED). At the individual patient level, the predictive validity of these
systems is limited.168 However, alternative scoring systems or simple pragmatic rules (such as relying on age
alone) are no more likely to be correct. Also across the population of people with AF, both CHA2DS2-VASc
and HAS-BLED are strongly predictive of the related outcomes. They therefore represent the best available
foundation for modelling treatment outcomes and cost-effectiveness of oral anticoagulation for people
with AF.
Modelling rate versus rhythm
Adaptation of the base-case model to address questions related to the choice of rate or rhythm control
strategy, and the choice of particular rhythm control drugs was less successful. The key problem was that
< 4 4239 4125 2932 875 –127 –757
< 3 1591 1496 675 –488 –967 –1018
< 2 –468 –576 –905 –1055 –1011 –1017
< 1 –992 –979 –1001 –1017 –1017 –1017
INB (mean £ per person, discounted)
Rivaroxaban/aspirin
CHADS2 threshold
None ≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
HAS-BLED threshold None –5319 –5240 –4138 –1379 436 1683
< 4 –3853 –3883 –2762 –176 1193 2019
< 3 –670 –673 137 1634 2326 2389
< 2 1765 1799 2168 2415 2391 2395
< 1 2399 2366 2394 2395 2395 2395
Mean results compared with the base-case strategy.
INBs calculated at a cost-effectiveness threshold of £20,000 per QALY.
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the direct trial evidence on rate compared with rhythm control was incompatible with the model structure.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58This might be seen as a problem with the trials in this field, which were confounded with between-arm
differences in rates of anticoagulant therapy and presented results using composite outcomes (such as
all-cause mortality and hospitalisation) which were difficult to interpret. However, some choices made in
designing the base-case model did limit our ability to capture all of the potentially important impacts of
rate and rhythm control strategies, and some reprogramming would be required to produce a convincing
evaluation of this topic.
First, the model does not currently allow for any independent effect of sinus rhythm on risk of TE. It is
controversial whether or not any such effect exists, although it might appear logical that it should (if a
cardiac arrhythmia increases the chance of the development of an embolism, reversion to sinus rhythm
might be expected to reduce this chance). However, evidence for this hypothesis is sparse. The only
evidence that we found came from a multivariate analysis of data from the AFFIRM trial.194 This was a
cox-proportional hazards regression of ‘on treatment’ data (i.e. not intention to treat). It corrected for a
number of covariates, including patient characteristics (age, coronary artery disease, CHF, LVD, mitral valve
disease, diabetes, prior stroke or TIA, and smoking) and concomitant treatments (warfarin, digoxin and
AADs). The estimated hazard ratio for mortality with sinus rhythm was 0.53 (95% CI 0.39 to 0.72). This
was of a similar magnitude to the hazard ratio for warfarin use (0.50, 95% CI 0.37 to 0.69), and use of
AADs were associated with increased mortality (1.49, 95% CI 1.11 to 2.01). The authors concluded that
one hypothesis that would explain these effects is that AADs have a beneficial effect on survival through
maintenance of sinus rhythm, but that this benefit might be offset by their adverse effects. However, it is
difficult to draw firm conclusions from this essentially observational study, as important confounders might
have been omitted. It is also difficult for us to apply these data to the model, since the results are reported
in terms of an impact on all-cause mortality. However, the model could easily be modified to allow a
‘what-if’ sensitivity analysis on this point, by adding a relative risk multiplier for the risk of TE.
A second limitation of our analysis on the rate versus rhythm question, relates to the way in which we
modelled adverse treatment effects. The model includes treatment discontinuation rates for all drugs, but
it does not differentiate discontinuation due to adverse effects, or attach any health consequences or
treatment costs for adverse effects other than bleeds for antithrombotic therapy and acute-onset
arrhythmias. This is appropriate for the majority of adverse effects that patients tolerate and for the more
minor adverse effects that might prompt treatment withdrawal, as these will not have significant or lasting
consequences. However, the omission of more serious adverse effects is a problem. This could be rectified
with some relatively straightforward reprogramming, and data is available to inform this extension of the
model. As always with adverse effect data, the large number of different types of effects that patients
experience and differences in reporting present a challenge. However, data is available to estimate rates
for three broad categories of adverse effects for the rate and rhythm control drugs: pro-arrhythmic events
(new cardiac arrhythmias potentially provoked by antiarrhythmic therapy), other serious adverse events and
minor adverse events.179,192 Estimates of the QALY impacts and costs associated with these types of
adverse events are also available from the economic analysis produced by Sanofi-Aventis for the NICE TA
of dronedarone.149–151
A third limitation of the use of the model to compare rate and rhythm control strategies is the weakness
of evidence on the effectiveness of rate control drugs. The model currently uses data from five small
randomised cross-over trials reported in CG36 (55 patients in total), meta-analysed using a simple
inverse-variance method. An alternative source of data was identified during the search for evidence to
inform the rate versus rhythm analysis. This comes from a post hoc analysis of AFFIRM trial data,192 which
estimated the effects of BBs, calcium-channel blockers and digoxin alone or in combination on the
achievement of adequate ventricular rate control (defined as average heart rate ≤ 80 b.p.m., with
additional criteria for maximum heart rate during exercise and on 24-hour ECG monitoring). Though
observational, this data set is larger than that included in the model (361 patients), it directly compares
single drug and combination therapies and it is presented alongside adverse effect rates. The model could123
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be adapted to make use of this data set, and to provide a firmer footing for comparison of rate and
rhythm control strategies.
Finally, the omission of interventional techniques from the end of the rhythm control pathway in the
model might have biased the results.
Comparison across the potential update topics
In the time available, we succeeded in conducting analyses for five of the eight potential update topics.
A simple two-drug comparison for topic B supported the current recommendation for the use of class 1c
drugs, rather than amiodarone, for PCV in patients without SHD. This finding was highly uncertain, and
CASE STUDY 2: FULL GUIDELINE MODEL FOR ATRIAL FIBRILLATION
124the estimated INB was relatively modest (< £50 per patient at a threshold of £20,000 per QALY). This is
not unexpected, first because there is little evidence of any difference in effectiveness between these drugs
(class 1c drugs may be faster acting than amiodarone, but overall success rates are similar). Second, this
topic is also only relevant for a subset of patients.
The analysis for topic C was speculative, as we believe it might have omitted some important factors.
Nevertheless, the findings do suggest that the balance between rate and rhythm control is potentially of
high economic importance. The model suggested that an overall rate control strategy could be more
effective and cost-effective than the current recommendation of selecting patients for rhythm control. The
size of the estimated INB for rate control compared with the base-case strategy was £2908 per patient
(at a threshold of £20,000 per QALY).
Taken together, the analyses of topics E and F suggest that there is also good potential for improving the
cost-effectiveness of the guideline pathway by better targeting of anticoagulation therapy on the basis
of stroke and bleeding risk scores. The model estimated that the optimum strategy for selecting patients
for warfarin (CHADS2 score ≥ 4 and HAS-BLED score < 4) would save money and improve patient
outcomes, yielding an INB of about £2500 per patient compared with the current guideline
recommendations at the £20,000 per QALY threshold.
In contrast, the model estimated more modest gains in cost-effectiveness from the use of newer OACs
rather than warfarin. Adding NICE TA recommendations for the use of dabigatran and rivaroxaban to
the CG36 recommendations for warfarin made no difference to the overall NB at NICE’s lower
cost-effectiveness threshold of £20,000 per QALY. Even at the upper threshold of £30,000 per QALY,
a small incremental gain in NB of £358 per patient was estimated.
The above analyses suggest that of the topics analysed, the targeting of rhythm control therapy and of
oral anticoagulation are the highest economic priorities for inclusion in an update of the guideline, as they
both show the potential for significant improvement in the NB of the treatment pathway. The choice of
drugs for oral anticoagulation and for PCV of patients without SHD are relatively lower priorities from an
economic perspective, as they appear to add less to overall NBs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
g handled in
is capable
line. This
has been suggested as a means of strengthening the analytical foundation of NICE CGs in order to apply
the Institute’s decision-making principles.6 Several generic disease models that could fulfil such a function
Model’, as they do not cover the entire breadth of the pathway from preclinical disease, diagnosis,
t described
tween the
stages of (i) problem-oriented conceptual modelling; (ii) design-oriented conceptual modelling; and
(iii) implementation modelling. However, the models did progress through these stages, and the distinction
between ‘service pathways’ and ‘disease processes’ was particularly helpful in understanding how to
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58conceptualise the models – this contrasts with conventional health economic decision models, where this
distinction is often blurred in the definition of ‘health states’.treatment and follow-up. The process of model development was also more iterative than tha
by Tappenden and colleagues, as during model development there was not a clear division behave been reported previously,41,42,44,46,48 and a methodological framework on how to design, build, check
and apply ‘Whole Disease Models’ has been published.49 Tappenden and colleagues63 have also
demonstrated how this concept could be applied to CGs by showing how their Whole Disease Model of
colorectal cancer could evaluate 11 of the 15 topics addressed in the NICE colorectal cancer guideline.39
It is uncertain, however, whether or not such large-scale models could be developed within the
constrained timelines and resources of the NICE CGs programme and, if so, whether they would provide a
greater quantity or quality of cost-effectiveness evidence to support guideline recommendations than
existing methods. There may also be a risk associated with devoting all analytical resources to the
development of a single complicated model. The MAPGuide project was therefore designed to further
explore the feasibility and usefulness of this approach.
Summary of main findings
Feasibility of full guideline modelling
Process of model development
The project comprised two selected case studies in which we developed models for published NICE
guidelines: prostate cancer and AF.54,136 The guidelines were developed in parallel by two teams of
modellers, who mostly worked independently but followed an agreed protocol and met regularly to
discuss their experiences and possible solutions to the problems encountered. The process of model
development for both teams broadly followed that described in the methodological framework developed
by Tappenden and colleagues.49 The MAPGuide models do not meet the definition of a ‘Whole Diseaseevaluate discrete aspects of diagnosis, treatment or ongoing care, with remaining aspects bein
a more qualitative way.
An alternative approach would be to develop a single model of the entire care pathway which
of providing a platform for evaluating the cost-effectiveness of multiple topics across the guideChapter 6 Discussion
Motivation for the Modelling Algorithm Pathways in
Guidelines project
The current approach to assessing cost-effectiveness in most CGs is partial. Some guideline developers do
not explicitly take account of cost-effectiveness, and those that do often have limited health economic
resources available to them.8 NICE is unusual internationally in requiring its GDGs to consider
cost-effectiveness and in providing resources to support them in this activity.35 Each guideline has a
dedicated health economist who reviews the economic literature and conducts new analyses for selected
questions. This usually involves the development of a small number of separate decision models to125
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opment
process took closer to 24 months, and more than one whole-time equivalent analyst per guideline was
DISCUSSION
126the model parameters were obtained from the evidence reported in the original guideline andrequired. This was due to several factors. Development of the conceptual models was initially slow as the
teams worked out how to articulate the models of the service pathways and disease processes. The teams
also had some difficulties in understanding the intent behind some of the guideline recommendations and
in converting the relatively informal guideline ‘algorithms’ into the fully articulated flow charts that are
required for quantitative modelling. Access to clinical advice was essential in resolving these uncertainties.
To some extent, the difficulty experienced may have related to the context in which we conducted this
research, which was outside of routine guideline development and in the absence of a constituted GDG.
The need to assemble a large number of data inputs and to convert them into the correct format to
estimate the time-to-event model parameters represented another challenge, as did the process of
verifying and validating such large models.
Overall, there was a steep learning curve for the health economists with little experience of DES, as the
structure and data requirements for DES models are quite different to those of conventional economic
decision models. Consequently, the teams relied more than was planned on advice and assistance from
experts in simulation modelling. Conversely, for simulation modellers without experience of health
economic evaluation there was also a learning process to understand how to jointly model disease
processes and service pathways together, and how to incorporate epidemiological and clinical trial data
into a DES format. There is currently a lack of applied texts and tutorial materials to fill this learning gap
between decision modelling for economic evaluation of health-care technologies and DES. One of the
strengths of the MAPGuide project was that it brought together experienced guideline developers, health
economists and simulation modellers, and facilitated an exchange of ideas, knowledge and skills.
This experience might suggest that it would not be possible to develop a full guideline model within
existing NICE CG development timelines and resources. However, some considerations might temper this
conclusion. Many of the problems encountered in this project related to understanding the general
principles of how to encode, implement and parameterise simulation models to conduct CEAs within CG
pathways. Having solved many of these problems for two illustrative examples, certain aspects of the
development of a third full guideline model might be easier: the descriptions of the two case study models
in this report provide a template for how to articulate service pathways and disease processes and the
relationship between them; and some key learning points on good practice in model development are
provided below. We have also developed a much better understanding of the type of expertise that is
needed for the successful completion of a full guideline model. We found that we did need specialist input
in simulation modelling to complement expertise in economic evaluation and decision modelling.
In some respects, model definition and parameterisation might also be easier in the context of real
guideline development than in this rather artificial research context. Interpreting the thinking underlying
the original guideline was often difficult, and access to the clinical expertise of a constituted GDG and the
information science and systematic reviewing skills of a NCC technical team would have helped greatly.
On the other hand, developing the prototype models concurrently with the ‘live’ guideline development
would have presented other challenges, particularly the need to explain and achieve acceptance of the
approach while learning how to implement it ourselves.
Scope of the models
The modelling teams succeeded in constructing individual-level simulations to predict how a
heterogeneous cohort of patients with incident disease would pass through the currently recommended
pathways of care, in order to estimate key clinical outcomes, QALYs and health-care costs. Data to inform16 months, with a total input of 12 months of analyst time per model. In the event, the develResource requirements
It must be acknowledged that the development of both models took longer and involved a greater input
of analytical resources than was initially envisaged. In the original project plan, we estimated that the
whole process from the preliminary literature review to writing up the model results would takeNIHR Journals Library www.journalslibrary.nihr.ac.uk
supplemented with more recent evidence where necessary. The modellers managed to cover the large
majority of the breadth of the guideline pathways, if not their entirety. Exceptions included the prevention
and treatment of post-operative AF, which was thought to be too different to AF not related to surgery to
d by missing
flexibility of
arts of the
pathway may be incompatible. An example of this that arose for the AF model related to the evidence
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58base on rate versus rhythm control strategies, which was confounded by differences in rates of
anticoagulation and the use of outcomes that could not be directly incorporated in the chosen model
structure (all-cause mortality). It should also be acknowledged that some of the analyses presented above
are essentially illustrative, due to limitations in the data and time available within this research project.
However, these analyses could be readily updated given clearer definitions of the decision problems,
systematic reviews of evidence and clinical advice. The models also have the capability to address most of
the topics not analysed in this report (e.g. when evidence of effectiveness and a market price becomes
available for some of the new drugs highlighted by stakeholders).
Overall, the case studies have shown that full guideline models can be adapted to address a wide range of
questions that might arise during an update. It is also likely that the models could be applied to other
decision problems and contexts – we envisage that both of these models will evolve further over time.
If full guideline models could be reused and adapted to address a series of guideline updates and HTAs,
this might represent a very efficient use of analytical resources. One might envisage a stock of such
‘standing models’ providing a valuable resource for NICE. However, it does remain to be shown that
guideline models are sufficiently flexible to adapt to new evidence and new technologies.There are some real constraints on the flexibility of the models (e.g. when the scope is restricte
information about natural history, as discussed above). Another factor that may constrain the
full guideline models to address all questions of interest is that evidence underlying different pmerge into a single model.
The modelling teams also had difficulty in representing the diagnostic sections of the pathway due to
inherent problems in quantifying test accuracy for conditions lacking a diagnostic ‘gold standard’, the lack
of good-quality data on natural history (particularly for prostate cancer) and the challenge of predicting
what happens to patients following a false-positive or false-negative test result. It is unclear whether this
difficulty in modelling diagnosis was a feature of the particular guidelines chosen as case studies, or
whether it reflects a more general problem in establishing diagnostic accuracy. If the latter, this would
represent a limitation on the usefulness of full guideline models, although it is unlikely that conventional
decision-analytic models would perform any better in such circumstances. In general, one might expect full
guideline models to be well suited to the evaluation of diagnostic tests, as they are designed to capture
the downstream pathways of treatment and care.204
Ultimately, though, any modelling exercise requires judgement about the level of detail to be represented
and the extent to which assumptions will be used to fill gaps in data. This is true for full guideline models,
as for more conventional economic decision models.
Usefulness of the full guideline models
Coverage of update topics
Both modelling teams were generally successful at adapting their model to evaluate the potential update
topics identified in the survey of guideline stakeholders. The prostate cancer model produced
cost-effectiveness estimates for six out of the nine shortlisted topics (two of which were modelled
together), and estimates of cost-effectiveness were produced for five of the eight AF topics. This represents
a much better coverage of clinical questions with economic evidence than is normally possible in
NICE CGs, albeit with a greater input of economic resources on the selected guidelines.127
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The key motivation for the full guideline modelling approach is to start to respond to Alan Williams’
earlier or
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128cohort. This is likely to introduce bias into the comparison of NBs for interventions that appearchallenge to map all of the relevant ‘highways and byways’ of the clinical pathway, rather than to focus
only on cost-effectiveness at ‘particularly tricky junctions’.6 There are two potential benefits of taking this
broader view. First, the cost-effectiveness of a decision option at a specific node may change if it is
evaluated in the context of different surrounding decisions. Second, it provides the ability to compare the
magnitude of health gains, cost impacts and NBs across decision options. Though irrelevant to
cost-effectiveness, this might provide useful information to prioritise and plan for implementation of
guideline recommendations.
Within the constraints of this project, we have only managed quite limited investigation of possible
interactions between changes to different parts of the care pathways. In the AF chapter, we examined
interactions between risk thresholds for TE and bleeding and the choice of drug for antithrombotic
therapy, and (not surprisingly) found that these decisions are closely related. However, we did not manage
to investigate possible interactions between antithrombotic and antiarrhythmic therapies. There are
reasons to suppose that the cost-effectiveness of antithrombotic strategies might depend on the choice of
antiarrhythmic strategy and vice versa, especially contraindications to coprescribing of drugs (notably
dronedarone and dabigatran), and the possibility of independent protective effects of rhythm control
against thromboembolic events.194 Although we have not succeeded in examining these effects within this
project, the model does offer the potential to do so. Another interesting possibility for further investigation
with the AF model relates to the placing of ablative procedures to control symptoms of arrhythmia within
the care pathway. Similarly, for the prostate cancer model we did not manage to examine topic
interactions within this project, but there is the potential to do so.
One aspect of the evaluations presented in this report that interferes with our ability to compare and
combine decision options at different points in the care pathway relates to the use of a single incidentInteractions between topicsComparison of model results with survey priorities
The model results are tentative as they are not based on up-to-date systematic reviews of evidence, or
informed by the expertise and experience of a GDG. However, they point to some aspects of the current
guideline pathways where an update could potentially yield particularly large health gains and/or cost
savings. The ‘economic priorities’ for inclusion in updates of the CGs, suggested by analysis with the full
guideline models, differed from the priorities stated by stakeholders.
The results of the analyses conducted with the AF model identified two priority areas for an update: first,
the related topics of the SR and bleeding risk thresholds for targeting of oral anticoagulation therapy; and
second, criteria for making the decision about the use of a rate or rhythm control strategy for patients with
persistent AF. Though far from definitive, both of these analyses suggested that the current guideline
recommendations might not be optimal and that there is a potential for both health improvement and
NHS financial savings. In contrast, the addition of newer OAC drugs to the treatment pathway did not
significantly improve overall NBs; essentially because they are currently priced at a level that puts them
close to the NICE cost-effectiveness threshold of £20,000–30,000 per QALY gained. In contrast to the
model results, stakeholders rated the evaluation of newer OACs compared with warfarin as the highest
priority for an update. This might possibly reflect a focus of stakeholders on clinical effectiveness rather
than cost-effectiveness.
Similarly, although the prostate cancer model predicted that the stakeholders’ first priority for an update –
the choice of surgical technique for radical prostatectomy – would be likely to improve cost-effectiveness,
the magnitude of the estimated gain in NB was relatively modest compared with some of the other topics
modelled (notably brachytherapy with HDR or LDR external beam radiotherapy for localised or locally
advanced prostate cancer, intermittent compared with continuous hormone therapy for metastatic disease
and pelvic radiotherapy with adjuvant hormone therapy for localised disease).NIHR Journals Library www.journalslibrary.nihr.ac.uk
cost-effectiveness estimates for the majority of topics considered. However, there were some topics for
or where
limits on the model scope or structure meant that we could not evaluate the topics within the
available time. We also only managed a very limited examination of possible interactions between the
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58cost-effectiveness of changes in different parts of the care pathways. The existence and magnitude of any
such interactions is important for assessing the added value of full guideline models, compared with a
more conventional piecemeal approach to modelling. The comparison of economic priorities, identified by
the models with stated priorities from the stakeholder survey, produced some interesting results, although
we were not able to complete the planned second round survey of stakeholders so we do not know how
they might have responded to these results. The main limitation of this study, however, is the rather
artificial research context, which meant that we did not test the feasibility of the approach alongside real
guideline development. First, we note that the guidelines used as case studies were purposively selected
from a list of published NICE guidelines that were due to be updated and that they are not necessarily
representative. On the basis of our experience, we believe that the full guideline modelling approach is
feasible for some NICE guidelines, but we do not believe that it would work for all guidelines.
Furthermore, the decision to use existing guidelines was a pragmatic convenience, as we could start withwhich we could not identify sufficient evidence to support a meaningful economic evaluation,later in the pathway. As it may take some time for the cohort to reach the end of the pathway,
discounting would have a greater impact on the costs and health outcomes of late interventions than
on those of early interventions. In reality there is not necessarily a lag in the impact of late-pathway
recommendations, as they may be implemented for prevalent cases soon after publication of the guideline.
This effect will not change the qualitative results of incremental comparisons between decision options at
a single point in the care pathway or the magnitude of estimated ICERs, provided that the discount rates
for costs and effects are the same.205 However, to estimate and compare absolute impacts of guideline
recommendations and to assess the magnitude of interactions between topics, a population approach is
required. This would involve starting the model with prevalent cases distributed throughout the pathway
and introducing incident cases into the model as it runs; or alternatively, a run-in period can be used to
build up to a steady-state distribution of patients throughout the pathway before results are collected.
This approach was adopted for the CHD policy model44 and is quite straightforward for DES models.
Strengths and limitations of the study
In summary, this study has shown that large portions of the care pathway can be successfully modelled
together within a single DES, at least for selected NICE CGs. This was demonstrated with two contrasting
case studies for two very different diseases (one cancer, one cardiovascular), underpinned by very different
types and levels of evidence. These full guideline models, together with the existing published Whole
Disease Model for colorectal cancer,49,63 provide templates which should help in the future development of
similar models. The parallel development of the two models provided opportunities for learning, as the
modelling teams discussed experiences and possible solutions to challenges. The involvement of a wider
group of methodologists involved in the NICE CGs programme provided an understanding of the
opportunities and constraints for developing and using the full guideline modelling approach in practice,
which are discussed below. The primary challenge demonstrated by this project was the time and
analytical resource required to develop the full guideline models. There were also some difficulties
associated with missing data (e.g. the lack of evidence relating to natural history and diagnostic accuracy
mentioned above).
The potential usefulness of the full guideline models for evaluation of the cost-effectiveness of a range of
topics within a guideline development process was tested through the modelling of potential update
topics. The separation between the researchers who chose the topics and the modelling teams meant that
the latter did not know what topics they would have to evaluate until after the base-case models had
been designed and programmed. This provided a test of the flexibility of the models to address
unexpected topics, which is a common occurrence in guideline development, despite attempts to identify
economic priorities at an early stage. Overall the models performed well in these tests, providing129
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present VOI
rce evidence
inty
surrounding the estimates of cost-effectiveness. In this situation, the robustness of VOI estimates would be
questionable. Second, it is unclear that such estimates would provide an indication of priority for updating,
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130which was the focus of our analyses. The decision to include a topic in an update of a guideline is broadly
dependent on two key factors: the perceived likelihood that the recommendation could change following
a systematic review and GDG debate; and the relative importance of any such change (expected impact on
population health and health-care expenditure). A high EVPI indicates that a decision is both important
and uncertain; however, one would not generally decide to include such a decision in a guideline update
unless there was a reasonable expectation that a systematic review and consideration by a panel of experts
could help to resolve the uncertainty. Therefore, there is not a clear relationship between EVPI and priority
for a guideline update.
This is not to say that VOI methods are not potentially of value in guideline development, as they might
help GDGs to decide on research recommendations. It is also possible that an EVPPI analysis – in which the
relative contributions of different model parameters, or groups of parameters, to EVPI is quantified – could
help to inform decisions about searching for better information to improve a full guideline model.
However, there are practical difficulties in estimating EVPPI for a DES model, as the conventional approach
requires an additional level of iteration which would considerably increase model run time.206
Implications for guideline development
Pathway versus piecemeal models
A number of claims may be made for the advantages of the full guideline modelling approach investigated
in this report compared with the current approach to economic evaluation in NICE CGs. The full guideline
models that we developed provide a framework for addressing a range of cost-effectiveness questions
using a consistent set of methods, assumptions and evidence. They allow assessment of if and how
interventions in one part of the pathway influence other parts of the pathway: capturing upstream and
downstream systemic effects. Once developed, the models are a resource that could be reused for future
guideline updates or adapted for other economic evaluations. There may also be potential spinoff benefits
for general guideline development, as modelling enforces greater clarity over the pathway and may help to
elucidate gaps and ambiguities in the existing evidence base.
There are, however, constraints on the routine adoption of this approach in the NICE CGs programme.
The most obvious is the time and resources that are required. Although it is possible that learning from
this project could enable faster development of full guideline models in the future, this would still be
difficult within the current timelines and economic resources available to the NCCs.information and the rational prioritisation of research budgets.65 In this report we chose not to
estimates for two key reasons. First, given the relatively informal methods that we used to sou
for the modelling exercises, we were not confident that we had fully characterised the uncertarecommended care pathways and systematic reviews of the relevant clinical evidence. Although it would
have been desirable to test the application of the approach alongside the development of a new guideline,
this was thought to be premature, as we could not be confident that the modelling teams would succeed
in developing the model in time to inform the development of guideline recommendations. There were
some disadvantages to conducting this study outside of ‘live’ guideline development. For example, the
modelling teams had more limited access to clinical expertise than would usually be available to
guideline economists, who can consult with clinical leads and other members of the GDG. This might
have influenced the assumptions used to interpret and link the guideline recommendations. Access to
the GDG and liaison with other members of the technical team should also help in identification of
relevant evidence.
Value of information analysis has become a fairly standard adjunct to economic evaluations of health-care
technologies. Statistics such as the EVPI, the expected value of partial perfect information (EVPPI), and the
expected value of sample information, can be used to inform decisions about the collection of furtherNIHR Journals Library www.journalslibrary.nihr.ac.uk
The two case studies presented in this report were selected from a list of possibilities largely on the basis
in the GDG
is essential.
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essential) for DES modelling, as it can build in rich correlations between risk factors. Access to THIN data
for the AF model strengthened the ability of the model to reflect variation between patients. In the
absence of a data source for key model parameters, calibration can be used to infer missing or
unknowable data, as in the prostate cancer model. In the absence of routine sources of individual patient
data for a topic, suitable data might sometimes be available from disease-specific clinical audit or registryanalysis. Communication to ensure understanding and agreement of methods and results withthat they were thought to be amenable to the full guideline modelling approach. It is unlikely that this
approach would work for all CGs; for some topics the current understanding of the service pathway or
disease process may be too poor, or data may be too sparse to allow credible modelling of the full
guideline. It should be noted that in such cases, conventional ‘piecemeal’ modelling is also likely to be
challenging. When it is feasible, the full guideline modelling does have the capacity to broaden the range
and to improve the consistency of CEA within NICE CGs. The case studies presented in this report have
demonstrated this potential, and further consideration of the approach is warranted.
Individual level simulation versus cohort models
Another lesson from this project is the potential value of DES for modelling the complex care pathways in
CGs. Although simplicity is to be valued in modelling, ‘more complex areas require models that respect
complexity’.50 In individual-level simulation models patients carry information with them, so the model can
keep track of varied, complex and evolving patterns of risk factors, clinical histories and comorbidities as
patients move through a complicated care pathway. This provides the flexibility to tailor decisions to a
person’s characteristics, and to model the resulting outcomes in a more realistic way. Models can also be
illustrated with more natural representations of care pathways, which are likely to be more accessible for
GDGs and stakeholders than ‘twiggy’ decision trees or Markov models with multiple health states. Another
useful feature of DES is that it can be readily extended from the single cohort approach (taking a group of
patients from some defined starting point and following them through to death) to model whole
populations of prevalent and incident cases. This population approach would facilitate estimation of cost
impact alongside cost-effectiveness within the same model, to provide NHS budget holders and
policy-makers with better estimates to inform implementation and planning. Although this could be
achieved with more conventional decision-analytic models,205 capturing this level of complexity in a Markov
or decision tree framework would be cumbersome to develop and hard to understand.
The main drawback to adopting a DES approach to modelling in NICE guidelines would be the need for
investment to develop (or to buy in) specialised skills. Most health economists do not have applied
experience of using DES, and in this project we did find that it took time to acquire the necessary
knowledge and understanding. We also had specialised experts in simulation modelling who worked
alongside health economists with experience of more conventional cost-effectiveness modelling
techniques, which worked well. Furthermore, although specialist software is not essential for simulation
modelling, it does make it easier. Thus an investment in software would be necessary (in terms of money
and learning time). Investment in hardware might also be necessary to keep model runtime manageable,
as models that combine individual-level simulation with probabilistic sensitivity analysis can be slow to run.
We did not find this to be a limiting factor in our case studies, although we did have access to a number
of fast personal computers (PCs) to run each model.
It is sometimes thought that DES requires more data than Markov models or decision trees. However, data
requirements are more a function of model size and complexity than technique.50,52 There are some
differences though in the type of data required, and modellers would need to learn how to identify and fit
data to inform time-to-event estimates. This might also present a challenge for systematic reviewers and
other guideline developers, although this will depend on the topic area and familiarity with survival131
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the case
studies are discussed below:
the impact
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132and perceived usefulness of the models within the NICE CGs programme. Research should be
conducted to seek the opinions of the members of the NCC technical team, the GDGs, stakeholders1. The case study models have been made available to the NCC teams who are now developi
updates of the AF and prostate cancer guidelines. This provides an opportunity to observel The need for clarity about the boundaries of the model. This should generally reflect the guideline
scope, but it might be extended where there are spill over effects from out of scope issues on the
cost-effectiveness of guideline topics or vice versa. For example, sometimes guidelines include referral
for specialist assessment but not the subsequent specialist treatment (e.g. AF guideline tertiary referral
and ablation). There may also be circumstances where parts of the pathway included in the scope are
difficult to model. For example, in both of our case studies, we found it difficult to model early case
identification due to lack of data on natural history and diagnostic accuracy.
l The need for clarity over whether the model pathway is meant to reflect recommended practice
(i.e. an existing guideline pathway) or current practice. For our case studies we aimed to model the
recommended pathway from the current guideline. However, we had to supplement this with
assumptions about current practice (as advised by clinical experts). During scoping it may be
appropriate to describe more than one pathway reflecting variations in recommended or
actual practice.
l It is essential to focus not just on the service pathway, but also to develop a model of the disease
process (how individuals’ health indicators and status progress over time). It is also essential to
understand how disease and service pathways interact with one another. Discussion with experts is
essential to understand pathways and disease processes. Other useful parallel sources to inform model
design are existing models, observational studies and effectiveness data (which define the important
and available outcome measures).
l Visual representation is extremely important in articulating pathway and disease models, both simple
schematic overviews and detailed flow charts. However, these are not sufficient; textual descriptions
of the pathway and disease models may help clinical experts, GDG members and stakeholders to
understand and critique models.
l As in any model, simplifying assumptions are essential, and these can restrict possible future uses
of the model. The art is in deciding at what level of resolution to reflect the different stages of the
pathway. This ultimately reflects the series of choices made during model development; these
judgements and their implications should be clearly articulated and justified in the light of
available evidence.
l There may be inconsistencies between different bodies of evidence that inform different sections of the
model. For example, the evidence base on antithrombotic therapy for patients with AF presented
results for the outcomes of thromboembolic and haemorrhagic events, and did not separate these into
fatal and non-fatal events. This made it impossible to model effects on all-cause mortality. However,
the evidence comparing rate and rhythm control focussed on the combined effects of treatment
through all-cause mortality, and all-cause hospitalisation. Similarly, in the prostate cancer case study,
the lack of evidence relating to the joint trajectories of PSA, Gleason score and disease progression,
and their impact on treatment decisions meant that it was not possible to fully reflect the way in which
clinicians use this information to make decisions about individual patients.
Recommendations for research
ng theimplementation and verification/validation is particularly crucial. Some key issues that arose indatabases. More generally, any modelling approach needs to make use of the best available evidence at
the time of analysis.
Good practice in model development
Owing to the size and complexity of full guideline models, observation of good practice in model design,NIHR Journals Library www.journalslibrary.nihr.ac.uk
and the NICE guidelines team to determine whether or not they made use of the models and, if so,
whether or not the results were useful in informing guideline recommendations.
2. Further development of the case study models to assess the existence and magnitude of possible
interactions between changes to different parts of the care pathways would be informative. The
existence of sizeable interactions is a crucial element in judging the value of full guideline modelling
compared with more conventional partial evaluation of sections of the care pathway.
3. Another useful development of the case study models would be to extend them to estimate budget
and health impacts across a whole patient population (rather than for a single incident cohort).
Currently, NICE conducts cost impact assessments for CGs separately from the CEAs conducted by
NCCs, which may lead to inconsistent estimates. Furthermore, extending the models to a population
perspective would enable more robust comparison of the NB of changes at different points in the care
pathway without artificial distortion from discounting.
4. The next step would be to apply the full guideline modelling approach to a new NICE guideline. This
would need additional resources to support the analytical effort, for example funding for a simulation
modeller to work with the NCC economist on the model development. Additional challenges to be
faced would include: how to develop the initial understanding of the care pathway through elicitation
from GDG members, stakeholders or other experts, particularly in areas where there are important
variations in current practice; how to work with the GDG in developing, using and interpreting the
guideline model; and how to communicate the methods and underlying assumptions to stakeholders.
5. There are some areas where further development of methods would be useful:
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58i. methods for eliciting expert opinion and reaching consensus about the structure of disease process
and service pathway models to inform guideline development and economic modelling
ii. methods for robust model calibration to infer missing or unobservable parameters in complex
decision models
iii. development of standardised software templates or methods of presentation to help guideline
economists to develop flexible and accessible full guideline models in consultation with other
guideline methodologists, GDGs and stakeholders
iv. methods to test the internal and external validity of full guideline models.133
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Economic modelling of diagnostic/treatment pathways in NICE clinical guidelines: feasibility and value for
info
Im
ry is
t particularly
tricky junctions, but also a small-scale map of the entire system covering all the relevant highways and
alth
onversely
the cost-effectiveness of a treatment depends on upstream selection of patients. Health economists and
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58decision analysts are very familiar with these complexities [6], which can be integrated by adopting a wider
boundary around the model and capturing a greater breadth in the pathway of care. Whether or not NICE
guidelines continue to define a formal pathway, it is important that recommendations are evaluated within
this broader context. A recent initiative, funded by the Department of Health, has demonstrated thispathway. For example, the sequencing of tests and treatments may radically alter costs and he
outcomes. The cost-effectiveness of a test depends on downstream treatment decisions, and cbyways, and estimating the traffic flows along each.
A piecemeal approach to economic analysis may ignore important connections and feedback in the patientprocess a strong dose of decision-analytic expertise, so as to ensure that the whole territo
mapped out in a systematic way . . . . we need not only a large-scale map of what to do aNICE clinical guidelines provide advice on appropriate diagnosis and care for people with specific diseases
and conditions in the NHS in England and Wales [1]. As of July 2009, 88 guidelines had been published,
covering a diverse range of patient groups and conditions, and 46 guidelines were in development.
Though compliance with NICE guidelines is not compulsory, they set standards for NHS organisations and
professionals, and have a major impact on patient care.
Guidelines are developed for NICE by four National Collaborating Centres (NCCs) and an in-house ‘short
guidelines’ team. As with technology appraisals and public health guidance, groups developing NICE
guidelines are expected to take account of cost effectiveness [2,3]. Health economists work alongside
other NCC technical staff, healthcare professionals and patient representatives in Guideline Development
Groups (GDGs). The special role of the economist is to provide evidence on cost-effectiveness and advice
on how this should be interpreted. But this is difficult because of the size and complexity of NICE
guidelines, which may cover up to 30 questions along a ‘pathway’ of care (or ‘algorithm’). This may
include aspects of assessment, diagnosis, treatment, long-term management and follow-up, and, although
few guidelines cover the whole pathway and recent efforts aim to produce more focussed guidelines, NICE
guidelines remain large and complex pieces of work. Guideline economists cannot evaluate every clinical
question in great depth, but instead use a selective approach; relying on published economic evidence
when this is of sufficient quality and relevance, conducting new analyses for key questions and
encouraging the GDG to use judgement about the broad balance of benefits, harms and costs for the
remaining issues [1]. This approach is pragmatic, and may be good enough, ensuring that the really
important economic issues are identified and addressed [4].
However, it is also possible that important issues are being missed or inadequately considered. Alan
Williams considered this dilemma in his 2004 OHE lecture [5], concluding:
I think that guideline development needs to be strengthened from the outset by injecting into the© Que
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APPENDIX 1
152approach by building a ‘whole disease’ model for colorectal cancer [7]. Discrete event simulation was
used to model current practice, following patients from initial presentation through to end-of-life care.
This model was then used as a comparator, against which the cost-effectiveness of potential service
developments was evaluated. In an NIHR fellowship building on this work, Paul Tappenden is now
developing a methods framework for whole disease models of cancer. This fellowship study will provide
guidance on the approach and how it may be usefully implemented.
The idea of building a model of the patient pathway to serve as a foundation for economic evaluation in
NICE guidelines is attractive. However, it may not be feasible given the challenging deadlines and resource
constraints of ‘live’ guideline development. We therefore propose to test the approach first within the
simpler context of guideline update decisions. The NICE guidelines programme has moved into a phase
where hard decisions are needed to balance demands to maintain the backlog of published guidelines
with demands for new guidelines to address emerging priorities. This creates a logistical problem for NICE,
but also an opportunity to test the feasibility and usefulness of pathway modelling. Our experience is that
eliciting an agreed pathway at the beginning of guideline development can be difficult – guideline topics
are usually identified precisely because there is high uncertainty or disagreement about what is, or should
be, standard practice. We will therefore start by selecting case studies of existing guidelines with
well-articulated pathways of care, and modelling these recommended pathways.
On their own, the pathway models will be of little use for decision-making; they may help us to estimate the
cost impact or burden of disease associated with a set of services, but cannot tell us how cost-effective those
services are. For that, we need to compare the standard pathway with some variations, reflecting possible
options for change – for example, substituting a different test or treatment at a given point in the pathway.
In the current process for updating NICE guidelines, NCCs search for new evidence and suggestions for
possible update topics [1]. We will observe this process for our case studies, and collate lists of suggested
update topics. We will then adapt the models to estimate the incremental cost-effectiveness of potential
changes to the pathway. These estimates will be subject to considerable uncertainty, but by modelling this
uncertainty we should be able to estimate the maximum value of updating each topic using a ‘value of
information’ approach [8]. This should help to identify aspects of the pathway that are both sensitive to
change and where the change would have an important impact on patient outcomes and NHS costs. Any
such topics may represent priorities for update. Or, if no such topics are identified; this may suggest that
an update is not warranted.
Finally, we will examine whether the priorities for update suggested by this modelling approach differ from
those that would be identified anyway. This will be assessed through a form of ‘Delphi’ survey, in which
people consulted during the routine updating process will be invited to rate topics first without the results
of the modelling, and then again with that information.
In summary, our primary research aims are:
l To investigate the feasibility of modelling pathways recommended in NICE clinical guidelines to
estimate associated patient flows, health outcomes and costs.
l To illustrate how such models can be used as a basis for assessing the incremental cost-effectiveness of
possible variations in the care pathway.
l To use this approach to estimate the value of updating selected topics within a guideline.
l To compare the update priorities obtained from formal modelling with those elicited from participants
in the routine updating process.
In order to achieve these aims, we will:
(a) Select two NICE guidelines to serve as illustrative examples.
(b) For each guideline, build a simulation model of the recommended pathway to estimate overall patient
flows, health outcomes and costs if the guideline is followed.NIHR Journals Library www.journalslibrary.nihr.ac.uk
(c) Collate suggestions for update topics and sources of new evidence by observing the NCC-led
runel
iques to
better model systems, and hence improve decision analysis. She has applied this modelling technique in
many different contexts including: information systems; business processes; new product development
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58for medical devices; evaluation of telemedicine; and the A&E department of a local hospital.
l GG is a research fellow in health economics in HERG. Prior to joining HERG in 2006, he was a research
fellow with the Centre for the Economics of Health, University of Wales Bangor (UWB), the Health Services
Research Unit (UWB) and has worked for Research Centre Wales (UWB). His research interests include the
economic evaluation of genetic health services, decision analytic modelling and discrete choice modelling.
The second modelling team, based at the London School of Hygiene and Tropical Medicine (LSHTM), will be
led by Alec Miners. Bernadette Li and Sarah Willis will lead on data collection and modelling respectively.
l AM is a lecturer in health economics in the Health Services Research Unit (HSRU) at the LSHTM.
Following graduation from the MSc in Health Economics at York, he worked for five years at the Royal
Free Medical School, London. He then went on to work in the Centre for Health Technology
Assessment at NICE as a Technical Advisor and as a honorary Research Fellow at Brunel University,
before joining the LSHTM in 2006. He is a member of NICE’s Technology Appraisals Committee andl JE is a research fellow in the Department of Information Systems and Computing (DISC) at B
University. Her main research interest is in applying advanced discrete event simulation technupdating process.
(d) Ask participants in the update process (NCC/NICE staff, clinical experts and patient representatives) to
rate the suggested topics in terms of priority for inclusion in an update.
(e) Adapt the models to estimate the incremental net benefit of possible changes to pathways.
(f) Use a value of information approach to estimate the maximum expected net benefit of updating each
suggested topic.
(g) Feedback the results from steps E and F to the people consulted in step D, and invite them to reassess
their ratings of priorities for update.
In addition to addressing an important methodological issue, this research could also be of practical use to
NICE, helping to inform decisions about updating the guidelines that we use for case studies. Building on
our experience, we will also make recommendations for future research into the broader potential for
pathway modelling in guideline development, and on possible strategies for deploying this approach
during routine guideline development.
Scientific potential
People and track record
The Principal Investigator, Joanne Lord, will take overall responsibility for leadership and management of
the project:
l JL is a reader in the Health Economics Research Group (HERG) at Brunel University. She worked for
four years in the guidelines team at NICE, where she provided advice within the Institute and to NCCs
on the use of economic evaluation in clinical guidelines. Before joining NICE, she was a lecturer in
health economics at Imperial College Management School and in the Public Health Department at
St George’s Hospital Medical School. She has conducted applied economic evaluations based on
clinical trials and modelling studies, and published on methodological aspects of economic evaluation.
JL will also lead the Brunel modelling team, which will develop and apply the model for one of the
case studies. Other members of this team are: Julie Eatock, who will lead on building the model; and
Gethin Griffith, who will lead on the collection of data to populate the model.153
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154Decision Support Unit. He leads a team of economists who provide analytical support to the National
Collaborating Centre for Cancer (NCC-C).
l SW is a research fellow in the HSRU. She has been working for over two years as a health economist on
NICE cancer guidelines. She led the economic programme of work for two guidelines: advanced breast
cancer (published 2009) and lung cancer (anticipated 2011). She has developed a large decision tree
model to assess the cost-effectiveness of sequences of chemotherapy. This model was informed by an
indirect treatment comparison model developed in collaboration with researchers at Bristol University.
l BL joined the HSRU as a research fellow working on NICE cancer guidelines in 2008. She provides
health economics input and advice to GDGs, undertakes economic modelling for high priority areas,
and supervises two research assistants. She has experience as a Senior Outcomes Research Manager,
Health Outcomes Scientist and Associate Product Manager in the pharmaceutical industry, and as an
Editorial Assistant for the editor of an international peer reviewed medical journal.
Simon Taylor will provide external advice to the modelling teams on simulation modelling techniques and
application. He will also take responsibility for model verification and validation.
l ST is a reader in DISC. His main research aim is to use novel computing technologies and techniques to
benefit operational research. His research interests include distributed systems and computing,
simulation modelling, distributed and web-based simulation, applications of Grid computing and the
Semantic Web. Before joining Brunel, Simon lectured at Westminster and Leeds Met. University.
Paul Tappenden will join the research team in December 2009, when his NIHR fellowship comes to an
end. He will lead on observing the conventional update process and eliciting expert ratings, preventing
premature feedback of this information to the modelling teams.
l PT is a senior research fellow in the Health Economics and Decision Science group in the School for
Health and Related Research (ScHARR) at the University of Sheffield. Since joining ScHARR in 2000,
he has led or contributed to the modelling work for 8 NICE technology appraisals, and has developed
health economic models for the NCCHTA, the Department of Health and NHS Cancer Screening
Programmes. He is currently undertaking an NIHR fellowship to develop, implement and evaluate a
methodological framework for modelling whole disease areas to inform resource allocation decisions.
In addition to the above researchers, the project steering group includes NCC and NICE economists and
reviewers with extensive experience of the NICE guidelines programme:
l Phil Alderson is a public health doctor who has worked in the field of research synthesis since 1996
at the UK Cochrane Centre and currently as Associate Director (Methodology) in the guidelines team
at NICE. His role there is to oversee the quality control and methodological development of NICE
clinical guidelines.
l Francis Ruiz is a health economist who joined the guidelines team at NICE as a technical adviser in
July 2006, having previously worked in the Institute’s Technology Appraisal programme. He provides
leadership within the guidelines programme for all aspects of health economic analysis. Prior to joining
NICE, Francis worked in clinical data management and health economics in the pharmaceutical sector.
l Ifigeneia Mavranezouli is a senior health economist at the National Collaborating Centre for Mental
Health (NCC-MH), based at UCL. She has worked at this centre for over 4 years. Previously, she
worked for a year as a health economist at the National Collaborating Centre for Women’s and
Children’s health (NCC-WCH). She has participated in 9 Guideline Development Groups as member of
the Technical Team of the NCC-MH and NCC-WCH. She is a medical doctor and has working
experience in primary and secondary care settings.
l Dave Wonderling is health economics lead at the National Clinical Guidelines Centre (NCGC), based
at Royal College of Physicians and Honorary Research Fellow at HERG, Brunel University. He has
worked on NICE clinical guidelines since April 2001, participating directly in 9 Guideline Development
Groups. He now co-leads a team of 8 health economists working concurrently on 14 NICE clinicalNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Additional expertise, and a degree of external oversight, will be provided by PT, based in the Health
Economics and Decision Science (HEDS) group in the School of Health and Related Research (ScHARR) at
the University of Sheffield. HEDS specialises in the application of economic evaluation and mathematical
modelling to the development of health services and the improvement of the public health. The School
employs around 200 multidisciplinary staff and attracts in excess of £6M per year in external support.
The two modelling teams will meet regularly to coordinate activity and exchange information. All
researchers and applicants will participate in regular steering group meetings, where the plans and
progress of the modelling teams will be presented and discussed.
Senior staff from the National Collaborating Centres (NCCs) with responsibility for the guidelines chosen as
case studies will also be invited to participate in steering group meetings as appropriate. This will include
early sessions when plans for the scheduling of modelling, observation of the NCC-led update process and
expert survey are discussed, as well as later discussions when results are presented and plans for(nursing, medicine, pharmacy).guidelines. He co-authored the first version of the cost-effectiveness chapter of the Guidelines Manual
and has been a member of the NICE Clinical Guidelines Joint Methodology Group since its inception.
Previously he was a lecturer in health economics at the London School of Hygiene & Tropical Medicine.
l Paul Jacklin is a senior health economist at the National Collaborating Centre for Women’s and
Children’s Health (NCC-WCH), and honorary lecturer at the LSHTM. He has worked on 14 clinical and
public health guidelines for NICE. Before joining NCC-WCH, he worked at the LSHTM and at Guy’s
and St Thomas’ hospital, where he developed models to evaluate the cost-effectiveness of different
diagnostic strategies for coronary artery disease.
l Maggie Westby is the clinical effectiveness lead at the National Clinical Guidelines Centre (NCGC),
based at Royal College of Physicians. She has worked on NICE clinical guidelines since 2005 and
participated in 8 Guideline Development Groups. Before this, she worked in the Royal College of
Nursing’s guideline programme and before that, for the UK Cochrane Centre on systematic reviewing
and its methodology. She currently oversees the clinical effectiveness methodology carried out by
19 systematic reviewers in 14 guidelines.
Environment
All participating academic groups were highly rated in the 2008 Research Assessment Exercise.
The Brunel modelling team brings together staff from two well-established departments with a long, and
ongoing, history of effective collaboration. The Health Economics Research Group (HERG) has an
international reputation in health economics, developed over more than twenty years. Its focus is on the
economic evaluation of a broad range of clinical and health service technologies. HERG is one of six
Specialist Research Institutes at Brunel University, which have special status as prestigious centres which
have enhanced the University’s research base and research income.
The Department of Information Systems and Computing (DISC) is an internationally recognised centre of
excellence in biological and healthcare informatics, human-computer interaction, information science,
information systems, intelligent data analysis, and software engineering. The Department is home to the
largest research group of its type in the country, with many years of experience with simulation modelling,
including evaluations of healthcare interventions [9,10].
The LSHTM modelling team currently provide economics input to the NICE National Collaborating Centre
for Cancer, working together to develop and deliver complex economic models to tight deadlines. The
Health Services Research Unit at the LSHTM was established in 1988, with the aim of carrying out research
that helps to improve the quality, organisation and management of health services and systems. Most of
their research is in high income countries and, in particular, the UK. Their staff is multi-disciplinary
(epidemiology, sociology, psychology, economics, history, statistics, health policy) and multi-professional155
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To allow sufficient time for modelling within the two-year study period, we need guidelines due for
We anticipate that the following guidelines are likely candidates: Prostate Cancer; Irritable Bowel
se area and
te model
structures and sources of data. Documentation for the current NICE guideline will also be reviewed in detail to
quirements
r mapping
complicated diagnostic/treatment pathways, and retain information about individual patient
history [11–13]. Models will be developed following a “rapid prototyping” approach in close collaboration
APPENDIX 1
156with relevant stakeholders to capture appropriate breadth and depth of detail. The visual animation
available in simulation software would also be beneficial in providing a user-friendly interface, enabling
better communication with non-economists. This would be important for the methods to be transferable
for later use in routine guideline development. However, it must be acknowledged that there can be a
technical difficulty with the use of discrete event simulation for economic evaluation, as these models canStep 3: Develop model
The modelling methodology and software will be decided after careful consideration of the re
for the case studies. A discrete event simulation approach would provide a flexible structure foensure understanding of the recommendations, the available evidence and GDG rationale for decisions.
Step 2: Design pathway model
Design model structure based on natural progression of the disease and the recommended guideline
pathway. The models will be designed to estimate the number of patients expected to receive different
interventions, health outcomes (QALYs) and costs if the guideline recommendations were to be fully
implemented. Results will be estimated for a population of incident and prevalent cases in England and
Wales over the three-year lifetime of the guideline; up to the next point at which the guideline will be
reconsidered for update. But to estimate the long-term impact of treatment decisions made during this
period, patients entering the pathway will be followed up for life. The models will follow the NICE
Reference Case [3]. The model structure and assumptions will be checked with clinical experts and NCC
reviewers and economists who are familiar with the guideline.Step 1: Review literature
The modelling teams will start by reviewing literature on published economic models for the disea
related models from NICE guidance (e.g. technology appraisals). This will help to identify appropriaSyndrome; Antenatal Care; Lipid Modification; and Stroke.
B. Model existing pathwaysupdate between December 2010 and May 2011 (see project plan below). The steering group will select
the case studies when the timetables for update are known, and following consultation with NICE and the
NCCs. Other criteria for the selection of the case studies include:
l Existence of a relatively well-formulated pathway in the current guideline.
l Guidelines for different patient groups or disease areas, and which are likely to present different
challenges for the modellers.
l Important topics likely to be updated (where the model is likely to have future value)
l But where there is uncertainty/controversy over what topics should be updated.A. Select case studiesdissemination agreed. This, together with the inclusion of senior technical staff from the guideline
programme as co-applicants, will ensure effective liaison with the NCCs and NICE. The steering group will
also take responsibility for assuring that the project does not adversely interfere with guideline production
by placing an unacceptable burden on NCC staff. Members of the steering group will co-author the case
study reports and resulting peer-reviewed publications.
Research PlansNIHR Journals Library www.journalslibrary.nihr.ac.uk
ls, and work
with the teams to ensure that any identified errors or inconsistencies are corrected.
e lists will be
supplied to the modelling teams to inform step E and F.
after step G.
DOI: 10.3310/hta17580 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 58Each variation will be evaluated in comparison with the original pathway, to estimate the incremental net
benefit of the change for the relevant population (incident and prevalent cases in England and Wales over
the three-year lifetime of the guideline). Additional data required to derive these estimates will be obtained
from the original guideline, new evidence identified in step C, or by elicitation from experts. Probabilistic
sensitivity analysis will be used to estimate the extent of uncertainty over the net benefit estimates. Topicsl addition of tests or treatments as an extra step in the pathway.E. Estimate net benefit of update topics
The modelling teams will identify possible variations in the pathways, which may include:
l substitution of different tests or treatments at given points in the pathway;
l changes to patient eligibility criteria or thresholds for tests or treatments;
l different sequencing of tests or treatments and/orcontacting them. The results of the rating exercise will not be given to the modelling teams untilD. Obtain experts’ initial ratings of topics
PT will then contact people involved in the update process, which may include NCC/NICE staff as well as any
patient representatives and clinicians who were consulted. They will be provided with the list of potential
topics identified in step C and asked to rate them in terms of priority for update. PT will liaise with the NCC
to identify an appropriate list of people to include in this rating exercise, and to agree procedures forpotential topics for inclusion in an update and a list of any new evidence will be collated. ThesC. Identify suggestions for update topics
The normal updating process is described in Chapter 14 of the NICE Guidelines Manual [1]. This is led by
the NCC, which undertakes literature searches for new evidence and seeks the views of experts, which
may include patient representatives and healthcare professionals (often members of the original guideline
group). The NCC then makes recommendations to NICE, who decide whether the guideline should be
updated, and if so, what are the key areas that need to be considered. This normal updating process will
be observed by a researcher working independently from the modelling teams (PT). This may involve
attending relevant meetings and reviewing documents as advised by the NCC. From these sources, a list ofexperienced modeller external to the modelling teams (ST) will independently review the modeStep 5: Verification and validation
The modelling teams will check for errors and inconsistencies throughout model development, following
best practice for quality assuring simulation [12,13] and decision analytic [14,15] models. The models will
be verified internally (to ensure correct programming) and validated externally (to ensure consistency with
expected results – for example, that survival times and levels of service use are realistic). In addition, anbe reflected through probabilistic sensitivity analysis [8].be very slow to run when combined with probabilistic sensitivity analysis. For example, it did not prove
feasible to conduct a value of information analysis of the colorectal ‘whole disease’ model, because of its
long run-time [7]. ST and JE will provide advice on the efficient design and use of the models to determine
how this problem can be overcome. They will also consider whether and how the modelling approach
could be adapted to create a prototype generic modelling tool for pathway analysis in clinical guidelines.
Step 4: Obtain data
Model parameters (incidence and prevalence, baseline risks, test accuracy, treatment effects, utilities and
costs) will be fitted using information available in the original guideline, supplemented with new evidence
identified through rapid literature searches and/or expert opinion (e.g. by contacting members of the
original guideline group). We will not conduct systematic reviews for all of these parameters, as this would
not be possible during routine updating. The extent and impact of uncertainty over model parameters will157
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with a greater net benefit offer more potential for gain from a change in recommendations, and are thus
o, in the
absence of the necessary primary data, EVPPI will be of limited use in guiding update decisions.
They will
also be presented with their previous ratings of the importance of updating each topic (from step D),
They will then be invited to re-rate the priority of the topics, and to comment on the reasons for their ratings.
Ethics and research governance
Brunel research ethics committee, and LREC if necessary.
Data preservation for sharing
, and to lay
members of guideline development groups.
We will also disseminate our findings through traditional academic channels, including national and
APPENDIX 1
158international scientific conferences (e.g. Guidelines International Network, Health Technology Assessment
International, Health Economists’ Study Group), and peer-reviewed journals (e.g. Health Economics,
Journal of Health Economics, Medical Decision Making, Health Care Technology Assessment).Exploitation and dissemination
For each case study, we will write a final report for the relevant NCC and NICE, summarising the findings
from our modelling and the expert surveys. We will also offer NCCs a working copy of the pathway
model, along with specific advice and support on its use.
We will present and discuss our overall findings at suitable meetings for NICE and NCC staff (e.g. the Health
Economist’s in Guidelines meeting, the NCC/NICE technical meeting and the NICE Technical Forum).guidelines. This could involve presentation to participants at stakeholder consultation meetingsNo primary data collection. We will provide on-line access to the models developed for this study.
Public engagement in science
If the research is successful, the models may be used in subsequent scoping or development of the clinicalThis study is based on secondary analysis of published data and will not involve any patient contact or use
of any individual patient data. We will be contacting experts consulted in the NICE updating process, and
will therefore ensure that appropriate ethical approval and research governance are obtained through thealongside estimates of the net benefit and EVPPI for each topic obtained from the modelling (steps E and F).participated in step D will be sent a copy of the modelling report, and invited to comment on it.G. Report results to experts and invite revised ratings
The modelling teams will each prepare a report summarising their methods and results. The people whothrough systematic review of the available literature and further cost-effectiveness modelling. Sa higher priority for inclusion in an update. All other things being equal, net benefits will be greater for
topics that affect a large number of patients, offer a large health gain per patient and/or a small increase
in costs.
F. Estimate value of information for topics
The modelling teams will then use the cost-effectiveness models to estimate the population Expected
Value of Partial Perfect Information (EVPPI) [16] for sets of parameters related to each topic. This provides
an estimate of the maximum amount that it would be worth paying to eliminate all uncertainty over the
relevant set of parameters. Topics with a larger EVPPI are predicted to offer a greater potential for gain if
uncertainty over them could be reduced through a guideline update. However, this does not mean that
that gain will necessarily be realised, since the update can only summarise the available information –NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Appendix 3 Stakeholder survey responses
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FIGURE 30 Prostate cancer survey – question 1 (rating of topics) n=18. (a) Topic A: pelvic radiotherapy with adjuvant
hormonal therapy; (b) topic B: effective techniques for performing radical prostatectomy; (c) topic C: HDR in addition
to external beam radiotherapy; (d) topic D: LDR in addition to external beam radiotherapy; (e) topic E: degarelix
(a LHRH antagonist) for men with advanced hormone-dependent prostate cancer; (f) topic F: intermittent hormone
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hormone-refractory prostate cancer and painful bone metastases; (h) topic H: IMRT and IGRT as an alternative to
conventional radiotherapy; and (i) topic I: AS in previously unscreened ‘low-risk’ men. (continued)163
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FIGURE 30 Prostate cancer survey – question 1 (rating of topics) n=18. (a) Topic A: pelvic radiotherapy with adjuvant
hormonal therapy; (b) topic B: effective techniques for performing radical prostatectomy; (c) topic C: HDR in addition
to external beam radiotherapy; (d) topic D: LDR in addition to external beam radiotherapy; (e) topic E: degarelix
(a LHRH antagonist) for men with advanced hormone-dependent prostate cancer; (f) topic F: intermittent hormone
therapy vs. continuous hormone therapy; (g) topic G: radium-223 chloride vs. strontium-89 for men with
hormone-refractory prostate cancer and painful bone metastases; (h) topic H: IMRT and IGRT as an alternative to
conventional radiotherapy; and (i) topic I: AS in previously unscreened ‘low-risk’ men. (continued)
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FIGURE 30 Prostate cancer survey – question 1 (rating of topics) n = 18. (a) Topic A: pelvic radiotherapy with adjuvant
hormonal therapy; (b) topic B: effective techniques for performing radical prostatectomy; (c) topic C: HDR in addition
to external beam radiotherapy; (d) topic D: LDR in addition to external beam radiotherapy; (e) topic E: degarelix
(a LHRH antagonist) for men with advanced hormone-dependent prostate cancer; (f) topic F: intermittent hormone
therapy vs. continuous hormone therapy; (g) topic G: radium-223 chloride vs. strontium-89 for men with
hormone-refractory prostate cancer and painful bone metastases; (h) topic H: IMRT and IGRT as an alternative to
conventional radiotherapy; and (i) topic I: AS in previously unscreened ‘low-risk’ men. (continued)
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FIGURE 31 Atrial fibrillation survey – question 1 (rating of topics) n=25. (a) Topic A: prophylaxis for the prevention
of post-operative AF; (b) topic B: AADs as PCV; (c) topic C: rhythm vs. rate control strategies for persistent AF;
(d) topic D: treatment for maintaining sinus rhythm after cardioversion; (e) topic E: alternative risk factor based
scoring systems to assess SR; (f) topic F: stratification tools to assess bleeding risk; (g) topic G: apixaban, rivaroxaban or
dabigatran etexilate; and (h) topic H: catheter ablation. AAD, antiarrhythmic drug. (continued)
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FIGURE 31 Atrial fibrillation survey – question 1 (rating of topics) n=25. (a) Topic A: prophylaxis for the prevention
of post-operative AF; (b) topic B: AADs as PCV; (c) topic C: rhythm vs. rate control strategies for persistent AF;
(d) topic D: treatment for maintaining sinus rhythm after cardioversion; (e) topic E: alternative risk factor based
scoring systems to assess SR; (f) topic F: stratification tools to assess bleeding risk; (g) topic G: apixaban, rivaroxaban or
dabigatran etexilate; and (h) topic H: catheter ablation. AAD, antiarrhythmic drug. (continued)
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IGURE 31 Atrial fibrillation survey – question 1 (rating of topics) n = 25. (a) Topic A: prophylaxis for the prevention
f post-operative AF; (b) topic B: AADs as PCV; (c) topic C: rhythm vs. rate control strategies for persistent AF;
) topic D: treatment for maintaining sinus rhythm after cardioversion; (e) topic E: alternative risk factor based
coring systems to assess SR; (f) topic F: stratification tools to assess bleeding risk; (g) topic G: apixaban, rivaroxaban or
abigatran etexilate; and (h) topic H: catheter ablation. AAD, antiarrhythmic drug. (continued)
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FIGURE 32 Prostate cancer survey – question 2 (ranking of topics) n=18. (a) Topic A: pelvic radiotherapy
with adjuvant hormonal therapy; (b) topic B: effective techniques for performing radical prostatectomy; (c) topic C:
HDR in addition to external beam radiotherapy; (d) topic D: LDR in addition to external beam radiotherapy;
(e) topic E: degarelix (a LHRH antagonist) for men with advanced hormone-dependent prostate cancer; (f) topic F:
intermittent hormone therapy vs. continuous hormone therapy; (g) topic G: radium-223 chloride vs. strontium-89;
(h) topic H: IMRT and IGRT as an alternative to conventional radiotherapy; and (i) topic I: AS in previously unscreened
‘low-risk’ men. (continued)
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FIGURE 32 Prostate cancer survey – question 2 (ranking of topics) n=18. (a) Topic A: pelvic radiotherapy
with adjuvant hormonal therapy; (b) topic B: effective techniques for performing radical prostatectomy; (c) topic C:
HDR in addition to external beam radiotherapy; (d) topic D: LDR in addition to external beam radiotherapy;
(e) topic E: degarelix (a LHRH antagonist) for men with advanced hormone-dependent prostate cancer; (f) topic F:
intermittent hormone therapy vs. continuous hormone therapy; (g) topic G: radium-223 chloride vs. strontium-89;
(h) topic H: IMRT and IGRT as an alternative to conventional radiotherapy; and (i) topic I: AS in previously unscreened
‘low-risk’ men. (continued)
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IGURE 32 Prostate cancer survey – question 2 (ranking of topics) n = 18. (a) Topic A: pelvic radiotherapy
ith adjuvant hormonal therapy; (b) topic B: effective techniques for performing radical prostatectomy; (c) topic C:
DR in addition to external beam radiotherapy; (d) topic D: LDR in addition to external beam radiotherapy;
) topic E: degarelix (a LHRH antagonist) for men with advanced hormone-dependent prostate cancer; (f) topic F:
termittent hormone therapy vs. continuous hormone therapy; (g) topic G: radium-223 chloride vs. strontium-89;
) topic H: IMRT and IGRT as an alternative to conventional radiotherapy; and (i) topic I: AS in previously unscreened
ow-risk’ men. (continued)
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IGURE 33 Atrial fibrillation survey – question 2 (ranking of topics) n=23. (a) Topic A: prophylaxis for the prevention
f post-operative AF; (b) topic B: AADs as PCV; (c) topic C: rhythm vs. rate control strategies for persistent AF; (d) topic
: treatment for maintaining sinus rhythm after cardioversion; (e) topic E: alternative risk factor based scoring
ystems for SR; (f) topic F: stratification tools to assess bleeding risk; (g) topic G: apixaban, rivaroxaban or dabigatran
texilate; and (h) topic H: catheter ablation. AAD, antiarrhythmic drug. (continued)
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FIGURE 33 Atrial fibrillation survey – question 2 (ranking of topics) n=23. (a) Topic A: prophylaxis for the prevention
of post-operative AF; (b) topic B: AADs as PCV; (c) topic C: rhythm vs. rate control strategies for persistent AF; (d) topic
D: treatment for maintaining sinus rhythm after cardioversion; (e) topic E: alternative risk factor based scoring
systems for SR; (f) topic F: stratification tools to assess bleeding risk; (g) topic G: apixaban, rivaroxaban or dabigatran
etexilate; and (h) topic H: catheter ablation. AAD, antiarrhythmic drug. (continued)
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IGURE 33 Atrial fibrillation survey – question 2 (ranking of topics) n = 23. (a) Topic A: prophylaxis for the prevention
f post-operative AF; (b) topic B: AADs as PCV; (c) topic C: rhythm vs. rate control strategies for persistent AF; (d) topic
: treatment for maintaining sinus rhythm after cardioversion; (e) topic E: alternative risk factor based scoring
ystems for SR; (f) topic F: stratification tools to assess bleeding risk; (g) topic G: apixaban, rivaroxaban or dabigatran
texilate; and (h) topic H: catheter ablation. AAD, antiarrhythmic drug. (continued)
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Appendix 4 Prostate cancer service pathway
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FIGURE 34 Prostate cancer service pathway. HIFU, high-intensity-focused ultrasound; MDT, multidisciplinary team;
PC, prostate cancer. (continued)
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FIGURE 34 Prostate cancer service pathway. HIFU, high-intensity-focused ultrasound; MDT, multidisciplinary team;
PC, prostate cancer. (continued)
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IGURE 34 Prostate cancer service pathway. HIFU, high-intensity-focused ultrasound; MDT, multidisciplinary team;
C, prostate cancer. (continued)
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Appendix 5 Prostate cancer data for update topics
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Appendix 6 Atrial fibrillation clinical pathway
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FIGURE 35 Atrial fibrillation clinical pathway. CAD, coronary artery disease; CXR, chest X-ray; NDT, non-drug
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FIGURE 35 Atrial fibrillation clinical pathway. CAD, coronary artery disease; CXR, chest X-ray; NDT, non-drug
treatment; PiP, pill in pocket. (continued)
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FIGURE 35 Atrial fibrillation clinical pathway. CAD, coronary artery disease; CXR, chest X-ray; NDT, non-drug
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FIGURE 35 Atrial fibrillation clinical pathway. CAD, coronary artery disease; CXR, chest X-ray; NDT, non-drug
treatment; PiP, pill in pocket. (continued)
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FIGURE 35 Atrial fibrillation clinical pathway. CAD, coronary artery disease; CXR, chest X-ray; NDT, non-drug
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FIGURE 35 Atrial fibrillation clinical pathway. CAD, coronary artery disease; CXR, chest X-ray; NDT, non-drug
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FIGURE 35 Atrial fibrillation clinical pathway. CAD, coronary artery disease; CXR, chest X-ray; NDT, non-drug
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